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1. CHAPTER 1

NANOPARTICLES AS DRUG DELIVERY VEHICLES

Introduction to Nanotheranostics
Nanomedicine and nano delivery systems have become a rapidly developing
technology as the nanomaterials serve as vehicles that deliver therapeutic agents and as
well as diagnostic tools. The site specific, target- oriented delivery of therapeutics through
the nanomaterials provides vast range of benefits in treating human chronic diseases.
These nanosized (1 to 100 nm) materials exhibit unique structural, chemical, mechanical,
magnetic, electrical, and biological properties.1 These unique properties have lead them to
be used as delivery agents of encapsulating or conjugating drugs and as disease diagnostics.
The current project will further explore the development of nanotherapeutics and
diagnostics using different nanomaterials by exploring their chemical and physical
properties.
These therapeutic and diagnostic applications are further discussed in detail in the
next chapters to come together with the recent therapeutic endeavors containing similar
constructs. Foremost, the synthesis of the nanoparticles into different targeted
nanoassemblies to facilitate different applications and the challenges that may dictate their
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efficiency will be illustrated. Background layout of the synthesis of nanoparticles to
nanoassemblies and their characteristic features that helps in respective applications will
be discussed.
Nanomaterials in drug delivery
1.2.1 Introduction
Drug delivery systems facilitate controlled release of a drug at a designated rate at
a targeted site of interest to ultimately serve the purpose of the drug. These drug delivery
systems should have enhanced permeability, stability, controllability, localized or targeted
delivery and reduced toxicity with enhanced therapeutic efficacy.1-3
Nanomaterials are small sized materials ranging from 1 to 100 nm. However,
depending on the dimensions, they can be subcategorized into 0D (nanoparticles), 1D
(nanorods, nanowires) and 2D (nanofilms, quantum dots).4 These smaller dimensions
facilitate unique physical, chemical, optical, electrical, and biological properties. Their
higher surface area and increased surface energy enhance their catalytical activity.
Furthermore, high surface area to volume ratio facilitates the drug loading and attachment
of more drugs onto the nanoparticle surface. Also, the ease of surface modification using
conjugate biomolecules supports the targeted delivery. These drugs can be loaded inside
the nanomaterials or coated with nanomaterials to prevent drug degradation or drug leakage
until it reaches the target site. Furthermore, these nanomaterials can be activated under
NIR, UV and Vis excitation or by magnetic or electrical fields for controlled release of the
drug at the interested vicinity.4 Once fluorescently labeled, these nanomaterials can be
tracked for their release and internalization. These nanomaterials can have the ability to
increase cellular uptake of drugs due to their size and surface charge and can control the
2

targeting affinity through attaching targeting ligands. Considering all these factors, there is
a fast-growing interest in using them as delivery vehicles for the existing drugs.
Therefore, the aim of this section is to discuss typical and detailed examples of
using silica-based nanomaterials as drug delivery vehicles to facilitate the drugs therapeutic
affinity by reducing off target toxicity and cytotoxity (quality of being toxic to cells).
1.2.2 Silica based nanomaterials
Most drug delivery systems experience high dose limitations, off target toxicity,
poor solubility and low bioavailability. Most small molecule drug therapies also struggle
with these limitations. However, nanotechnology-based drug delivery has overcome these
previously mentioned limitations by using nanomaterials in drug delivery. Due to their
larger surface area, adjustable pore size, and facile surface modification ability, siliconbased nanoparticles and their oxides have become very popular as investigative drug
delivery platforms.5 The silicon-based materials have vastly been used in biomedical
applications such as dental fillers, dietary supplements, implants and contact lenses.6-8
Furthermore, silicon-based nanoparticles have attracted tremendous attention due to its
superior biocompatibility, optical properties, low density, controllable structure, higher
surface area, adsorption capacity and low toxicity.9-11 These unique characteristics have
significant influence on biological systems in biodistribution5,, blood circulation12, cellular
uptake13, drug release, etc.1 Furthermore, the silanol groups present on the nanoparticle
surface facilitate attachment of targeting ligands, stimuli responsive protective gate keepers
which will further increase the therapeutic efficacy of the drugs by directed targeting
affinity and reducing side effects.12
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Silica-based nanoparticles can be classified into nonporous (solid) and mesoporous
(2 to 50 nm pore structure), both having a similar amorphous silica structure and
composition.9 The properties, differences, and similarities of these solid and porous silica
nanoparticles will be discussed in the sections to come.

1.2.2.a Silica nanoparticles
Silica nanoparticles are the most widely used nanoparticles in drug delivery due its
ease of synthesis and biocompatibility.13 Due to their amorphous structure, smaller size,
higher stability, and tunable surface properties via their hydrophilic surface, silica
nanoparticles are good candidates for the delivery of drugs and genetic material.14
Fluorescently labeled silica nanoparticles can be used in bioimaging due their ability to
protect drugs from immune responses and also in drug delivery, immunodiagnostics and
cancer research.15 Oliveira et al. reported the use of folate tagged amino functionalized
silica nanoparticles loaded with curcumin to target and deliver drugs to prostate cancer
cells.16 A study by Lee et al. mentioned the use of mesoporous dye doped (Rhodamine B
isothiocyanate) silica nanoparticles immobilized within magnetite nanocrystals for
simultaneous MRI, fluorescence imaging and anticancer drug delivery.15,

17

This

dissertation focuses on using silica based nanoparticles for theranostic applications.
1.2.2.b Mesoporous silica nanoparticles
Mesoporous nanoparticles (MSNs) have been nominated as a drug delivery vehicle
since the 1990s due to their excellent biocompatibility, internal pores (typically ca. 2 to 6
nm) controllable particle size (50 to 200 nm), pore volume (0.6 to 1 cm3/g), large surface
area (700 to 1000 m2/g), and flexible surface modification capabilities.18, 19 Therefore,
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tuning pore volume, internal properties of pores, size and shape morphology and surface
functionalization impact the MSN's ability to act as drug delivery systems.9 The silanol
containing surface of these MSNs can be easily modified with a targeting moiety to target
the drug to a directed location by increasing specificity and diminishing undesired side
effects. There are two types of modifications: (i) active targeting through conjugation of
peptides, small molecules, proteins, antibodies, aptamers and etc., and (ii) dual targeting
where grafting two targeting agents to enhance more selectivity.20 These modifications
further facilitate the uptake of nanoparticles from the blood stream.
MSNs possess a solid framework with a porous structure and a large surface area
which facilitates loading and attaching drugs easier than the solid silica nanoparticles.
Furthermore, the larger surface area facilitates faster lixiviation of the silica matrix due to
enhanced contact with physiological medium.21 Furthermore, the pore geometry can be
changed depending on the application. They are vastly used in research studies in
controlled and targeted drug delivery due to their low toxicity and high drug loading
capacity. The presence of tunable pores provides the advantage of loading higher quantities
of hydrophilic/ hydrophobic and positively/negatively charged drugs following subsequent
stimuli responsive controlled release using gate keepers. Also, MSNs allow for the
transportation of two or more drugs synergistically which open doors for combinational
therapy for multidrug resistant diseases. Additionally, loading fluorescently labeled drugs
or contrast agents helps in biomedical imaging in real time treatments. The possibility to
reduce premature cargo release by blocking the pores with a stimulus responsive linker is
another added advantage of using MSNs as drug delivery vehicles. These can be internal
stimuli such as enzymes, pH, redox potential, and external stimuli such as NIR, magnetic
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field, ultrasound, etc.

21, 22

Cheng et al. reported the enzyme induced drug release from

MSNs at the tumor vicinity.23 Also, Zhao et al. has studied the use of NIR triggered drug
release from MSN for cancer therapy.24
Compared to liposomes these MSNs are very stable against external mechanical
stresses and degradation forces due to their strong Si-O bonds.20 The other advantage of
these strong Si-O bonds is their susceptibility to break down through nucleophilic attacks
by hydroxides or water present in the SiO2 network. This reaction promotes the hydrolytic
breakdown of the siloxane (Si-O-Si), leaching orthosilicic acid (Si(OH)4).25 This byproduct
is highly biocompatible and excretes well with urine making these MSNs a suitable
candidate to be used as nano drug delivery system (DDSs).
Irrespective to the advantages, there are obvious challenges in elevating MSNs to
clinical level DDSs. One of the major problems is scaling up the MSN synthesis for
commercialization. Even though the reproducibility in small scale is easy, mass scale
reproduction is very difficult and very costly.20 Also, passing through all the pre-clinical
and clinical trials up to getting Food and Drug Administration (FDA) approval will be quite
challenging and time consuming.
Song et al. has reported the use of a silica nanopollen which has rough mesoporous
silica hollow spheres that mimic the bacteria cell surface, which makes these nanoparticles
to have enhanced adhesion towards bacteria.26 Furthermore, they have loaded these
nanoparticles with lysozymes and checked its antimicrobial affinity towards E. coli.26 Zhao
et al. also used succinylated casein coated mesoporous silica nanoparticles to load an
antimicrobial peptide to check its antibacterial action against multidrug resistant E. coli.27
Also, Chen et al. studied the use of monodispersed zinc-containing mesoporous silica
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nanoparticles for the treatment of triple negative breast cancer cells without causing any
cytotoxic effects to the healthy cells.28 Chapters 2 - 4 discuss on how the mesoporous
nanoparticles are used for the therapy against intracellular bacteria, bacteria biofilms and
lung cancers.
1.2.3 Liposomes
Liposomes are another common drug delivery system (DDS) based on one or more
self-assembled concentric lipid bilayers enclosing an aqueous core, where polar head
groups of phospholipids facing inner and outer aqueous phase. This unique feature of the
liposomes facilitates loading and delivery of large payloads of various kinds of drugs.29
For examples, hydrophilic drugs can be loaded into the inner aqueous phase, whereas
hydrophobic drugs are loaded in between the lipid bilayer and amphiphilic drugs reside at
the outer lipid/water interphase. The other important fact is that the loaded drugs are
protected from external environment preventing drug degradation due to exposure to
enzymes, plasma clearance, chemical or immunogenic inactivation of drugs.29
Furthermore, these liposome-based DDSs have become very successful in the clinic
due to their biocompatibility, non-toxic and non-immunogenic nature, structural versatility,
and biodegradability. These liposome-based DDSs have shown increased therapeutic
efficacy of the drugs by enhancing stability of the nanosystems, promoting higher cellular
and tissue uptake, and further increasing the biodistribution of the drugs to the targeted
site.30 The efficient cellular uptake of these liposomes is due to the fact of having
amphiphilic phospholipids which can mimic the natural cell membrane which promotes
excellent interactions between liposomes and mammalian cells.31, 32
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The stability and efficiency of liposomes depends on the selection of lipids, lipid
composition, charge of the lipids and the phospholipid head group and chain length.
Furthermore, the liposomes ability to serve as DDSs depends on the number and rigidity
of lipid bilayers, lipid organization, size, surface charge and surface modification.29 The
surface of the liposomes can be easily modified using a targeting ligand (antibody, peptide,
protein, carbohydrate, PEG and small molecule) or a functionalized imagine agent. Surface
targeting can be classified into passive targeting where the targeting is based on the
properties of the tissue vasculature and active targeting is through receptor specific ligands
conjugated onto the liposome surface to promote cell binding.29
However, there are some limitations of using liposomes solely as DDSs due to their
unstable colloidal structure. Additionally, there is a chance of the loaded drugs to interact
with the liposome phospholipids, which will further challenge liposome stability.
Therefore, the liposomes will be coated around MSNs to enhance their physical stability
to serve as an efficient DDS.
The examples indicated below show how the liposomes are used as drug delivery
vehicles against bacteria. A study by Ma et al. focused on the use of nanoliposomes
encapsulated with tobramycin for in vitro Pseudomonas aeruginosa therapy. They tested
how the liposome size, charge and composition affect the bacterial therapy.33 Furthermore,
Pornpattananangkul et al. studied vancomycin loaded chitosan modified gold nanoparticles
tagged onto the surface of liposomes against methicillin-resistant Staphylococcus aureus
(MRSA).34 Wu and his group reported the use of calcium peroxide and rifampicin
encapsulated liposomes for MRSA treatment. Here they proved that the bacteria toxin
triggered antibiotic release.35
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1.2.4 Targeted drug delivery
Nano-enabled targeted drug delivery is an emerging powerful field for the treatment
of bacterial infections and cancers. Targeted delivery refers to the ligand receptor
interaction after the nanoparticle reached the targeted site of action via systemic
circulation.36 This targeted therapy promotes higher concentration of drug at the site of
interest, thereby reducing dose limited side effects. Also, this targeted therapy will protect
healthy cells from cytotoxic compounds. Nanoparticles, liposomes, dendrimers, micelles,
hydrogels, and mesoporous particles can be surface modified with different targeting
ligands to serve this purpose.37
Targeted drug delivery can be achieved through passive or active delivery. Passive
targeting ensures the encapsulation of the therapeutic agents in a nanosized drug delivery
vehicle to prevent premature drug release and side effects by prolonging systemic
circulation, whereas in active targeting, the nanocarrier or the therapeutic agent is modified
with a tissue or cell specific ligand.38 For example, loading therapeutics agents into MSNs
will be passive targeting and conjugating liposome coated, drug loaded MSNs with a
targeting ligand will be active targeting. Due to the effectiveness of using both passive and
active targeting, the nanoassemblies discussed in Chapters 3 - 5 will be composed of both
passive and active targeting moieties.
Active targeting ensures the drug, genes or theranostics will be delivered to the site
of action. Compared to the free drug or passively targeted DDSs, active targeting can
significantly increase the quantity of therapeutic agents at the targeted site. Proteins,
peptides, small molecules, aptamers, antibodies and glycans (carbohydrates) act as
common targeting moieties.
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There are two main factors to be focused on when using these targeting moieties:
(i) close contact between the target cell and the nanocarrier, and (ii) effective ligandreceptor interaction upon contact.39 After selecting the targeting moiety, it must be
conjugated onto the drug loaded nanocarriers. This can be done by chemical or physical
modification of the nanocarrier surface, which must have appropriate functional groups.
Most of the conjugation chemistries are based on covalent conjugation of targeting ligands
onto the nanoparticles. Most of the chemical reactions focus on (i) carbonyl reactive groups
that react with hydrazide or alkyoxyamine to form hydrazone or oxime bonds, (ii) amino
groups that react with activated carboxylates or imidoesters to form amide or amidine
bonds, (iii) sulfhydryl groups that react with maleimide, haloacetyl, pyridyl disulfide or
gold surface, to form thioesters, disulfides, or gold-thiol bonds and using (iv) click
chemistry where azides reacts with phosphines or alkynes to form amide bonds or triazole
rings.40 There is also another very strong non-covalent interaction that is commonly used
between (strept)avidin and biotin.
A study by Le et al. reported the use of antibiotic loaded polymeric nanoparticles
covalently conjugated with S. aureus antibodies to successfully target S. aureus biofilms.41
Moreover, Ledermann et al. used the most commonly used small molecule, folate tagged
nanoparticles, to target highly expressed folate receptors on cancer cells.42 Also, Cui et al.
reported detection and therapy of gram-negative E. coli and gram-positive S. aureus using
b - galactosidase coated magnetic nanoparticles confirming the use of enzymes as
targeting agents.43
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1.2.5 Bioconjugation on nanoparticle surface
Various bioconjugation techniques are available to surface conjugated targeting
ligands onto the surface of a nanoparticle. These include covalent and noncovalent types
of conjugation. Common covalent conjugation techniques involve conjugation of
functional epitopes such as thiol groups (thiol- thiol), carboxylic acids, primary amines,
maleimides, thiols, aldehydes, hydrazides with functional group on the nanoparticle
surface.40 Noncovalent bonding is based on physisorption or electrostatic attraction of
targeted ligands onto the nanoparticle surface. However, non-covalent attraction is weak
and cannot be controlled. Non-covalent interactions are less desired as there is less control
of the targeting ligand orientation.44 Targeting ligands include aptamers, antibodies,
peptides, protein, and small molecules. For example, Busch et al. reported the
bioconjugation polyclonal antibodies (pAb) against Listeria monocytogenes to gold
nanoparticles (GNPs) through 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) /
N-hydroxysuccinimide (NHS) between carboxyl and amine groups. pAb modified GNPs
were used to detect Listeria monocytogenes.45 Peng et al. studied a rapid, inexpensive and
sensitive colorimetric method to detect Escherichia coli, Pseudomonas aeruginosa , Vibrio
cholerae and Xanthomonas campestris by EDC/NHS assisted coupling of respective
antibodies conjugated onto GNPs.46 Following attachment, the nanocarrier-bioconjugate
functionality can be characterized by UV-Vis absorption, circular dichroism, dynamic light
scattering and gel electrophoresis.47
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1.2.6 Targeting with peptides, and antibody ligands
Peptides are larger than small molecules but smaller than antibodies, with more site
specificity and affinity. Peptides can also be used as therapeutic agents as well as molecular
probes in imaging where they typically bind to the target proteins on the cell membrane.48
Most of the nanocarriers will be chemically modified to react with a unique functional
group of a peptide terminus allowing for site specific binding. Chapter 3 discusses the
covalent binding of a terminal amino group of the peptide LL-37 onto the COOH groups
present on liposomes to successfully target PA14 bacteria that infected mammalian cells.
Furthermore, antibodies have gained much attention in targeting due to their
availability and specificity. However, most of the conjugation techniques lack binding
directionality onto the nanocarrier due to the presence of multiple reactive functional
groups on the antibody. Therefore, orientation of the antibodies on the nanoparticles differs
vastly, reducing its functionality and targeting affinity.
1.2.7 Targeting with small molecules
Small molecules are used vastly as targeting moieties due their low cost, ease of
conjugation and stability. Most of the targeting receptors do not accommodate natural small
molecules that specifically interact with their extracellular domains. Therefore, these small
molecule targets are synthesized based on natural substrates, inhibitors, or inducers.49
These linkers can be conjugated through PEG linkers or covalent bonds. One of the most
commonly used small molecule for cancer therapy is folic acid (Vitamin B9). Folic acid
can successfully conjugate to nanoparticles to target overexpressed folate receptors on
cancer cells.50 Chapter 4 discusses the use of folic acid to target lung cancer cells. These

12

folic acid conjugated nanoparticles showed internalization via receptor mediated
endocytosis and targeted folate receptors on the cancer cells.
Carbohydrates also work as receptor mediated glyco-targets which is based on
endogenous lectin interactions with carbohydrates. However, these carbohydrate
interactions are weak compared to others since they require multiple carbohydrates to form
strong interactions.40
1.2.8 Targeting with enzymes
Bioconjugation of nanomaterials with enzymes has gained much attention due to
their use in biosensors, nanotherapeutics and diagnostics. These bioconjugations have
shown increased protein loading per volume of support, increased stability, reduced
gravitational sedimentation, enhanced enzyme - substrate interactions, decreased lateral
protein-protein and protein-surface interactions.51 When nanoparticles interact with
enzymes, they might change the enzymes' conformation thereby altering the enzymes’
native function. Therefore, checking the enzyme activity on the nanoparticle after enzyme
conjugation is necessary to ensure enzymes' optimum activity. Furthermore, the conjugated
enzymes’ activity depends on the size of the nanoparticle, surface chemistry, surface
curvature, number of enzymes on the nanoparticle, ligands and etc.,52 Therefore, the
following subsections discuss how the enzyme activity changes upon binding to the
nanoparticle surface. It has been suggested that increased diffusion of nanoparticles,
modified microenvironment, higher surface curvature, and increased density of enzymes
can lead to enhanced enzyme activity on the nanoparticle surface.53
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1.2.8.a Change in enzyme activity with the size of the nanoassembly
Covalent conjugation of enzymes and proteins onto the nanoparticles might change
the protein or enzymes’ ability to perform its enzymatic function. Nanoparticle size,
surface curvature and the number of enzymes attached, dictate the enzymes' ability to
function after conjugation onto the nanoparticle (Table 1.1).54 It has been found that the
structure of the enzyme, enzyme adsorption/ conjugation pattern onto the nanoparticle and
thereby the functioning of the enzyme are strongly dependent on the nanoparticle size.55
The smaller the size of the nanoparticle, the higher the surface curvature. This will
ultimately lead to a higher enzymes/surface area ratio and a greater distance from the
nanoparticle surface to the enzyme edge leading to lesser interactions (both coulombic and
hydrophobic) between the nanoparticle and enzymes;56 whereas larger nanoparticles
possess a lower surface curvature (pseudo-flat surface). Therefore, the enzymes tend to
spread through the flat surface leading to stronger interactions with the nanoparticle.51, 57

Table 1.1. Difference in the change of enzyme activity with the size of Nanoassembly.
Smaller nanoparticles
Higher surface curvature

Larger nanoparticles
Lower curvature - pseudo-flat surface

Protein molecule is at a greater distance Protein has more space to spread (larger
from the silica surface – less interactions interaction area)- more damage to the
b/w the particle and protein
secondary structure (interaction energy is
higher for a large interaction area)
Less interaction (both Coulombic and Stronger interactions (higher electrostatic
hydrophobic) between the protein and potential) protein and the particle
smaller nanoparticles
Also, less protein-protein lateral
Higher intramolecular interaction –
interactions
greater lateral-lateral interactions
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1.2.8.b Change in enzyme activity with the density of the enzymes tagged onto the
nanoassembly
The concentration of the enzymes and state of the enzymes on the nanocarrier are
very important factors in determining enzyme's activity on the nanoparticles. Therefore, it
is important to understand the enzyme/protein lateral - lateral interactions. Lateral - lateral
interactions play a role in changing the enzyme activity after conjugation into the
nanocarrier. This can be studied by changing the enzyme amount on the nanocarrier by
controlling the concentration of enzyme binding linker on the nanocarrier. It has been
found when there is an excess amount of proteins on the nanocarrier they tend to interact
with each other rather than interacting with the substrate thereby reducing the
enzyme/protein activity and leading to enzyme unfolding and loss of activity.55, 58 Also, it
will increase protein-protein electrostatic repulsion. Therefore, the reduction of enzymes
on the nanoparticles will lead to decreased lateral interactions with adjacent proteins and
thereby increase collisions with substrates to facilitate enhanced enzyme activity.51, 57
1.2.8.c Change of enzyme kinetics after conjugating enzymes on to the nanoassembly
In order for the nanoparticles to perform their drug delivery or diagnostic tasks, the
enzymes should retain their native structure and function. Therefore, evaluation of enzyme
kinetics before and after conjugation onto the nanoparticles is of utmost importance.55
Enzyme kinetics can be measured using Michaelis-Menten (MM) kinetics, which gives a
better understating of the native enzyme kinetics and the apparent kinetics after conjugation
of enzymes onto nanoparticles. Although MM was developed strictly for freely diffusing
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enzymes and substrates, the apparent kinetics can compare many different systems, such
as the nanoparticle-based enzyme systems. 53
In MM kinetics, the Km (Michaelis constant) is the substrate concentration at which
the rate of the reaction is half of the maximum velocity (Vmax), and Km is a good indicator
of the affinity of the enzyme for a substrate (a lower Km signifies higher affinity). The kcat
parameter is known as the turnover rate, and it describes the fastest rate at which the
enzyme can transform substrate (S) into product (P).53 After conjugation of the enzymes
Km, (Vmax), and kcat values are supposed to change. However, if the values significantly
deviate from the native enzyme that implies the enzyme activity has been destroyed. If the
Km increases and kcat decreases after conjugation, that will imply lower affinity of enzymes
to the substrates.59

Drug delivery platforms for infections and cancers
1.3.1 Treatments of bacteria based infectious diseases
Pathogenic bacteria capable of causing infections have evolved to escape
bactericidal mechanisms in the body. The first physical defense mechanism against
bacterial infections is the epithelial surface of the host which is capable of producing
chemicals that inhibit microbial entry and growth. After entering the body, these microbes
are identified and often killed by mononuclear phagocytes, or macrophages, that reside in
tissues.60 Furthermore, this entry of pathogens leads to an inflammatory response by
accumulating plasma proteins to further defense the pathogenic attack.60 However,
pathogenic bacteria have polysaccharide structures to evade epithelial phagocytosis. For
example, biofilms produced by Pseudomonas are capable of preventing phagocytosis.61
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Furthermore, some pathogenic bacteria have special ways of residing within the epithelium
and protect themselves against antibiotics and host antimicrobial peptides.62 They also can
avoid fusion with acidic lysosomes carrying bacteria degrading enzymes by manipulating
cellular trafficking.60 Also, these bacteria are capable of altering their phenotype to escape
from host immune mechanisms to cause infections.63 This is described in section 1.3.1.a.
Therefore, it is clear that a nanotechnology driven approach using therapeutic
nanoparticles such as liposomes, inorganic nanoparticles, dendrimers, and polymeric
nanoparticles to selectively target and destroy pathogenic bacteria has gained much
attraction in antimicrobial treatment.64 These nanotechnology-based platforms provide the
advantage of using the existing antibiotics by enhancing hydrophobic drug solubility,
increasing bioavalability, modulating drug release characteristics, targeting drugs to the
desired site, delivering multiple drugs at the same time and offering stealth properties for
immune evasion.65-69 Due to these unique features, they are able to improve the
pharmacokinetic profile and therapeutic index (range of drug dose where the medication is
effective without causing any adverse effects) of drug payloads when compared with free
drug counterparts.2, 70 This will further minimize systemic drug exposure and development
of resistance.
1.3.1.a Antimicrobial Resistance (AMR) /Multi drug resistance in bacteria (MDR)
Developing antibiotic resistance was identified as one of the top ten global public
health threats by the WHO in 2021 due to the rise of resistance to antibiotics.71 Most
frequent problematic species among the gram-positive bacteria are Staphylococcus
aureus, Enterococcus faecalis, and Streptococcus pneumoniae. Among the gramnegative strains, Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, and

17

Acinetobacter baumannii have been the most common displaying multi drug resistance.72
MDR is transmitted genomically and most commonly accompanied by an extra
chromosome in genetic elements through horizontal gene transfer.73 Bacteria use protective
mechanisms, such as production of degrading enzymes, having efflux pumps, low
permeability of the outer membranes specifically in gram negative bacteria and
modification of targets to avoid antibiotic entrance and activity.74 Furthermore, antibiotic
resistance has started spreading due to excessive use of antibiotics, use of multiple broad
spectrum antibiotics, misuse of antibiotics and globalization.72 Due to the rapid
development in antibiotic resistance in bacteria, there is decreasing interest in the
pharmaceutical industry to invest in research and development for new antibiotic drug
discovery.75 Therefore, it is essential to find innovative ways to use existing antibiotics to
treat bacterial infections.
In 2019, the CDC evaluated MDR-Pseudomonas aeruginosa (PA) as a serious
bacterial threat. In 2017, MDR-Pseudomonas aeruginosa was responsible for 2,700
fatalities and $767M healthcare costs in the US.76 Pseudomonas infections are usually
treated with a combination of antibiotics, such as antipseudomonal beta-lactams and
aminoglycosides.77 Exposure to higher doses of various antibiotics and cross-resistance
between antibiotic agents has led to the MDR- PA development.78 PA specifically has
altered chromosomal mutations and transferable resistance mechanisms which assist in
drug resistance.79,80 MDR- PA occurs frequently in patients with cystic fibrosis where
continuous exposure to PA leads to sequential emergence of resistance to multiple
antibiotics. Patients with MDR-PA infections are at an increased risk of receiving
inadequate initial antimicrobial therapy and the delay in effective antibiotic therapy is
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associated higher mortality rates in critically ill and immunocompromised patients.78, 79
Therefore, PA has been identified as the second most common cause of pneumonia
(18.1%), the third most common cause of urinary tract infection (16.3%) and the eighth
most frequently isolated pathogen from the bloodstream (3.4%).81
Researchers have used multiple nano-based drug delivery systems to eliminate
Pseudomonas infections by using the existing antibiotics in an effective manner. Arora et
al. reported the use of titanium oxide nanoparticles in combination with the antibiotics
ceftazidime and cefotaxime to eradicate MDR- Pseudomonas aeruginosa with UVirradiation.82 Long et al. studied the use of molecularly imprinted polymeric nanoparticles
to specifically target the lipopolysaccharides of Pseudomonas aeruginosa.83-85
1.3.1.b Intracellular bacteria
Intracellular pathogenic bacteria can develop a relationship with a susceptible host
via an intracellular multiplication process.84, 85 Bacteria finds their way to a host through
an open wound, airways or through skin and multiply within the host without getting caught
by the host defensive mechanisms.84 This will lead to a bacterial infection.86 These bacteria
will localize cytoplasmically in the phagosomes (Listeria monocytogenes), localize in
nonacidic vacuoles of endosomes (Mycobacterium spp.) or localize in intra-lysosomal
acidic or hydrolytic compartments (Yersinia).84 They use macrophages and phagocytes like
epithelial and endothelial cells as sites of infection.86 Examples of intracellular pathogens
are

Brucella

abortus, Listeria

monocytogenes, Chlamydia

trachomatis, Coxiella

burnetii, Mycobacterium tuberculosis, and Salmonella enterica, which cause brucellosis,
listeriosis, tuberculosis, and salmonellosis.87 In this thesis Pseudomonas aeruginosa (PA)
was studied as an opportunistic human pathogen, which is responsible for various acute
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infections and also a major cause of mortality in cystic fibrosis and immunocompromised
patients.88
PA can enter the human body through multiple passages and can cause different
types of pathogenic diseases (pneumonia, endocarditis, meningitis). Epithelial surfaces,
such as the cornea (contact lenses wear), skin (burn wounds), airways, (intubated and cystic
fibrosis patients), are the main targets for infection where other bacteria are resisted and
cannot infect.89-92 PA infection has become notoriously difficult to treat using available
therapies, as PA has a large number of genes devoted to survival and adaptation including
developing resistance to antibiotics.93 Therefore, it has been very difficult to target and
inhibit intracellular PA.
Kwon et. al. reported the use of porous silicon nanoparticles loaded with
antibacterial tandem peptides to kill intracellular PA.94 These particles were able to
successfully eradicate lung infection of PA in infected mice over untreated mice. Salomoni
et al. studied the use of antimicrobial silver nanoparticles to treat two acquired nosocomial
infectious strains of PA.95 This study showed effective treatment of PA spp. over traditional
antimicrobial agents with enhanced microbial activity.

However, these nano based

deliveries lack targeted delivery of antibiotics and controlled release at the site of infection.
In Chapter 2 a nanoassembly based antibiotic delivery system targeting intracellular PA
will be introduced.

1.3.1.c Bacterial biofilms
Bacterial biofilms consist of a cluster of bacteria, which is attached to a surface or
to each other and embedded in a protective self-produced extracellular polymeric

20

substances (EPS) matrix. Furthermore, biofilms have developed survival strategies against
host immune mechanisms.96 This matrix is mainly composed of polysaccharides such as
alginates, other biomolecules include proteins, extracellular DNA, and lipids. In addition,
they have virulence factor production such as rhamnolipids, pyocyanin which can further
stabilize the biofilms.97 It has been reported that rhamnolipids can form a heat stable
rhamnolipid shield around the bacteria within the biofilm. Furthermore, quorum sensing
(QS), a form of bacteria communication within the biofilms is present within the bacteria
residing within the biofilm. P. aeruginosa has 3 QS systems where each system contributes
to the virulence factor production (e.g., rhamnolipids, elastase, exotoxins ) and stabilization
of biofilms.97 These cell associated or secreted compounds known as virulence factors are
produced as a result of survival strategies for pathogens to evade immune defense to
progress with pathogenesis.98 Bacteria residing within the biofilm are difficult to treat
because of these protective mechanisms such as these outermost EPS matrix, QS systems
and virulence factors . These biofilms are the main cause of persistent infections in medical
implants, urinary tract infections, chronic obstructive pulmonary infections, chronic
wounds, and cystic fibrosis.99
Wan et al. reported the use of alginate lyase guided silver nanocomposite for
treating P. aeruginosa biofilms.100 They have shown low pH- dependent drug release at
the acidic niches of biofilm. Also, they were successful in treating P. aeruginosa biofilms
from mouse lungs without causing any serious side effects. Also, Ho et al. reported the use
of squalenyl hydrogen sulfate nanoparticles (SqNP) co-loaded with tobramycin and an QS
inhibitor to eliminate P. aeruginosa bifilms.101 These drug-loaded SqNPs showed an
improved biofilm penetration and enhanced efficacy in relevant biological barriers
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(mucin/human tracheal mucus,biofilm), leading to complete elimination of PA biofilms at
16-fold lower Tob concentration than Tob alone.
An engineered nanoassembly system targeting P. aeruginosa biofilms will be
discussed in Chapter 3. A drug and a QS inhibitor were co-loaded to MSNs and covered in
a rhamnolipid based liposome to permeate through the rhamnolipid shield of the biofilms.
Alginate lyase is conjugated to the exterior of the liposome to enable the degradation of
the alginate physical barrier of the biofilms.
1.3.2 Drug delivery platforms in treating carcinomas
Cancer has become the second leading cause of human mortality and the prevailing
treatment options have gaps that has to be addressed. Using drug delivery platforms to treat
cancer have gained traction due to their enhanced permeability, improved stability,
biocompatibility, targeting ability, reduced side effects, and retention effects.2,

102-104

Furthermore, they have shown increased capability to overcome cancer-related drug
resistance by targeting drug resistance mechanisms such as the hypoxic environments of
the cancer cells, drug efflux transporters, and defective apoptotic pathways.105 One of the
major drawbacks of small molecule based chemotherapy treatments is their inability to
target only tumor tissue, leading to serious side effects including hair loss, bone marrow
suppression, fatigue, weight changes, loss of bone density, urinary and fertility issues and
gastrointestinal reactions.106-108 Therefore, the ability of drug delivery platforms to act only
at the tumor location is very desirable in cancer treatment. 105
Delivery platforms targeting non-small cell lung cancers (NSCLS) were studied in
the course of this work. Lung cancer, which is the number one cancer killer in both women
and men worldwide, can be broadly divided into small cell lung cancer (SCLC) and non22

small cell lung cancer (NSCLC), with NSCLC being the most commonly diagnosed type
(A549 cells).109 Current treatment options for NSCLC include surgery, targeted therapy,
chemotherapy, and radiation therapy. Systemic treatments (chemotherapy, targeted
therapy, or immunotherapy) are required for the vast majority of patients.110
In general, the treatment for NSCLC typically is platinum-based chemotherapy,
cisplatin or carboplatin doublets.111 However, nano drug delivery systems (NDDS) have
shown increased potential for the delivery of active pharmaceuticals for NSCLC.111
There are organic nanoparticles (liposomes, polymers and dendrimers), inorganic
nanoparticles (gold, silica, carbon nanotubes, magnetic nanoparticles and quantum dots)
and hybrid nanoparticles (lipid-polymer, organic-inorganic and cell membrane coated)
used as drug delivery vehicles for cancers.111,

112

Doxil is the first nanoliposome

formulation containing doxorubicin approved by FDA in 1995 to treat cancers.113
Furthermore, Lipoplatin

was developed by encapsulating cisplatin within lipid

nanoparticles to reduce adverse effects associated with cisplatin, such as acute
nephrotoxicity and ototoxicity.109

Wang et al. reported the use of Afatinib (irreversible

epidermal growth factor inhibitor) loaded, Transferrin (Tf) modified redox-sensitive lipidpolymer hybrid nanoparticles for targeted inhibition of NSCLC cells in in vitro and in vivo
studies.114 Tf is a glycoprotein which can target and conjugate with overexpressed
transferrin receptors on lung cancer cells. This study was able to confirm significant
inhibition of tumor growth with this nanoassembly.114 Furthermore, Ren et al. reported the
use of the highly specific and strongly effective targeting peptide (MT2-MMP) conjugated
with fluorescent mesoporous silica nanoparticles loaded with the anticancer drug
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Doxorubicin to target NSCLC cells.115 This nanoassembly has shown increased targeting
affinity following a boost in drug release in an acidic tumor environment.115
A mesoporous silica core shell nanoassembly was loaded with the ROS inducing
drug paclitaxel and coated with a liposome layer to avoid premature drug release and
improve the stability. Two different cancer targeting ligands were attched to improve the
targeting affinity. The folic acid (FA) and epidermal growth factor receptor (EGFR)
targeting peptide GE11 were used as a dual biomarker target for cancer cells. We
hypothesize that ROS inducing drug and dual targeting will enhance the chemotherapeutic
effects towards cancer cells. The results are presented in Chapter 4.
Diagnostics
1.4.1 Nanomaterials in diagnostics
For the past few decades nanomaterials have shown great strides in diagnostic
platforms and biosensing based on molecular recognition of enzymes, catalytic antibodies,
aptamers, DNA, RNA, and any labeled biomolecule.116
Unique characteristics of nanomaterials, such as optical, fluorescent, electrical
magnetic properties can be used in enhancing sensitivity towards a particular molecular
recognition interaction.117 Specifically, plasmonic nanomaterials, such as gold and silver
nanoparticles are widely used for bacterial detection.118 These nanoparticles can be
modified with recognition elements (e.g., antibody, phage, or aptamer), to detect particular
bacteria species.119 Once these targeting ligands or recognition elements bind to bacteria,
these nanoparticles show plasmon peak shift or aggregation, leading to color changes that
are visible to the naked eye.119 Furthermore, the specific binding of nanoparticles to
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bacteria is also monitored using spectrometry, optical imaging, and electrochemical
sensing.120
When it comes to bacteria detection, magnetic nanoparticles (MNPs) are used most
of the time. MNPs such as Fe3O4 and γ-Fe2O3 are used in clinical diagnosis of cancer,
neurological diseases and cardiovascular diseases due to their ability to enhance contrast
for magnetic resonance imaging (MRI), biocompatibility and excellent magnetic
properties.121 MNPs are attached to antibodies specific to a bacterial strain and once the
nanoparticle-bacteria conjugate forms it can be removed using an external magnetic
field.122
Fluorescence immunoassays are also commonly used for bacteria detection that
uses fluorescent labels such as Fluorescein isothiocyanate (FITC) on nanoparticles. The
conjugation of these fluorescently labeled nanoparticles with the proteins or other
biological materials of bacteria facilitates the diagnosis of bacteria.123 Chapters 2 - 4
describe how these fluorescently labeled nanoparticles are used for the detection of
Pseudomonas aeruginosa.
1.4.1.a MNPs in bacteria diagnostics
Most MNPs are iron oxide based for example: Fe3O4 and γ-Fe2O3 are considered as
ideal MNPs due to their stability, biocompatibility, high surface area to volume ratio and
super-paramagnetic properties. Due to their characteristic magnetic properties, and
peroxidase like activity they have been the focus for diagnostics and therapy against
bacteria.124 MNPs in the past have been modified to selectively target specific strains of
bacteria to facilitate rapid efficient separation.125 The surface of MNPs has been modified
with aptamers, antibodies, antibiotics, antimicrobial peptides, and bacteriophages.
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Shen et al. reported the use of mesoporous TiO2 - coated MNPs modified with a
targeting aptamer which are incubated with a blood sample carrying S. aureus and/or E.
coli. They have shown enhanced capturing efficiency at low bacterial concentration (102000 CFU/mL) within 2 hours.126 Furthermore, Jae at al. reported the use of an aptamer
adsorbed onto Fe3O4 MNPs for the diagnosis of a special protein (MPT64) of
Mycobacterium tuberculosis.127 They used the stable and tunable peroxidase-like activity
of MNPs.127
Naked Fe3O4 MNPs are prone to oxidize in air and to lose their magnetic properties.
Therefore, MNPs have been coated with polymers, carbon, metal oxides and noble
metals.128 Silica was used as an inert coating material for MNPs as it increases the
bioavailability, biodegradability, and stability of the particles by preventing aggregation of
super paramagnetic MNPs in liquid media.128, 129 Also, the silanol groups provided by silica
coating will further facilitate functionalization with organosilanes.130 Silica coating can be
achieved through either the Stöber method or reverse microemulsion.131 Silica coated
MNPs have been widely used in extraction and purification of genomic DNA. Bai et al.,
studied the use of amino-rich silica coated MNPs to capture Salmonella genomic DNA.
They have used 3-aminopropyltriethoxysilane (APTES) for amine modification of silica
coated MNPs using the reversed micro emulsion method.132
The joint project is based on a silica coated MNP based nanoassembly modified
with lectins that can recognize specific carbohydrate epitopes in Mycobacterium cell wall.
The data of this shared project have been presented in a dissertation by Unnati S. Patel
UAH April 15th, 2022.133
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2. CHAPTER 2

TARGETED ANTIBIOTIC THERAPY USING A LIPID COATED
MESOPOROUS SILICA CORE SHELL NANOASSEMBLY FOR
INTRACELLULAR AND EXTRACELLULAR PSEUDOMONAS THERAPY

Introduction

This chapter focuses on the synthesis of a targeted mesoporous core-shell
nanoassembly to target intracellular Pseudomonas aeruginosa (PA). PA is an opportunistic
pathogen, which causes serious lung infections in immunocompromised patients.
Traditional oral intake of large quantities of small-molecule antibiotics to treat bacterial
infections leads to off-target toxicity and development of drug-resistant bacteria. Improved
delivery systems of antibiotics to the targeted site of bacterial infections would help reduce
the need for a high intake of antibiotics. Infections with PA have been treated using two
antibiotics from different classes (beta-lactam and an aminoglycoside, carbapenems with
antipseudomonal quinolones) to reduce the risk of development of antibiotic resistance.77
In 2017, there were 32600 reported hospitalizations, 2700 reported deaths due to PA
infections, with reported healthcare cost in the US of $767 million.76 PA is known to
colonize tissue and form stable biofilms, which makes treatment of PA difficult.134
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The outer membrane of PA has low permeability to most antimicrobial agents, which
makes traditional treatment with small molecule antibiotics very challenging. 135, 136 135, 136
Therefore, drug loaded nanoparticles have been explored in the past to treat PA based lung
infections.134, 137, 138
Colistin (Col) is a bactericidal cyclic polycationic peptide used as a last resort
treatment of multidrug resistant (MDR)-PA strains.5,13 Many clinical studies have shown
that Col is highly efficacious against PA infections.139-141 Col acts by interacting with
anionic lipopolysaccharides (LPS) in the outer membrane (OM) of gram-negative bacteria
like PA displacing Ca2+ and Mg2+ from the OM. This dramatically decreases the stability
of the OM and increases the permeability of the OM leading to cytoplasmic leakage and
subsequent bacterial death.142 However, a common side effect of treatment with Col is
nephrotoxicity and neurotoxicity,143 which has somewhat restricted the use of Col in the
treatment of MDR-PA.143 To overcome the above side effects, Col will be encapsulated in
the engineered nanocarrier to reduce off target toxicity. Col is first entrapped within MSN
(Col@MSN).144
The presence of negatively charged silicate on the surface of MSN offers
electrostatic loading of cationic drug molecules, which makes them ideal carriers for
cationic antibacterial peptides such as Col. However, the porous structure does not offer
controlled release and lacks targeting ligands. To overcome these issues MSNs are coated
with biocompatible organic shells, such as liposomes or cell membranes which facilitate
attachment of targeting ligands for specific cell recognition and improve biocompatibility.
Yang et al. used lipid encapsulated gentamicin loaded MSNs to successfully target
Staphylococcus aureus by using the secretion of bacterial toxins for the disruption of the
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lipid layer exposing the drugs to the bacterial local environment.145 The present work
utilizes an environmentally responsive liposomal shell to wrap Col loaded MSNs
(Col@MSN@LL). The liposomal outer shell prevents premature drug release and
increases the stability of the drug containing MSN by reducing aggregation in solution.146,
147

Liposomal degradation will be triggered in the presence of bacteria that secrete enzymes

such as lipases and phospholipases.144, 145, 37 ,148
Active targeting with a drug delivery nanocarrier involves the binding of target
ligands such as antibodies, aptamers and peptides to the exterior of the nanocarrier to
promote specific interactions between the diseased tissue and the carrier.145, 149, 150 In this
work, the antimicrobial peptide (AMP), LL-37 was used as the targeting ligand to target
bacteria.145,

151,152

This amphiphilic peptide was known for recognition of the outer

membrane (OM) of PA. The positively charged portion interacts with the negatively
charged phospholipid A of lipopolysaccharide (LPS) of the OM (Scheme 1).153
The nanocarrier synthesized Col@MSN@LL-(LL37) was shown to be successful
in simultaneous targeting and inhibition of the growth of PA14, the PA clinical strain used
in this work. It was found that the Col encapsulated in Col@MSN@LL-(LL37) is 6.7-folds
more efficacious than the free Col. Furthermore, Col@MSN@LL-(LL37) was able to
inhibit PA even in the co-infected human lung epithelial carcinoma cells (A549 cells) is
shown.
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Scheme 2.1. Hypothetical mechanism of action of Col@MSN@LL-(LL37) upon
interaction with PA14.

Materials
Cetyltrimethyl ammonium bromide (CTAB, >99%), tetraethylorthosilicate (TEOS,
98%), Colistin (Col), phosphate buffer saline (PBS, 0.5x), ammonium hydroxide (NH4OH,
25%), hydrochloric acid (HCl, >99%), sulfo-N-hydroxysuccinimide (sulfo-NHS, 99%),
Rhodamine B isothiocyanate (RITC) were purchased from Sigma-Aldrich (St. Louis,
USA). 1,2- dipalmitoyl sn-glycero-3-phosphocholine (DPPC), 1,2-dioleoyl- sn -glycero-3phosphoethanolamine (DOPE), cholesterol (ovine) and 1,2-distearoyl- sn -glycero-3phosphoethanolamine-N- [carboxy(polyethylene glycol)-2000] sodium salt(DSPEPEG(2000)CA) and the mini-extruder kit were purchased from Avanti Polar Lipids
(Alabama, USA). 1-ethyl-3-(3 dimethylaminopropyl)- carbodiimide (EDC) was obtained
from (Alfa Aesar, USA). The peptide LL-37 was obtained from ProteoGenix
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(Schiltigheim, France) (LL37-LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES).
A549 lung cancer cells were purchased from American Type Culture Collection (ATCC,
CCL-185)

(Virginia,

USA).

(3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium

Bromide) (MTT) cell proliferation kit, live/dead® BacLightTM bacterial viability kit,
Hoechst, 4′,6-diamidino-2- phenylindole (DAPI) and calcein AM were purchased from
ThermoFisher Scientific (Massachusetts, USA). Ham’s F-12K nutrient mixture with Lglutamine (F-12K, 1X), fetal bovine serum (FBS, 10%), trypsin EDTA (2.21 mM) and
Penicillin Streptomycin (Pen-Strep, 1X) were obtained from Corning (New York, USA).
The particle hydrodynamic diameter was evaluated by dynamic light scattering
(DLS) Malvern Zetasizer, Malvern Panalytical INC., (Massachusetts, USA). Nitrogen
adsorption−desorption was performed using a surface area and porosity analyzer (Autosorb
iQ-C-MP/XR, USA). Thermogravimetric analyses were performed by Discovery Q550 TA
Instrument (Massachusetts, USA). All the absorbance and fluorescence readings were
taken from Molecular Devices SpectraMax M2 multimode microplate reader (Silicon
Valley, USA). Fluorescence microscopic images were taken by CKX53 inverted
fluorescence microscope (Olympus, USA). The transmission electron microscopy (TEM)
images were taken from the FEI Tecnai Osiris™ (USA) operating at 200 kV in Vanderbilt
University. The FT-IR spectra were taken by Nicolet iS50 ATR FT-IR ThermoFisher
Scientific (New Jersey, USA).
The mammalian cells were grown in a CO2 incubator and the PA14 was cultured
in a class II biological safety cabinet (ThermoFisher Scientific). Sterile media, sterile
glassware and sterile disposables were used for all experiments. Unless specifically
mentioned otherwise all media and glassware were sterilized using a bench top BioClave
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liquid sterilizer (New York, USA). The viable bacteria count was determined from the
Corning cyto smart automated cell counter (USA). The PA14 clinical strain was kindly
donated by Dr. Tatyana Sysoeva from the Department of Biological Sciences, UAH.

Methods
2.3.1 Synthesis of MSNs
MSNs were prepared using CTAB template method with some modifications
(Figure 2.1).154

155

TEOS was used as the silica source. CTAB (204 mg, 4 mmol) was

dissolved in 140 mL of water and TEOS, (1688 µL, 7.6 mmol) was added dropwise to the
mixture NH4OH (25 v/v%, 1688 µL) was then added to the mixture and stirred overnight
at room temperature. On the following day, the white turbid solution was separated by
centrifugation at 12000 rpm for 10 min. After removing the supernatant, the solid
precipitate (MSNs) was resuspended in water and centrifuged at 12000 rpm for 10 min.
This was repeated three times. To remove the excess CTAB, MSNs were centrifuged and
resuspended in 50 mL of ethanol with 200 µL of concentrated HCl. This mixture was
stirred at 60 °C for 12 hours. The resulting product was purified three times with ethanol
by centrifuging at 12000 rpm for 10 min. The size of MSNs was characterized through
DLS and TEM.

2.3.2 Col encapsulation in MSN (Col@MSN)
MSNs were loaded with Col by mixing 20 mL of MSN (10 mg/mL) with Col (20
mg, 17 µmol). This mixture was stirred overnight at room temperature. Excess Col was
removed by centrifugation at 5000 rpm for 5 min, yielding Col@MSN.
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2.3.3 Synthesis of Silica nanoparticles (SNP) and Col loading
SNPs were synthesized using a modified Stöber protocol, which requires hydrolysis
and subsequent condensation of TEOS in the presence of NH4OH.156 TEOS (0.8 mL) and
NH4OH (2.8 mL, 6.25 v/v%) were added to ethanol (34 mL) and stirred overnight at room
temperature. The product was purified three times with ethanol. Thereafter, SNPs were
loaded with Col, by mixing 20 mL of SNP (10 mg/mL) with Col (20 mg, 17 µmol), and
stirring overnight at room temperature. Excess Col was removed by centrifugation at 5000
rpm for 5 min, yielding Col@SNP.
2.3.4 Liposome preparation
Liposomes were prepared as described by Yang et al.145 Briefly, DPPC (15 mg, 20
µmol), DOPE (1.25 mg, 1.7 µmol), cholesterol (7.5 mg, 3.2 µmol), and DSPEPEG(2000)CA (1.25 mg, 0.45 µmol) were dissolved in 3 mL of chloroform and evaporated
in a rotary evaporator, which yielded a thin lipid film. The lipid film was rehydrated in 2.5
mL of PBS (0.5X, pH 7.4) at a lipid concentration of 10 mg/mL and extruded 15 times
through a polycarbonate membrane (pore size 400 nm) using the mini extruder. Resultant
liposomes were stored at 4 °C until further use.
2.3.5 Modification of liposomes with LL-37
LL-37 was conjugated to the exterior of the liposomes by EDC/NHS activation
chemistry (Figure 2.3). Liposomes containing DSPE-PEG (2000) CA (2.25 x 10-1 mmol)
were activated with EDC (2.25 mmol) and sulfo-NHS (5.6 mmol) for 2 h at 37 °C.
Thereafter, LL-37 (0.1 mg, 0.02 µmol) was added to the activated liposomes in a molar
ratio of 1:10. The mixture was incubated for 24 h at 37 °C. At the end of the incubation
period, LL-37-modified liposomes (LL-(LL37)) were purified by centrifugation at 12000
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rpm for 30 min at 4 °C and resuspended in PBS (pH 7.4). The purified product was
lyophilized and stored at −20 °C until further use.
2.3.6 Liposome encapsulations of Col@MSN
To prepare liposome coated Col@MSN, 50 mg of Col@MSN was resuspended in
liposomes (2 mL, 25 mg/mL) in PBS and mixed for 20 min on ice. Liposome coated
nanoassembly (Col@MSN@LL) were separated from empty liposomes by centrifugation
at 12000 rpm for 5 min and repeatedly (3x) washing in PBS. The resultant Col@MSN@LL
was lyophilized at −20 °C until further use.
2.3.7 Characterization through TEM and DLS
The ultrastructure of bare MSNs, Col@MSN, and Col@MSN@LL-LL37 was
examined through TEM. 200 mesh carbon thin film coated Cu grids were used. The grid
was drop casted using a diluted solution (ca. 5 mg/mL) of material and left to vacuum dry
overnight and was visualized using TEM operating at 200 kV. The hydrodynamic size and
zeta potential were measured using DLS and presented together with standard deviation.
2.3.8 Surface area and pore volume determination of MSNs and Col@MSN
The surface area of MSN and Col@MSN were determined using the
Brunauer−Emmett−Teller (BET) method. Using the surface area and porosity analyzer
Autosorb iQ-C-MP/XR (Quantachrome, USA).

The cumulative pore volume was

calculated from the adsorption branch of the isotherm using the Barrette−Joyner−Halenda
(BJH) model. A 100 mg of sample was used for analysis.
2.3.9 TGA of Col content in Col@MSN
TGA was carried out under argon (99.999%) where dried Col@MSN (ca. 1 mg)
was heated at a rate of 5 oC/min to 100 °C and then kept isothermal for 15 min followed
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by 5 oC/min ramp to 700 °C. The Col encapsulated in Col@MSN was calculated by the
analyzing the percentage weight loss difference between MSN and Col@MSN.
2.3.10 Col release studies from Col@MSN@LL-(LL37)
The release profile of Col from Col@MSN@LL-(LL37) was obtained by
ultraviolet−visible (UV−vis) light absorbance using the multimode microplate reader
equipped with a UV−vis detector. Briefly, Col@MSN@LL-(LL37), 20 mL (10 mg/mL)
was dispersed in 10 mL PBS (0.5X) and incubated while shaking at 200 rpm at 37 °C. An
aliquot of 1 mL of solution was withdrawn at predetermined time intervals and filtered
through a 0.5 µm at nylon syringe filter (ThermoFisher scientific). The tube was refilled
with an equal amount of PBS at each withdrawal. The Col content in the filtrate was
determined by measuring the maximum absorbance at 220 nm.
2.3.11 Morphological characterization of bacteria
Morphological changes in bacteria upon interaction with Col@MSN and
Col@MSN@LL-(LL37) assemblies were assessed by TEM. PA14 (107 CFU/mL), was
incubated with Col@MSN and Col@MSN@LL-(LL37) (20 μg/mL) for 5 h and
centrifuged at 5000 rpm for 10 min. The obtained precipitate (nanoassemblies interacted
with PA14) was fixed with 2.5% glutaraldehyde for 18 h at 4 °C. Following washing the
precipitate for three times with PBS, TEM grids were prepared. The sample coated TEM
grids were dehydrated in a graded series of ethanol (30%−100%) for 30 min and imaged
by TEM.
2.3.12 Determination of MIC of nanoassemblies
PA14 was cultured in tryptic soy broth (TSB) on a shaking incubator (200 rpm) at
37 °C. 200 μL of fresh tryptic soy broth and 20 μL of each sample (Col, Col@MSN,
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Col@MSN@LL and Col@MSN@LL-(LL37)) having Col concentrations of 0.1-1000
mg/mL were added to a 96 well plate. Then 10 μL of PA14 (107 CFU/mL) was added into
each well and shaken at 37 °C in a shaking incubator for 18 h. On the following day the
viability of bacteria was determined by cell viability WST-8 colorimetric assay. The assay
was performed by incubating 170 μL of sterile broth, 20 μL of each sample (see above)
incubated with bacteria and 10 μL of coloring agent, WST-8 at 37 °C on a shaker bed for
2 h. The absorbance was recorded at 460 nm. The student's t-test was performed to
determine the mean difference between the free drug Col and the final nanoassembly
Col@MSN@LL-(LL37).
2.3.13 Live/dead assay
Live/dead assays were carried out using a kit according to the manufacturer’s
instructions. PA14 (106 CFU/mL) treated with Col, MSNs, Col@MSN, Col@MSN@LL
and Col@MSN@LL-(LL37) at their MIC concentrations were collected by centrifugation
at 8000 rpm for 5 min after 18 hrs of incubation. Thereafter, the bacteria were stained with
SYTO 9 and propidium iodide (PI) for 30 min at 37°C and visualized with an inverted
fluorescence microscope.
2.3.14 A549 cell proliferation
A549 cells were grown in T75 flasks in complete growth medium. Complete
growth medium was prepared by mixing Ham’s F-12K nutrient mixture with L-glutamine
(F-12K) (1X, 445 mL), FBS (10%, 50 mL) and Pen-Strep (1X, 5 mL) followed by sterile
filtration. The cells were grown in 20 mL of fresh and prewarmed (37 °C) medium at 37
°C in a humidified atmosphere of 5% CO2. Cell viability was assessed by Trypan blue
assay and counted using an automatic cell counter.
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2.3.15 Cellular uptake of Col@MSN@LL-(LL37)
In order to monitor the cellular uptake of nanoparticles by fluorescence microscopy,
MSNs and Col@MSN@LL-(LL37) were labeled with the red fluorescent dye RITC. A549
cells (103 cells/mL) were cultured in a 6-well plate for 24 h until complete adhesion occurs.
After adhesion and confluency (~ 90%) were achieved, the cells were incubated with MSNs
(25 μg/mL) and Col@MSN@LL-(LL37) (25 μg/mL) for 0.5, 1.0 and 3.0 h at 37 °C. The
cells were washed three times with cold PBS and stained with DAPI staining for 10 min
and calcein AM (10 µM) staining for 30 min at 37 °C. Afterwards, the samples were
analyzed by fluorescence microscopy.
2.3.16 Intracellular antibacterial activity
A549 cells (103 cells/mL) were seeded on 24 well plates and cultured overnight. A
volume of 10 µL PA14 (45 ´103 CFU/mL) was added to each well and incubated for 2
hours. After incubation, the supernatant was discarded, and the infected cells were washed
twice with PBS (1X). Then the mammalian cell culture medium was replaced with a
medium supplemented with 30 μg/mL Col to kill the remaining extracellular bacteria
without affecting the intracellular bacteria. The infected A549 cells were cultured in fresh
medium in the presence of Col, MSN, Col@MSN, Col@MSN@LL and Col@MSN@LL(LL37) at a Col concentration of 2 μg/mL. After 24 h of incubation the infected A549 cells
were lysed, and the lysate was plated on tryptic soy agar (TSA). The intracellular bacterial
survival was determined by counting the bacterial colonies. The student's t-test was
performed to determine the mean difference between the free drug Col and the final
nanoassembly Col@MSN@LL-(LL37).
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2.3.17 A549 cell viability assays
Mammalian cell viability was evaluated by using a MTT assay. First, A549 cells were
seeded onto 24-well plates at a density of 103 cells per well. After 24 h, they were incubated
with different concentrations (0.1- 1 mg/mL) of Col, Col@MSN, and Col@MSN@LL(LL37) for 24 h. Then, 10 μL of the MTT solution (1 mg/mL) was added into each well,
and the cells were further incubated for 4 h. Afterwards, the culture medium was discarded,
and 150 μL of DMSO was added into each well. The absorbance intensity was determined
at 490 nm by a microplate reader. Results were presented as the percentage viable cells
with respect to untreated control cells.

Results & Discussion
2.4.1 Preparation and Characterization of Col@MSN@LL-(LL37)
In this study, a targeted drug delivery nanoassembly was created using a liposome
encapsulated

MSN

nanostructure

loaded

with

an

antibacterial

peptide,

Col,

(Col@MSN@LL). The surface of the liposomes was tagged with PA targeting LL-37
peptide to results in the final nanoassembly (Col@MSN@LL-(LL37)) (Scheme 2.2).

38

Scheme 2.2. Schematic illustration of synthetic route and application of the
nanoassembly (a.) Synthetic route of Col@MSN@LL-(LL37), final nanoassembly.
MSNs were prepared following surfactant-template method as described in section
2.3.1.155 TEOS was used as a hydrolytic inorganic silica precursor and the surfactant CTAB
as the porogen species.144 The CTAB forms nanomicelles, which act as a framework for
the growth of TEOS-based silica shell (Figure 2.1). CTAB acts both as a stabilizer and
mesostructural-directing agent. Base catalyst NH4OH hydrolyzes TEOS to silicate.157 The
negatively charged silicates condense on the positively charged CTAB micelles to form a
silica network (Figure 2.1). The removal of CTAB will leave pores in the material leading
to formation of MSNs.158 Excess CTAB was removed by reacting with concentrated HCl
and repeated centrifugation and purification in ethanol. Purified MSNs were finally redispersed in water (Figure 2.1).
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Figure 2.1. Synthesis of Mesoporous Silica Nanoparticles (MSN)s.

Following synthesis of the MSNs, they were loaded with the antibacterial peptide,
Col (Figure 2.2). Cationic antibacterial peptide, Col, is popularly used as a last resort
treatment for PA infections.94, 159 Col was loaded into the pores of MSNs electrostatically
taking advantage of the negative surface charge of silica and cationic charge of Col. Col
recognizes the LPS of the OM in gram-negative bacteria.160-162 The initial binding is
facilitated by long-range electrostatic interactions between the negatively charged
phosphates of LPS and the positively charged cationic diaminobutyric acid of Col. After
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initial electrostatic attraction, the binding progresses through the hydrophobic interactions
between the hydrophobic tails of the lipid A of LPS and the hydrophobic domains of Col.162
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Figure 2.2. Structure of Colistin peptide.

Following, the Col loaded Col@MSN was encapsulated within a liposome layer
(Col@MSN@LL) as explained in the methods. Herein, the amphiphilic phospholipids selfassemble around the Col@MSNs to create spherical lipid layer (LL). The –NH2 moieties
of the lipid DPPC provides hydrophilicity to the bilayer, which allows encapsulation of
hydrophilic MSNs.138 Addition of cholesterol enhances the membrane fluidity and
increases Col retention.146 The polar head groups of phospholipids, DPPC and DOPE offer
hydrophilicity to the liposome.145 The large PEG group of DSPE-PEG(2000)CA lipid in
liposomes is known to reduce immunogenicity and antigenicity.163 The liposome layers
acts as a gatekeeper and restrict pre-mature release of Col. The exterior of the liposome
was tagged with a PA specific peptide LL-37.
LL-37 recognizes the OM protein I (OprI) of PA.152, 164, 165 DSPE-PEG(2000)CA
acts as anchor to conjugate LL-37 (Col@MSN@LL-(LL37)).145,
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166

Where the -NH2

moieties of LL-37 were conjugated to the –COOH moiety of the lipid through sulfo-NHS
and EDC mediated conjugation (Figure 2.3).
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Figure 2.3. EDC/NHS activation chemistry. Formation of amide bond between liposomeCOOH and peptide-NH2.

Bacteria secreted phosphatases, lipases, and phospholipases accumulated at the site
of infection will trigger the degradation of the liposome and release of Col.144, 145, 148 After
liposomal degradation the exposed Col@MSN can cause physical aberrations on the OM
of bacteria. The released Col displaces Ca2+ and Mg2+ from the OM of PA, which disrupts
the stability of OM.145 The final nanoassembly Col@MSN@LL-(LL37), was qualitatively
characterized by DLS, TEM and FT-IR and quantitatively by BET and TGA.
The structure of the nanoassemblies was further examined by TEM (Figure 2.4).
The TEM images confirmed the mesoporous structure of bare MSNs. The reduction in
porosity was observed in the drug loaded MSNs (Col@MSN) compared to the bare MSNs
(Figure 2.4a &b). Also, Col@MSN displayed a change in morphology probably due to
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surface interactions with the positively charged Col (Figure 2.4b). In Col@MSN@LL, the
single lipid layer coated around each Col@MSN was clearly observed through TEM as
shown from arrows (Figure 2.4c). This confirms the presence of liposomes around the
Col@MSN@LL (Figure 2.4c).

a.

b.

c.

Figure 2.4. TEM images of (a) MSNs (inset: magnified view of mesoporous structure
of MSN) (b) Col@MSN (c), and Col@MSN@LL (inset: magnified view of Col@MSN
covered with liposome layer shown with arrows) (scale bar = 100 nm).
The dried diameter of the particles was measured from TEM whereas the
hydrodynamic diameter was measured from DLS. TEM images of MSNs analyzed by
ImageJ displayed a dried diameter of 80 ± 9 nm (Figure 2.4a) and after drug loading the
diameter remained similar (85 ± 5 nm). The hydrodynamic diameter of MSNs was
measured to be 300 ± 9 nm and it went up to 380 ± 7.9 nm after Col loading. Liposomal
coated nanoassembly had an increased hydrodynamic size of 500 ± 9.6 nm and a dried
diameter of 98 ± 1.6 nm. This confirmed the successful coating of lipid layers. The final
nanoassembly Col@MSN@LL-LL37 had a dried size of 125 ± 3.4 nm (Table 2.1). The
hydrodynamic diameter determined by DLS increased from 500 ± 9.6 nm for
Col@MSN@LLs to 620 ± 10.6 nm for the final nanoassembly (Table 2.1). The greater size
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determined by DLS was possibly due to particle swelling and agglomeration in solution.
The size of the SNPs and Col@SNPs determined by DLS were 98 ± 4 nm and 101 ± 2.1
nm respectively (Table 2.1).

Table 2.1. Hydrodynamic size, dried size distribution and the zeta potential
of nanoassemblies. Data are represented as mean ± SD.
Hydrodynamic
Diameter from
diameter (nm) from
TEM (nm)
DLS

Zeta
potential
(mV)

SNP

98 ± 4 (PDI 0.1)

N/A

-38 ± 2.3

Col@SNP

101 ± 2.1 (PDI 0.2)

N/A

-8 ± 0.8

MSN

300 ± 9 (PDI 0.4)

80 ± 9

-30 ± 1.5

Col@MSN

380 ± 7.9 (PDI 0.5)

85 ± 5

+5.0 ± 1.1

Col@MSN@LL

500 ± 9.6 (PDI 0.5)

98 ± 1.6

+2.5 ± 1.2

Col@MSN@LL(LL37)

620 ± 10.6 (PDI 0.7)

125 ± 3.4

+10.2 ± 2.9

Colistin (Col)

N/A

N/A

+10 ± 0.9

Material

The zeta potential measurements reflected the surface charge of the
nanoassemblies. Zeta potential measurements were used to track the surface change in each
step of the synthesis of the nanoassembly. The negative zeta potential of -30 ± 1.5 mV of
bare MSNs was due to the presence of negatively charged silicate on the surface of the
MSNs. The positive zeta potential of 5.0 ± 9.1 mV upon drug loading indicated successful
loading of Col. Furthermore, the liposome coated Col@MSN brought the zeta potential
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down to 2.5 ± 1.2 mV confirming that it is due to positively charged phospholipid heads
(DOPE) which are facing the exterior. The final nanoassembly displayed a positive zeta
potential of 10.2 ± 2.9 mV proving successful conjugation of cationic peptide LL-37 on
the liposome exterior.

Figure 2.5. N2 adsorption−desorption isotherm for MSNs and Col@MSN.

The typical N2 adsorption−desorption isotherm for MSNs confirmed the porosity
of MSNs (Figure 2.5). These gas adsorption measurements indicate the sum of particle
surfaces including the surface pores and roughness.167 The elevated hysteresis loop of
MSNs indicated the higher volumes adsorbed by the MSNs compared to the hysteresis loop
of Col@MSN. This confirms the presence of more pores in MSNs than Col@MSNs.
As described in section 2.3.8, multi point BET analysis by the BJH method
calculated the surface area to be 880.8 m²/g and a pore volume of 2.416 cm3/g of the MSNs.
The pore size (radius) of the MSNs was calculated to be 18.09 Å according to BJH method
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(Table 2.2). Porosity was observed to reduce in drug loaded MSNs (Col@MSN) compared
to the bare MSNs (Table 2.2). BET analysis of Col@MSN had a smaller surface area of
646.4 m²/g, a smaller pore volume (1.372 cm3/g) and a smaller pore radius of 11.81 Å
(Table 2.2). The reduction in surface area, pore volume and pore size of Col@MSNs was
due to the successful loading of the drug Col into the pores of MSNs.

Table 2.2. Table of surface area, pore volume and pore size data of MSN and Col@MSN
from BET analysis.

MSN

Col@MSN

Surface area
(MultiPoint BET)

880.8 m²/g

646.4 m²/g

Pore volume (BJH
method)

2.416 cm3/g

1.372 cm3/g

Pore size (BJH
method)

18.09 Å

11.81 Å

Qualitative analysis of the products was done by Fourier-transform infrared
spectroscopy. FT-IR spectral analysis tracked and confirmed the successful drug loading
into the MSNs (Figure 2.6). FT-IR of MSN displayed characteristic absorption peak at
1020 - 1110 cm-1 which can be assigned to the Si-O-Si asymmetric stretching vibration,
and a peak at 960 cm-1 indicative of the asymmetric bending and stretching vibration of SiOH.168 FT-IR of Col@MSN displayed amide I and II bands at 1646 and 1538 cm-1
indicating the presence of amide groups on the peptide Col. Therefore, this confirms the
successful loading of Col. The peak at 1099 cm-1 confirmed the presence of sulphate
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counter ion found in commercial colistin.169 The successful liposome coating was also
confirmed by the FT-IR functional groups (Figure 2.6).

Figure 2.6. FT-IR spectra of MSNs, Col@MSN, Col@MSN@LL and Col@MSN@LL(LL37).

The antisymmetric and symmetric C-H stretching at 2918 cm-1 and 2850 cm-1
respectively were the characteristic signals for the long carbon chain of the lipids used in
the liposome coated MSNs. Also, the C=O stretching vibration around 1735 cm-1 and the
PO2 symmetric stretching vibration around 1090 cm-1 are from phospholipids confirming
the successful liposome coating.170,171 The FT-IR spectrum of the final nanoassembly
Col@MSN@LL-(LL37) indicated characteristic peaks of an amide bonds from the LL-37
peptide such as C-N bending at 1645 cm-1, N-H bending at 3367 cm-1 and N-H stretching
vibrations at 3287 cm-1. Presence of these spectral lines confirmed the peptide LL-37
conjugation in Col@MSN@LL-(LL37) (Figure 2.6).172,173 The high resolution spectra of
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each nanoassembly is presented in appendix A Figure A.1, Figure A.2, Figure A.3, Figure
A.4, Figure A.5 and Figure A.6.

Figure 2.7. TGA curves recorded for MSNs, Col@MSN, Col@MSN@LL and
Col@MSN@LL-(LL37) (n=3).

The quantitative analysis of nanoassembly after each step of synthesis was done
through TGA. Percentage (%) weight loss between the Col@MSN and MSN was
calculated to determine the amount of Col loaded onto MSNs. The Col loading was found
to be 58 ± 7 mg per gram of MSNs (58 ± 7 mg/g) which corresponds to 6 ± 0.9 % loading
(Figure 2.7). Drug loading to porous MSNs were compared to non-porous silica
nanoparticles (SNPs) of the same diameter. Col loading in SNPs was 1.7 ± 0.2%, which is
~ 3X folds lower compared to the Col loading to MSNs (Appendix Figure A.7).174 This
further confirms the porosity of MSNs. Also, the percentage weight loss between
Col@MSN@LL and Col@MSN displayed that the coated lipid layer is 10 ± 1.5% of
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Col@MSN@LL. TGA analysis done on Col@MSN@LL-(LL37) and Col@MSN@LL
indicated a total peptide LL-37 content of 110 ±2 µg/g in Col@MSN@LL-(LL37) (Figure
2.7).
Encapsulation efficiency (EE), loading capacity (LC) and Col release from MSN
were measured using UV-vis spectroscopy as shown below. Absorbance of Col was
analyzed at 220 nm and correlated with the concentration.175 The average EE % of three
experiments (with the SD) was calculated to be 79.3 ± 3.5 % and LC was calculated to be
9.8 ± 0.5%, which is 98 ± 7 mg of Col per g of MSN. The lower LC compared to higher
EE was probably due to the use of larger quantity of MSNs (200 mg) compared to the
amount of Col (20 mg) used in loading. The comparatively high EE is probably due to
electrostatic attraction between positively charged Col and the negatively charged MSNs
benefiting encapsulation. The LC calculated through TGA was 6 ± 0.9 %, which is slightly
lower than the LC determined by the UV-vis spectrophotometry (Figure 2.7).

Equation 2.1. Equations used for the calculations of EE% and LC%.

EE% =

total mass of drug added- mass of unencapsulated drug
× 100
total mass of drug added

LC % =

total mass of drug added- mass of unencapsulated drug
× 100
total mass of MSNs
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2.4.2 Targeting PA14 and Responsive Antibiotic Release
As clearly shown in the TEM images of Figure 2.8a, there are more nanoparticles
attracted to PA14 with the presence of targeting peptide (Col@MSN@LL-(LL37))
compared to the nanoassembly without the targeting peptide, Col@MSN. Furthermore, a
comparative intensity of interaction of PA14 with red fluorescent RITC-Col@MSN and
RITC-Col@MSN@LL-(LL37) was qualitatively evaluated using fluorescent microscopy
(Figure 2.8b). Blue fluorescent, Hoechst dye stained PA14 was incubated with red
fluorescent RITC-Col@MSN and RITC-Col@MSN@LL-(LL37).

a.

RITC- conjugated nanoassemblies

Col@MSN@LL-(LL37)

Hoest stained PA14

Merge

RITC-Col@MSN@LL-(LL37)

RITC-Col@MSN

b.

Col@MSN

Figure 2.8. Evaluating the targeting and antibacterial ability of Col@MSN@LL(LL37) against PA14 (a.) TEM images showing Col@MSN and Col@MSN@LL(LL37) targeting PA14 (b.) Fluorescence microscopy images showing the interaction
between the red fluorescent RITC-Col@MSN and RITC-Col@MSN@LL-(LL37)
with PA14. PA14 is stained with blue fluorescent Hoechst dye (blue), and the merged
images showing both red and blue fluorescent overlay (scale bars represent 10 μm).
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After incubation the samples were visualized under fluorescent microscope (Figure
2.8b). As shown in Figure 2.8b, interaction between the red fluorescence RITC-Col@MSN
with blue fluorescence PA14 was much poorer and more distributed compared to the
interaction between PA14 and RITC-Col@MSN@LL-(LL37). It confirms that the targeted
nanoassembly, Col@MSN@LL-(LL37) was able to target and attract PA14. As confirmed
by the Figure 2.8a and Figure 2.8b, pronounced binding affinity of the nanoassembly was
seen in the presence of the LL-37, Col@MSN@LL-(LL37).
Following the Col release in the presence and absence of bacteria, PA14 was
assessed. The Col release through Col@MSN@LL-(LL37) was measured using UV-vis
spectroscopy at 220 nm. Results confirmed that there is a significant increase in the Col
release in the presence of PA14 (Figure 2.9). Col release of 90 ± 1.8 % was observed at 40
h in the presence of PA14. Whereas in the absence of PA14, at 80 h only 75 ± 0.5 % of Col
was released.

Figure 2.9. Cumulative release of Col from Col@MSN@LL-(LL37) in the presence
and absence of PA14 measured at 220 nm.
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These results confirmed that the presence of PA14 played a role in Col release
(Figure 2.9). Higher release of Col, could be due to the breaking down of the liposome by
bacteria secreted lipases and phospholipases.176, 177
Following that the ability of the targeted nanoassembly to target and inhibit PA14
bacteria in vitro was evaluated from TEM. Col@MSN@LL-(LL37) was interacted with
PA14 for 24 hours and the effects of interaction was evaluated within different time
intervals (4 hrs, 15 hrs, 20 hrs). The in vitro evaluation confirms that the bacteria PA14 is
targeted by Col@MSN@LL-(LL37) and degradation follows within 20 hrs in effective to
drug release after interaction as shown by Figure 2.10. This confirms that the final
nanoassembly, Col@MSN@LL-(LL37) was capable of successful elimination of PA14
within 20 hours of interaction.

4 hours

15 hours

20 hours

bacteria (PA14)

Figure 2.10. TEM images showing the interaction of Col@MSN@LL-(LL37) with
PA14 monitored through 4 - 20 hours. The images showed attraction of final
nanoassembly towards bacteria started after 4 hours of interaction, followed by
degradation of bacteria within 20 hours. (scale bars represent 500 nm).

Therefore, the minimum inhibitory concentration (MIC) of free Col, Col@MSN,
Col@MSN@LL, Col@MSN@LL-(LL37) and their respective controls were measured
against PA14 is reported in Table 2.3 and Figure 2.11.
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Table 2.3. The MIC of nanoassemblies and the amount of encapsulating Col present within
the nanoassemblies. Data are presented as the mean ± SD.

Nanoassembly

MIC of nanoassembly Col
encapsulated
in
(µg/mL)
nanoassembly (µg/mL)

Colistin

4 ± 0.3

N/A

Col@MSN

10 ± 0.6

0.98 ± 0.1

Col@MSN@LL

8 ± 0.1

0.8 ± 0.2

Col@MSN@LL-(LL37)

20 ± 0.2

0.6 ± 0.2

LL-37

16 ± 0.4

N/A

Col@MSN@LL-(PAB)
(+) control

19 ± 0.8

N/A

None

N/A

LL, MSN (-) control

The MIC was assessed by microdilution method using colorimetric WST-8 assay
and verified with colony counting. WST-8 produces a yellow color formazan dye
(absorbance maximum 460 nm) upon reduction of tetrazolium by dehydrogenase enzymes
in live bacteria. The absorbance of produced formazan was measured at 460 nm, which is
proportional to the number of live bacteria (Figure 2.11).178 The MIC established by WST8 assay, is 4 μg/mL for free drug Col. At the MIC, the free drug equivalent encapsulated
in Col@MSN@LL-(LL37) is 0.6 μg/mL (Table 2.3 & Figure 2.11). This shows the final
nanoassembly is 6.7-fold efficacious than the free drug Col. Antibacterial peptide; LL-37
displayed a MIC of 16 μg/mL against PA14. Since the conjugated LL-37 present on
Col@MSN@LL-(LL37) was 11 ± 2 μg/mL at the MIC, that antibacterial activity is not
primarily due to LL-37. MSNs and bare liposomes displayed no antibacterial activity even
at high concentrations.
53

Figure 2.11. MIC of different nanoassemblies was measured by WST-8 cell viability
assay. Data are presented as the mean ± SD. (n = 3, *** indicates p < 0.001).
The results from the WST-8 assay were verified using bacterial colony counts and
were reported as percentage viability of PA14 (Figure 2.12). MSN did not have any
antibacterial activity. PA14 showed ~100% viability upon interacting with MSN (Figure
2.12). Col and Col@MSN@LL-(LL37) at their MIC’s killed 33% and 93% of bacteria
respectively (Figure 2.12). Targeting ability of LL-37 was compared to the known PA
targeting ligand Pseudomonas polyclonal antibody (PAB).

Figure 2.12. Percentage viability of PA14 in the presence of MSN, Col, Col@MSN,
Col@MSN@LL and Col@MSN@LL-(LL37) at their MICs determined by colony
counting. Data are presented as the mean ± SD. (n = 3, *** indicates p < 0.001, ****
indicates p < 0.0001).
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PAB had no measurable antibacterial activity even at 1 mg/mL. The MIC of
Col@MSN@LL-(PAB) was 19 ± 0.8 µg/mL (synthesis is in Appendix A). Both
nanoassemblies Col@MSN@LL-(PAB) and Col@MSN@LL-(LL37) have similar
antibacterial activity due to the loaded Col.
Agar diffusion assay was performed to analyze the antibacterial activity of
Col@MSN@LL-(LL37).

The

inhibitory

zone

for

free

Col,

Col@MSN

and

Col@MSN@LL-(LL37) at their MICs were measured by agar diffusion. (Figure 2.13).
The inhibitory zone diameter for each of the samples were 1.2 ± 0.5, 1.4 ± 0.3 and 1.6 ±
0.7 cm respectively indicating that Col@MSN@LL-(LL37) has better antibacterial activity
than free drug Col (Figure 2.13).

a.

b.

c.

Figure 2.13. Inhibition zone diameter of (a.) Col (b.) Col@MSN and (c.)
Col@MSN@LL-(LL37) measured from agar well diffusion method (n=3).

To further visualize antibacterial efficacy of nanoassemblies live/dead fluorescence
assay was performed (Figure 2.14). Free Col, MSN, Col@MSN, Col@MSN@LL and
Col@MSN@LL-(LL37) at their MICs were incubated with PA14 and the results were
observed through fluorescence microscopy. Green fluorescent nucleic acid dye SYTO 9
penetrates the cell membrane of both live and dead bacterial cells. Red fluorescent nucleic
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acid dye propidium iodide (PI) only penetrates cells with damaged cell membranes. In the
presence of both dyes, bacteria with intact cell membranes appear fluorescent green,
whereas membrane-compromised bacteria appear in red.179 Negative control MSN showed
high green fluorescence indicative of live bacteria. Col, Col@MSN, Col@MSN@LL and
Col@MSN@LL-(LL37) exhibited strong red fluorescence indicating compromised
membranes which increases permeability to red fluorescent PI (Figure 2.14).
Fluorescence microscopy analysis shows high bacterial aggregation in the presence
of Col@MSN@LL-(LL37) compared to that of Col@MSN@LL due to LL-37 mediated
crosslinking (Figure 2.14). LL-37 mediated adhesion of Col@MSN@LL-(LL37) to the
surface of PA14 and subsequent cell capsule damage possibly enhances the antibacterial
activity of the nanoassembly compared to that of Col@MSN@LL.180
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Live

Live

Dead

Dead

Merge

Merge

MSN

MSN

Col
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MSN

Col@MSN

Col@
MSN-LL

Col@MSN@LL

Col@M
SN-LL(LL-37)

Col@MSN@LL-(LL37)

Figure 2.14. Comparison of antibacterial efficacy of nanoassemblies using BacLight® live/dead
assay. Fluorescence microscopy images showing the presence of live bacteria (green) and dead
bacteria (red) following treatment with MSN, Col, Col@MSN, Col@MSN@LL and
Col@MSN@LL-(LL37) at their MICs (scale bars represent 50 μm).
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2.4.3 Targeting of Intracellular PA14 in infected mammalian A549 lung cells
The intracellular distribution of Col@MSN@LL-(LL37) in A549; mammalian
non-small cell lung carcinoma epithelial cell line was compared with the non-targeted
Col@MSN by fluorescence microscopy (Figure 2.15). Col@MSN@LL-(LL37) taken up
by the A549 cells were distributed throughout the cytoplasm after 3 h of incubation (Figure
2.15). The comparison of fluorescence microscopy images of Col@MSN with
Col@MSN@LL-(LL37) showed increased internalization of Col@MSN@LL-(LL37) as
shown with increased red fluorescence inside and closer to the green fluorescent
mammalian cells (Figure 2.15). This suggests that liposome and LL-37 modification has
improved the ability of Col@MSN@LL-(LL37) internalization and consequently increase
Col delivery into the mammalian cells.

Figure 2.15. Internalization of nanoassemblies into A549 mammalian cells.
Internalization of RITC-Col@MSN and RITC-Col@MSN@LL-(LL37) (red) into A549
cells (green).
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PA14 is able to invade, survive inside, and reproduce after they have been
endocytosed by mammalian lung cells, which hinders extracellular antibiotic
treatment.181,182 PA14 infected A549 cells was used to evaluate the intracellular
antibacterial activity of Col@MSN@LL-(LL37). As described further in Section 2.3.16,
the A549 cells were infected with 45 ´ 103 CFU/mL PA14 from which 29 ´ 103 CFU/mL
was internalized. The infected A549 cells were then treated with different concentrations
of MSNs, Col@MSN and Col@MSN@LL-(LL37). The schematic representation of the
PA14 infection and subsequent treatment is shown in Scheme 2.3.

Scheme 2.3. Schematic illustration of infection with PA14 and subsequent treatment (AInfection with PA14, B- Introducing final nanoassembly Col@MSN@LL-(LL37) to the
infected A549 cells, C- LL-37 mediated adhesion of Col@MSN@LL-(LL37) on to PA14
surface, D- Degradation of liposome layer and drug release, E- Degraded PA14 due to
the released drug).
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As mentioned above, A549 cells were infected with PA14 and internalization of
RITC- conjugated red fluorescent Col@MSN@LL-(LL37) within green fluorescent
calcein AM stained, PA14 infected mammalian cells were imaged through fluorescence
microscopy (Figure 2.16).

Merged image in Figure 2.16a shows internalized

Col@MSN@LL-(LL37) in PA14 infected mammalian cells. This reflects that the targeted
nanoassembly is capable of targeting intracellular PA14.
Furthermore, a comparison study between RITC conjugated Col@MSN@LL(LL37) and Col@MSN was performed, and the results were imaged to see their ability to
target intracellular PA14. As displayed in Figure 2.16b the merged fluorescence
microscopy image showed a notable increase in Col@MSN@LL-(LL37) in PA14 infected
A549 cells, presented by the high red fluorescence in A549 cells (Figure 2.16b). In contrast
to the merged image of Figure 2.16b with Col@MSN showed a considerably low red
fluorescence inside the A549 cells indicating less internalization of particles in PA14
infected mammalian cells.
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a.

RITC-Col@MSN@LL-(LL37)

b.

Merge

Bright field (A549 cells + PA14)

Merge

Col@MSN@LL-(LL37)

Col@MSN

RITC- conjugated nanoassemblies

Calcein- A549 cells + PA14

c.

Figure 2.16. Antibacterial efficiency in PA14 infected A549 mammalian cells (a.)
Fluorescence microscopy observationsd.of A549 cells infected with PA14 incubated
with Col@MSN@LL-(LL37) for 3 h, the images show Col@MSN@LL-(LL37)
tagged with red fluorescent RITC, A549 cells stained with green fluorescent calcein
AM, and the merged images show overlay of both red and green fluorescent channels
(scale bars represent 50 μm) (b.) Fluorescence microscopy images of PA14 infected
A549 cells treated with RITC conjugated nanoassemblies, merged images of red
fluorescent and bright field A549 cells with PA14 (scale bars represent 50 μm).
With 0.1 mg/mL
Col@MSN@LL-(LL37)

With 1 mg/mL
Col@MSN@LL-(LL37)

After treating with the nanoassemblies, the A549 cells were lysed, and the lysates
were plated on tryptic soy agar (TSA) to confirm how many bacteria were surviving after
treatment. The infected A549 cells treated with the concentrations of 0.1, 0.5 and 1.0
mg/mL of Col@MSN@LL-(LL37) had 1000 ± 16, 120 ± 19, and 12 ± 3 CFU/mL of viable
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PA14 colonies (Figure 2.17a) remaining after treatment. The highest concentration of 1
mg/mL, Col@MSN@LL-(LL37) can effectively kill 99% of internalized PA14 (Figure
2.17a).

a.

b.

With 0.1 mg/mL
Col@MSN@LL-(LL37)

With 1 mg/mL
Col@MSN@LL-(LL37)

Figure 2.17. (a.) Photographs of agar plates of grown cell lysates of PA14 infected A549
cells after treating with different concentrations of Col@MSN@LL-(LL37) (b.) MTT
assay showing the percentage of cell viability of A549 cells incubated with different
concentrations of nanoassemblies, MSN, Col@MSN and Col@MSN@LL-(LL37)
respectively for 24 hrs.

Finally, the cytotoxicity of different concentrations of Col, Col@MSN, and
Col@MSN@LL-(LL37) towards A549 lung cells was investigated using MTT cell
viability assay as described in section 2.3.17. Metabolically active mammalian cells reduce
the yellow tetrazolium salt in the MTT assay by the action of dehydrogenase enzymes. The
resulting intracellular purple formazan product was identified as an indicator of live cells.183
The results demonstrated that neither high concentrations (1 mg/mL) of Col@MSN nor
Col@MSN@LL-(LL37) has any significant cytotoxicity towards A549 cells (Figure
2.17b).
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Conclusion
A nanoassembly was developed that is based on porous silica particles. The
nanoparticles were loaded with a drug (Col) and then coated with a liposome that was
modified with the targeting peptide, LL-37 (Col@MSN@LL-(LL37)). This nanoassembly
is capable of targeting intracellular PA. The liposome coating acts as a gate that prevent
drug release before the nanoassembly reaches the targeted bacteria. The liposomal cover is
degraded by the lipases secreted by bacteria which triggers drug release. The nanoassembly
efficiently targeted PA14, and effectively inhibits its growth in in-vitro studies. Infection
studies done on the PA14 infected mammalian lung cancer cells have shown the
intracellular targeting ability of Col@MSN@LL-(LL37) without causing cytotoxic effects
on the mammalian cells. The nanoassembly has shown increased internalization affinity
towards PA14 infected mammalian cells and selective inhibition of PA14. This confirms
that the nanoassemblies are biocompatible could be used in in-vivo studies. Compared with
the free antibiotic Col, nanoassembly encapsulated with Col was 6.7-fold more efficacious.
Encapsulated Col in (Col@MSN@LL-(LL37) is protected from inactivation and
overcoming cellular barriers when treating intracellular PA14 bacteria. Environmentally
responsive Col release (90 ± 1.8 %) in the presence of PA14 can be adapted to deliver any
other antibiotic targeting different strains of bacteria for the treatment of a broad range of
intracellular infections.

63

3. CHAPTER 3

TARGETING PA14 BIOFILMS USING AN ALGINATE LYASE GUIDED
RHAMNOLIPID LIPOSOME COATED DRUG DELIVERY PLATFORMS FOR
SYNERGISTIC DELIVERY OF AN ANTIBIOTIC AND A QUORUM SENSING
INHIBITION

Introduction
The delivery vehicle discussed in this chapter is expected to penetrate the
extracellular polymeric substances (EPS) produced by a variety of bacteria, including
PA14. Herein, AL enzyme will be used to degrade the alginate based outermost
exopolysaccharide layer to facilitate the entrance of the nanoassembly into the biofilm.
Wan et al. reported the use of AL tagged silver nanocomposite for the treatment of PA in
lungs.100 A rhamnolipid liposome layer will be used to facilitate integration of the
nanoassembly through the rhamnolipid shield. Upon entrance, the nanoassembly will
release the loaded QSI and Tob. The purpose of QSI is to inhibit bacterial communication.
The antibiotic Tob will be released to attack PA bacteria residing in the BF. Ho et al.
reported successful simultaneous delivery of an QSI and Tob in squalenyl hydrogen sulfate
nanoparticles to treat PA biofilms.101 The Rh shield also acts against host immunity by
lysing leukocytes and monocyte-derived macrophages, resulting in necrotic cell death.97
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The inhibition of Rh and the QS system of the BF would significantly increase the
chances of clearing PA BF.123 It is hypothesized that the final nanoassembly will be
effective in clearing biofilms resulting in an increased affinity compared to the free
antibiotic Tob (Scheme 3.1). It is furthermore hypothesized that this nanoassembly will
successfully clear the ex-vivo biofilms grown in mammalian lung cancer cells.

Scheme 3.1. Proposed mechanism of action of the nanoassembly (MSN@Q@Tob)RhAL.
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Materials
In addition to the materials listed in Chapter 2.2, the following materials were used.
D-(+) glucose solution, gram's iodine solution, alginate lyase, and sodium alginate were
purchased from Sigma-Aldrich (Missouri).
Live/dead® viability kit, micro-BCA™ protein assay kit, Dil stain (1,1'-Dioctadecyl3,3,3',3'-Tetramethylindocarbocyanine Perchlorate ('DiI'; DiIC18(3))) and FITC conjugated
Pseudomonas polyclonal antibody was purchased from ThermoFisher Scientific
(Massachusetts).
Confocal microscopic images were taken by Zeiss 700 laser scanning microscope.
Drug release studies of the hydrophobic drug were conducted with High Performance
Liquid Chromatography (HPLC) using a Hitachi Primaide Separation module and a 1430
diode array detector and Malvern plate reader.
Methods
3.3.1 Synthesis of the Silica Nanoparticles (SNP)
The SNP synthesis is explained in Section 2.3.3. However, TEOS and NH4OH
amounts were adjusted in order to prepare different size SNPs. TEOS (0.7 mL) and NH4OH
(0.7 mL, 6.25 v/v%) were added to ethanol (34 mL) and stirred overnight at room
temperature to obtain SNPs around 10-20 nm. Following that it was purified 3 times with
ethanol. Likewise, TEOS (1.7 mL, 2.8 mL) and NH4OH (1.7 mL, 2.8 mL 6.25 v/v%) were
added to ethanol (34 mL) to obtain SNPs around the size of 100 nm and 200 nm
respectively. They were also purified as mentioned above using ethanol.
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3.3.2 Rh Liposome Preparation
Liposomes were prepared, as described by Rathnayake et al. with minor
modifications.184 Briefly, DPPC (7.5 mg, 10.2 μmol), rhamnolipid (15 mg, 23.5 μmol),
cholesterol (1.25 mg, 3.2 μmol), and DSPE-PEG(2000) CA (1.25 mg, 0.45 μmol) were
dissolved in 3 mL of chloroform with 0.2% (w/w) DiI lipophilic membrane stain and
evaporated in a rotary evaporator, which yielded a thin lipid film. The lipid film was
rehydrated in 2.5 mL of PBS (pH 7.4) at a lipid concentration of 10 mg/mL and extruded
15 times through a polycarbonate membrane (pore size 400 nm) using the mini extruder.
Resultant liposomes were stored at 4 °C until further use. Liposomes without rhamnolipids
were also synthesized using a similar method with DPPC (15 mg, 20 µmol), DOPE (1.25
mg, 1.7 µmol), cholesterol (7.5 mg, 3.2 µmol), and DSPE-PEG(2000) CA (1.25 mg, 0.45
µmol).

3.3.3 Modification of Rhamnolipid (Rh) Liposomes with AL (Rh-AL)
Alginate lyase (AL) was conjugated to the exterior of the liposomes by EDC
activation chemistry. One batch of Rh liposomes (25 mg/mL) containing DSPEPEG(2000) CA (1.25 mg, 0.45 μmol) was activated with 10 fold molar excess of EDC
compared to DSPE-PEG(2000) CA (4.5 μmol, 0.86 mg) and 25 fold molar excess of sulfoNHS ( 11.25 μmol, 1.29 mg) for 2 h at 37 °C. After activation of the COOH groups of
DSPE-PEG(2000) CA by ECD and sulfo-NHS, the AL (5 mL, 1 mg/mL) was added and
incubated overnight at 37 °C. At the end of the incubation period, AL-modified Rh
liposomes were purified by centrifugation at 12000 rpm for 30 min at 4 °C and resuspended
in PBS (pH 7.4). The purified product was lyophilized and stored at −20 °C until further
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use. The amount of conjugated AL was determined by the micro-BCA protein assay
(Appendix Figure B.1).
3.3.4 Assessment of AL activity after conjugation on to the Rh liposomes
The activity of AL was determined using enzyme substrate reaction. The above
synthesized SNPs were coated with a Rh liposome layer tagged with AL ((SNP)Rh-AL).
The activity of the conjugated AL will be determined based on absorbance spectroscopy.
Native AL (0.15 ml, 1 mg/mL) and immobilized AL (0.15 mL having 1 mg/mL AL) was
reacted with sodium alginate (4.5 mL, 0.1 mg/mL) for 15 min.185 One unit of enzyme
activity is defined as the amount of AL required to increase the absorbance by 1.0 at 235
nm/min.185 Activity retention was expressed as the percentage activity relative to the free
AL and compared the difference of free AL to the conjugated AL using student's t-test.
Furthermore, to examine the change in enzyme activity with respect to the AL
density on NA, the NA was conjugated with lower density (i.e.: 50%) of AL compared to
the maximum AL loading. To achieve this, Rh liposomes were synthesized using half the
amount of DSPE-PEG(2000) CA (0.625 mg, 0.225 µmol). The density of conjugated AL
was quantified by protein assay - bicinchoninic acid assay (micro-BCA). The activity
changes with the varying densities of AL on NA were tested and the relative activity
retention was expressed as the percentage activity compared to the free AL.
3.3.5 Determination of enzyme kinetics of AL tagged nanoassembly (NA)
The Michaelis-Menten kinetics of the free enzyme AL, and the apparent kinetics of
the immobilized AL (on AL-NA) was determined. A concentration gradient of the substrate
sodium alginate (0.1 mM, 0.2 mM, 0.4 mM, 0.8 mM, 1.6 mM, 3.2 mM, 6.4 mM, 12.8 mM,
25.6 mM) was prepared and reacted with free AL (1 mg/mL) and AL-NA (where AL is
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presented at 1 mg/mL equivalence). The reaction was allowed to proceed for 30 min at
each concentration. An aliquot of the reaction mixture was withdrawn every 5 min and the
reaction was stopped using NaOH to measure the absorbance at 235 nm to determine the
product conversion. Initial slopes from absorbance vs time plots were determined for each
substrate concentration [S] to calculate the reaction velocity (V). Thereafter, Michaelis
constant (Km) and Vmax were extrapolated from nonlinear regression of a plot of velocity
versus substrate concentration using Michaelis–Menten enzyme kinetics (GraphPad
Software). The turnover number (kcat) was determined by dividing the Vmax by the initial
enzyme concentration assuming a molecular weight of 29.9 kDa for the enzyme (Figure
3.2).186 The Km, Vmax and kcat values of the immobilized AL (AL-NA) were compared with
the free AL using students’ t-test.
3.3.6 Growth of PA14 biofilms
PA14 was cultured in Tryptic soy broth (TSB) medium at 37 °C for 18 h, and the
absorbance of bacterial suspensions at OD600 was measured. Briefly, 100 μL of cell
suspension having 0.5 OD600 (approximately 2 x 107 CFU/mL) was inoculated in 100 μL
TSB medium in each well and 200 μL of autoclaved distilled water was added in peripheral
wells to reduce the water loss. The well plates were closed with peg lids and incubated 24
hours at 37 °C without shaking. The biofilms were allowed to grow on peg lids. After
incubation, the lid with biofilms was transferred to a rinse plate containing 200 μL PBS
buffer and the pegs were washed twice to remove the planktonic bacteria. Adherent
biofilms on the pegs were fixed with 200 μL of 100% methanol prior to staining with
crystal violet. Thereafter, the lid was dipped in a plate with 200 μL of crystal violet solution
(0.1%) for 15 min. Then the lid was removed and placed in sterile water plate to remove
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excess dye and then placed again in a plate with 95% ethanol to dissolve the bound crystal
violet. Thereafter, the biomass was determined by measuring the absorbance at OD570.
3.3.7 Assessment of the degradation of the alginate by AL-NA
The degradation of biofilm alginate in the presence of AL-NA and free AL was
determined quantitatively and qualitatively. For quantitative determination, an absorbance
assay was used. The increase in absorbance at 235 nm due to the formation of a C=C bond
in the β-elimination reaction was tested. For qualitative determination, a halo test was
performed with free AL, and AL-NA. In the halo test PA14 was first grown on agar plates
to form BF colonies and a filter paper disk soaked in AL (1mg/mL) or AL-NA (having AL
of 1mg/mL) solution were placed in the middle of agar plate and was incubated overnight
to evaluate the formation of halos (appearance of a cleared area around the paper disk on
an PA grown agar plate).187 On the following day, the diameter of the formed halos were
measured and the plates were stained with Gram's iodine solution to clearly visualize the
halos.
3.3.8 Synthesis of MSNs
MSNs were prepared using a protocol with some modifications using CTAB as the
porous template as mentioned in Chapter 2 Section 1.3.1. TEOS was used as the silica
source. CTAB (4 mmol) was dissolved in 140 mL of water and TEOS (1688 μL, 7.6 mmol)
was added dropwise to the mixture. NH4OH (25 v/v%, 1688 μL) was then added to the
mixture and stirred overnight at room temperature. On the following day, the white turbid
solution was separated by centrifugation at 12000 rpm for 10 min. After removing the
supernatant, the solid precipitate (MSNs) was resuspended in water and centrifuged at
12,000 rpm for 10 min. This was repeated three times. To remove the excess CTAB, MSNs
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were centrifuged and resuspended in 50 mL of ethanol with 200 μL of concentrated HCl.
This mixture was stirred at 60 °C for 12 h. The resulting product was purified three times
with ethanol by centrifuging at 12,000 rpm for 10 min. The size of MSNs was characterized
through DLS and TEM.

3.3.9 Encapsulation of quorum sensing inhibitor (QSI) in MSNs (MSN@Q)
MSNs (10 mL, 5 mg/mL) were loaded with QSI trans-cinnamaldehyde (20 mg) in
5 mL of DMSO. This was stirred overnight at 37 °C temperature. The unconjugated QSI
was removed by centrifugation at 12,000 rpm for 10 min, yielding MSN@Q. Encapsulation
of QSI in MSN was further analyzed by UV-Vis spectroscopy.

3.3.10 Encapsulation of antibiotic (Tobramycin) in MSN@Qs (MSN@Q@Tob)
MSN@Qs (10 mL, 5 mg/mL) were surface conjugated with the antibiotic
tobramycin (Tob, 20 mg). MSN@Q and Tob were stirred overnight at 37 °C temperature.
The unconjugated Tob was removed by centrifugation at 5000 rpm for 10 min, yielding
MSN@Q@Tob. Tob encapsulation was further determined by HPLC.
Drug encapsulation efficiency and loading capacity was calculated using the
following equations.

Equation 3.1. Equations used for the calculations of EE% and LC%.

EE% =

total mass of drug added- mass of unencapsulated drug
× 100
total mass of drug added
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LC % =

total mass of drug added- mass of unencapsulated drug
× 100
total mass of MSNs

3.3.11 Encapsulations

of

MSN@Q@Tob

into

AL-modified

Rh

liposomes

(MSN@Q@Tob)Rh-AL
To prepare liposome coated drug loaded MSN (MSN@Q@Tob), 25 mg of
MSN@Q@Tob was resuspended in AL-modified Rh liposomes (1 mL, 25 mg/mL) in PBS
and mixed for 20 min in an ice bath. The liposome-coated AL tagged nanoassembly
(MSN@Q@Tob)Rh-AL was separated from empty liposomes by centrifugation at 12,000
rpm for 5 min and repeatedly washing in PBS. The resultant (MSN@Q@Tob)Rh-AL was
lyophilized and dried at −20 °C until further use.
Three different sizes of SNPs also encapsulated within AL tagged Rh liposomes
((SNP)Rh-AL) as mentioned above to determine the optimum size of nanoassembly to be
used in the study.
3.3.12 Characterization through TEM and DLS
The ultrastructure of bare MSNs, MSN@Q@Tob, and (MSN@Q@Tob)Rh was
examined through TEM. Carbon thin-film-coated Cu grids (200 mesh) were drop-casted
using a diluted solution (100 µL, 5 mg/mL) of the material and left to vacuum dry overnight
and visualized using a TEM operating at 200 kV. The liposomal layer was examined
through TEM following staining with 10% uranyl acetate. The hydrodynamic size and zeta
potential of all nanoassemblies were measured using DLS.
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3.3.13 Surface Area and Pore Volume Determination of MSN, MSN@Q and
MSN@Q@Tob
The surface areas of MSN, MSN@Q and MSN@Q@Tob were determined using
the Brunauer−Emmett−Teller (BET) method using a surface area and porosity analyzer.
The cumulative pore volume was calculated from the adsorption branch of the isotherm
using the Barrette−Joyner− Halenda (BJH) model.

3.3.14 TGA of the conjugated ligand content in MSN@Q, MSN@Q@Tob and
(MSN@Q@Tob)Rh-AL
TGA was carried out under an argon atmosphere (99.999%) where dried MSN@Q
(ca. 1 mg) was heated at a rate of 5 °C/min to 100 °C and then kept isothermal for 15 min
followed by 5 °C/min ramp to 700 °C. The Q encapsulated in MSN@Q was calculated by
analyzing the percentage weight loss difference between MSN and MSN@Q. Likewise,
the other conjugated ligands were analyzed using weight loss analysis.

3.3.15 Assessment of the Liposome coated nanoassembly distribution through the
biofilm
Coverslips (18 x18 mm) were placed in a 6-well polystyrene plate with a lid and
each well was filled with 2 mL of 0.5 OD600 PA14 bacterial suspension. The coverslips
were positioned to be completely immersed in the bacterial suspension. Thereafter the
plates were kept in the incubator at 37 °C for 24 h for biofilm formation on the coverslips.
After 24 hours the unattached bacteria were removed, and 2 mL of fresh TSB medium was
subsequently added. Then, the grown biofilms were treated with the DiI-labelled liposomal
nanoassemblies

with

((MSN@Q@Tob)Rh)

or
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without

rhamnolipid

liposomes

((MSN@Q@Tob)LL) (200 μg/mL) for 2 h, 6 h and 12 h. After treatment the slides were
rinsed to remove excess nanoassemblies and fixed with 5% glutaraldehyde for 15 min in
an incubator. Then, 200 μL of SYTO 9 solution was added and incubated for 15 min to
stain the biofilm cells. Finally, the slides were washed to remove excess dye and examined
under confocal laser scanning microscopy. For each slide three representative Z-stacks
along the full thickness of the biofilm were captured. The image processing and analysis
were carried out by the Zen 2.3 software and ImageJ software.

3.3.16 QSI and Tob release studies from (MSN@Q@Tob)Rh-AL
The biofilms were grown on coverslips as described in Section 3.3.15. Thereafter,
the grown biofilms were treated with the (MSN@Q@Tob)Rh-AL (200 μg/mL). At
different time intervals (0.5h, 1h, 2h, 4h, 8h,16h, 24h, 40h) the biofilms were processed to
determine QSI and Tob release. The release profile of QSI from (MSN@Q@Tob)Rh-AL
was obtained by ultraviolet−visible (UV−vis) light absorbance using the multimode
microplate reader equipped with a UV−vis detector (at 310 nm). After processing the
biofilms, the released QSI was extracted from the supernatant using ethyl acetate. Released
Tob amounts were quantified by reverse phase high performance liquid chromatography
(RP-HPLC). A reverse phase C18 column (4.6 mm x 250 mm and particle size 5.0 μm)
was used as stationary phase. The column temperature was kept at 25 °C. The mobile
phase was composed of solvent A (mili Q water adjusted to pH 11 with 2.5 N NaOH) and
solvent B (acetonitrile containing 0.1% v/v TFA), solvent ratio A:B was 95:5, and the flow
rate was 1 mL/min with an injection volume of 20 μL.101
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3.3.17 Determination of Minimum Inhibitory Concentrations (MICs)
The antimicrobial properties of the MSNs, Tob, QSI, MSN@Q@Tob, and
(MSN@Q@Tob)Rh-AL were investigated by cell viability WST-8 assay. A volume of 200
μL of fresh TSB medium and 20 μL of each sample (MSNs, Tob, Q, MSN@Q,
MSN@Q@Tob, and (MSN@Q@Tob)Rh-AL) having Tob concentrations of in the range
of 3.125 - 200 μg/mL (QSI concentration was kept constant at 20 μM ) were added to a 96
well plate. A suspension of PA14 (10 μL) having 0.5 OD600 was introduced into each well
and shaken at 37 °C in a shaking incubator for 18 h. On the following day the viability of
bacteria was determined by cell viability WST-8 colorimetric assay. 170 μL of sterile broth,
20 μL of each sample mentioned above was incubated with 10 μL of WST-8 at 37 °C on a
shaker bed for 2 h. The absorbance was recorded at 460 nm.
3.3.18 Determination of Minimum Biofilm Eradicating Concentration (MBEC)
MBEC assays were performed according to a reported protocol with minor
modifications. Biofilms were grown on the MBEC assay plates as mentioned in section
3.3.6. Once the biofilms were grown on the pegs, the peg lid was removed and transferred
into another 96-well microtiter plate containing sterile water for 1 min before being
transferred into a treatment plate to remove the planktonic bacteria. The treatment plate
consisted of aliquots (200 μL) of MSNs, Tob, Q, MSN@Q, MSN@Q@Tob, and
(MSN@Q@Tob)Rh-AL. In the aliquots the Tob concentrations ranged from 3.125 - 200
μg/mL and QSI concentration was kept a constant at 20 μM. Sterile PBS was used as a
control. After washing with sterile water, the peg lid was transferred into the treatment
plate and incubated for 24 h at 37 °C in the shaking incubator. After 24 h incubation, the
peg lid was transferred to a fresh plate containing sterilized water to inhibit treatments. The
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remaining biofilms were dislodged by bath sonicating the plates for 30 min. Serial dilutions
and agar dilutions were prepared. Colonies were reported as colony forming units
(CFU/mL). The MBEC value was therefore determined as the minimal antibiotic
concentration that did not result in re-growth of bacteria from the treated biofilm.

3.3.19 Biofilm Formation and Degradation Assay
In order to observe how the different nanoassemblies affect in biofilm formation,
briefly, a 150 μL of cell suspension having 0.5 OD600 was placed in the microtiter plate and
150 μL of different concentrations of Tob, AL, MSN@Q@Tob and (MSN@Q@Tob)RhAL (3.125 - 200 μg/mL) were added into each well and sterile PBS as the control. This
plate was closed with a peg lid and incubated for 24 h at 37 °C without shaking. After
incubation, the lid with biofilms was transferred to a rinse plate containing 200 μL PBS
buffer and washed the pegs twice to remove the bacteria. Adherent biofilms on the pegs
were fixed with 200 μL of 100% methanol prior to staining with crystal violet. Thereafter,
the lid was dipped in a plate with 200 μL of crystal violet solution (0.1%) for 15 min. Then
the lid was removed and placed in sterile water plate to remove excess dye and then placed
again in a plate with 95% ethanol to dissolve the bound crystal violet. Thereafter, the
biomass was determined by measuring the absorbance at OD570.
In addition, to observe the degradation effects of different nanoassemblies on the
biofilm formed by PA14, the biofilms were first grown on peg lids as mentioned in section
1.3.6. After biofilm formation, the peg lid was transferred into a treatment plate containing
different concentrations (3.125 - 200 μg/mL) of Tob, AL, MSN@Q@Tob, and
(MSN@Q@Tob)Rh-AL in each well. The plate was incubated for 24 h at 37 °C without

76

shaking. Thereafter the biofilms were processed as mentioned above to determine the
absorbance at OD570.

3.3.20 Biofilms live dead assay
As mentioned earlier, biofilms were grown on cover slips. Coverslips 18 x18 mm
were placed in a 6-well polystyrene plate with lid and each well was filled with 2 mL of
bacterial suspension of 0.5 OD600. The coverslips were positioned completely immersed in
the bacterial suspension. Thereafter the plates were kept in the incubator at 37 °C for 24 h
for biofilm formation on the coverslips. After 24 h the unattached bacteria were removed,
and 2 mL of fresh TSB medium was subsequently added again. Thereafter, the grown
biofilms were treated with MSN, Tob, MSN@Q@Tob (MSN@Q@Tob)Rh-AL (50
μg/mL) for 6 h. After that, live/dead assays were carried out using a kit according to the
manufacturer’s instructions. After treatment, the cover slips were washed with sterile PBS
and the adhered bacteria were stained with SYTO 9 and propidium iodide (PI) for 30 min
at 37°C and visualized with a Zeiss 700 laser scanning confocal microscope.

3.3.21 Determination of changes in virulence factor Pyocyanin upon Q release
Pyocyanin assay was performed as previously reported.101 Briefly, a 100 μL of cell
suspension having 0.5 OD600 (approximately 2 x 107 CFU/mL) was inoculated in 100 μL
TSB medium in a 96 well plate closed with a peg lid to form biofilms. After 24 h of
incubation, the peg lid was transferred to a treatment plate containing 200 μL of different
concentrations - 2.5, 5, 10, 15, 20 mM of free QSI, MSN@Q, and (MSN@Q@Tob)Rh-
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AL. PBS (200 μL) was used as a control. After further incubation of 24 h at 37 °C,
pyocyanin in bacteria biofilms was extracted as follows.
Biofilm was dislodged into PBS solution by bath sonication for 30 min. This was
followed by extraction with 900 μL of chloroform. After extraction, the solution was reextracted with 250 μL of 0.2 M HCl to collect pyocyanin. After that, the pyocyanin level
in 80 μL of extract was determined by absorbance measurement at 520 nm. Furthermore,
the pyocyanin production in the presence of QSI, MSN@Q and (MSN@Q@Tob)Rh-AL
at 12 and 24 h were analyzed.
3.3.22 A549 cell proliferation
A549 cells were grown in T75 flasks in complete growth medium. Complete
growth medium was prepared by mixing Ham’s F-12K nutrient mixture with L-glutamine
(F-12K) (1X, 445 mL), FBS (10%, 50 mL) and Pen-Strep (1X, 5 mL) followed by sterile
filtration. The cells were grown in 20 mL of fresh and prewarmed (37 °C) medium at 37
°C in a humidified atmosphere of 5% CO2. Cell viability was assessed by Trypan blue
assay and counted using an automatic cell counter.
3.3.23 Internalization of (MSN@Q@Tob)Rh-AL into PA14 infected mammalian cells
In order to monitor the cellular uptake of nanoparticles by confocal microscopy,
(MSN@Q@Tob)Rh-ALs were labeled with the red fluorescent dye RITC. A549 cells (103
cells/mL) were cultured in a chamber slide for 24 h until complete adhesion occurs. After
adhesion and confluency (~ 90%) was achieved, the cells were incubated with PA14
bacteria (0.5 OD600 having approximately 2 x 107 CFU/mL) until biofilms are formed.
Thereafter, the slides were washed with sterile PBS to remove unadhered bacteria and
treated with RITC-(MSN@Q@Tob)Rh-ALs (200 μg/mL) for 6 h at 37 °C. After
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incubation, the cells were washed three times with cold PBS and stained with DAPI
staining for 10 min and FITC- Pseudomonas antibody (20 μL) staining for 10 min at 37
°C. Following that the samples were washed to remove excess dye and analyzed by
confocal microscopy.

3.3.24 Assessment of the antibacterial efficacy of (MSN@Q@Tob)Rh-AL within host
epithelial cells to kill ex-vivo PA14 biofilms
A549 cells were grown in chamber slides and infected with PA14 biofilms as
mentioned in Section 3.3.23. The ex-vivo biofilm grown A549 cells were then treated with
MSN@Q@Tob)Rh-ALs (200 μg/mL) for 6 h at 37 °C. After treatment cells were washed
and stained with bacterial live/dead assay kit as mentioned in section 3.3.20 to visualize
the antibacterial efficacy of MSN@Q@Tob)Rh-ALs towards ex-vivo grown biofilms.

3.3.25 Quantitative

evaluation

of

Intracellular

antibacterial

activity

of

(MSN@Q@Tob)Rh-AL within host epithelial cells to kill ex-vivo PA14 biofilms
A549 cells (103 cells/mL) were seeded on chamber slides and cultured overnight.
A volume of 100 μL of bacteria suspension having 0.5 OD600 (32 x 107 CFU/mL) was
added to each chamber and incubated for 24 h until biofilms are formed. After incubation,
the supernatant was discarded, and the infected cells were washed twice with PBS (1X).
Then the mammalian cell culture medium was replaced with a medium supplemented with
20 μg/mL Tob to kill any remaining extracellular planktonic bacteria without affecting the
intracellular bacteria. The infected A549 cells were cultured in fresh medium in the
presence of (MSN@Q@Tob)Rh-ALs (200 μg/mL). After 18 h of incubation, the cells were
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washed and the infected A549 cells were lysed, and the lysate was plated on tryptic soy
agar (TSA). The intracellular bacterial survival was determined by counting the bacterial
colonies.

3.3.26 A549 cell viability MTT assay
Mammalian cell viability was evaluated by using an MTT assay. First, A549 cells were
seeded onto 24-well plates at a density of 103 cells per well. After 24 h, they were incubated
with different concentrations (10, 100, 1000 μg/mL) of MSN, MSN@Q@Tob and
(MSN@Q@Tob)Rh-AL for 18 h. Then, 10 μL of the MTT solution (1 mg/mL) was added
into each well, and the cells were further incubated for 4 h. Afterwards, the culture medium
was discarded, and 150 μL of DMSO was added into each well. The absorbance intensity
was determined at 490 nm by a microplate reader. Results were presented as the percentage
viable cells with respect to untreated control cells.

Results and Discussion
3.4.1 Optimizing the enzyme activity on Alginate Lyase (AL) conjugated SNPs
When nanoparticles interact with proteins or enzymes, there is a tendency that they
might alter protein/enzyme conformation, expose new epitopes on the protein surface, or
perturb the normal protein function, change cellular uptake mechanism which could induce
unexpected biological reactions and lead to toxicity.188 Furthermore, the nanoparticle
protein/enzyme interaction also depends on unique properties of nanoparticles, such as
size, ligands, surface chemistry, surface curvature, surface charge, and environmental
impacts.52
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Therefore, as mentioned in Section 3.3.1, silica nanoparticles (SNPs) of three
different sizes were synthesized and coated with a rhamnolipid liposome layer and then
conjugated with the enzyme AL. Activity retention of AL was evaluated after conjugation
to nanoparticles of the described sizes and compared to the specific activity of the native
enzyme. After covalent conjugation, enzymatic activity was retained on all sizes of
particles (Figure 3.1a). It was observed that activity retention was inversely proportional
to particle size.

a.

b.

Figure 3.1. (a.) Activity retention of AL in the native form and conjugated
nanoparticles having sizes of 20nm, 90 nm, and 200 nm. (b.) Influence of enzyme
loading on the activity retention of AL conjugated to nanoparticles of 20 nm, 90 nm,
and 200 nm. Error bars represent SD of the mean.

Relative to the free enzyme, the highest activity retention (95.4 ± 3.8%) was seen
after conjugation of AL to 20 nm particles followed by 82.1 ± 3.2% and 37.29 ± 5.1 %
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activity retention after conjugation to 90 nm and 200 nm particles, respectively (Figure
3.1a). However, a significant decrease (p < 0.05) was seen in activity retention of the
conjugated enzyme in the 200 nm particles. These results further indicate that activity
retention is a function of particle size, and smaller carriers can yield recoverable conjugates
with specific activity values approaching that of the free enzyme. The increase in activity
retention with decreasing size of carrier has been documented for enzymes adsorbed or
conjugated to the surface of the materials including nanoparticles and nanotubes.51
Enhanced activity retention with decreasing particle size has been attributed to reduced
interactions between enzyme molecules on the surface of the nanoassembly. The smaller
the size of the nanoparticle, the larger the surface area: volume ratio as well as the higher
the surface curvature. This will ultimately lead to higher enzymes/surface area ratio and a
greater distance from the nanoparticle surface to the enzyme edge leading to lesser
coulombic and hydrophobic interactions between the nanoparticle and enzymes.56 This will
ultimately increase the enzyme activity on smaller particles. on the other hand, when the
particles are larger in size, they will have a lower surface curvature, leaving more space for
the enzymes to spread on the nanoparticle surface. This will further increase the enzyme
lateral- lateral interactions and stronger enzyme- nanoparticle interactions. Therefore, this
will reduce collision rates between the conjugated enzyme and the substrate and also
diminish substrate diffusion due to increased boundary layers with the particles size.54
It is been reported that lateral protein–protein interactions on the surface of the
nanoparticle carrier can lead to a decrease in activity retention due to associations between
adjacent enzyme molecules on the surface of the carrier.189 By decreasing the size of a
particle, the curvature of the particle increases and lateral protein-protein interactions are

82

reduced. To determine if lateral protein–protein interactions were responsible for decreased
activity retention as a function of particle size, the amount of enzymes conjugated were
decreased to one half as mentioned in Section 3.3.4. (Figure 3.1b). Reducing the conjugated
enzyme loading on the nanoparticles is expected to yield reduced interactions between
adjacent protein molecules on the surface of the carrier. So, if lateral protein–protein
interactions are responsible for loss of enzymatic activity, an increase in activity should be
observed with decreasing protein loading. In order to reduce the amount of enzyme loaded
onto the nanoparticle surfaces, the amount of COOH ligands (DSPE-PEG(2000)CA) on
liposome surface was reduced by half. With reduced enzyme conjugation no significant
difference in enzyme activity was observed in 200 nm (2.02 ± 0.3 %) nanoassemblies.
However, a significant decrease in activity (p < 0.05) was observed for the 20 nm (17.32 ±
0.5 %) and 90 nm (15.21 ± 0.2 %) nanoassemblies (Figure 3.1b). The decrease in activity
for the 20 nm and 90 nm particles may be due to enhanced surface interactions between the
enzyme and carrier that increase when these interactions are not restricted by neighboring
enzyme molecules under high loading conditions.190 These interactions may be less when
the enzymes are conjugated onto 20 nm particles, regardless of enzyme loading, due to
surface curvature of the particle.51 Likewise, neighboring molecules may only have a little
influence on restricting enzyme-material interactions when the enzyme is conjugated to
large particles ( 200 nm particles) or planar surfaces and therefore not a significant change
in the activity.51 However, these results suggests that lateral protein-protein interactions are
not the primary cause of loss of enzyme activity retention as a function of size.
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Figure 3.2. Michaelis- Menten scheme. E- enzyme, S- substrate (k1 and k-1 are the
rate constants for the formation and separation of the active E-S complex, k2 and k2 are the rate constants for the product formation and reverse catalysis reaction.)
Vmax - maximum reaction velocity, Km - Michaelis- Menten constant, kcat - turnover
number.

Enzymes conjugated to nanoparticles can be made mobile so they can diffuse and
collide with substrates in a similar manner to native free enzyme. Reducing the size of the
nanoparticle has been shown to increase the rate of collisions between the conjugated
enzyme and susbstrate.191
Additionally, thin films formed around the surface (boundary layers) of a carrier
can limit the substrate diffusion and product conversion. However, these boundary layers
usually decrease with the size of the particle.51 Boundary layers become larger when
enzymes attached to larger particles with flat a flat surface.
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Table 3.1. Kinetics of free al and al- conjugated nanoassemblies. Data are represented as
mean ± SD.
Vmax (nM s-1)

Km (mM)

kcat (s-1)

AL

1.665 ± 0.12

22.37 ± 0.40

0.0067 ± 0.0003

AL-NA (90 nm)

1.312 ± 0.09

23.03 ± 0.42

0.0069 ± 0.0002

AL-NA (200 nm)

3.519 ± 0.30

17.36 ± 0.50

0.0052 ± 0.0005

Enzyme activity can also decrease when substrate diffusion is limited. The enzyme
kinetics were determined after conjugation of the enzymes onto nanoassemblies (Figure
3.2). The kinetics were calculated using the above-mentioned equations (Figure 3.2). The
kinetic results are listed in Table 3.1 and Figure 3.3. These values would further explain
the reduction of activity retention with increase in nanoassembly size (Figure 3.3).

Figure 3.3. Enzyme kinetics. Sodium alginate (substrate) concentration vs enzymatic
reaction velocity with free AL, NA-AL (90 nm) and NA-AL (200 nm) (n=3). Error bars
represent SD of the mean.
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As shown in Figure 3.3, no significant change in Km, Vmax and kcat values were seen
in 90 nm nanoassemblies compared to the free AL as confirmed by the student's t-test.
However, according to the student's t-test performed between the free AL and AL
conjugated 200 nm particles, in 200 nm particles the Km, Vmax and kcat values were
significantly different from the free AL. Basically, the Km value has increased in ~2 folds
decreasing the enzymes' affinity to the substrate. This further indicates that molecular
collisions between the enzyme conjugates are decreasing with increasing particle size
which will further lead to loss of activity retention with increasing particle size.
Furthermore, the reduction in kcat on 200 nm particles could be correlated to
denaturation or reorientation of the enzyme on the surface of the nanoassembly. kcat value
is calculated from the Vmax and the total concentration of enzyme assuming that all
enzymes in the solution are enzymatically active (Figure 3.3).51 Therefore, the presence of
inactive enzyme on the nanoassembly would generate lower kcat values. Reduced kcat also
indicates lower enzyme-substrate interactions. Which could be due to increased surfaceenzyme interactions due to the increased of curvature of the large size of the 200 nm
nanoassembly.52 Based on these enzyme activity retention and kinetic experiments, it was
decided to use nanoparticles with the size of 90 nm for the remainder of the experiments.
In addition, the activity of AL after conjugation onto the nanoassemblies was also
quantitatively and qualitatively assessed as described in Section 3.3.7.
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Figure 3.4. β - elimination mechanism of Alginate degradation by Alginate Lyase.
Alginate is the main exopolysaccharide in the extra cellular polymeric matrix (EPS)
of biofilms. AL is known to break down alginates through β - elimination mechanism
(Figure 3.4). Breaking down the EPS matrix will control biofilm formation. For
quantitative determination, an absorbance assay was used where it measures the increase
in absorbance at 235 nm due to the formation of a C=C bond (Figure 3.4) at the product
generated from lyase mediated cleavage of alginates.
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Figure 3.5. Quantitative determination of Alginate Lyase activity by absorbance
assay. Error bars represent SD of the mean.

Both free AL and nanoassembly conjugated AL showed increase in absorbance
over time indicating the continuous product formation with time (Figure 3.5). However, as
shown in Figure 3.5, higher slope of AL conjugated nanoassemblies (AL-NA) confirmed
higher rate of product formation by AL-NA compared to free AL. This confirms that the
AL-NA is more efficacious in degrading alginates than the free AL.
Furthermore, the qualitative determination of AL activity was determined through
the gram’s iodine test (Figure 3.6). The agar plates were inoculated with biofilm forming
PA14 bacteria and a paper disk soaked with free AL and AL conjugated nanoassembly
(AL-NA) and incubated overnight. On the following day the cleared area around the paper
disks were measured and stained with grams iodine solution. Gram’s iodine a chromogenic
agent used to reveal hydrolyzed alginate. Gram’s iodine forms a bluish-black complex with
the alginates, but not with hydrolyzed alginates. Alginate lyase activity hydrolyzes alginate
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and therefore Gram’s iodine can be used to reveal areas where alginate lyase activity can
be seen. On an agar plate Gram’s iodine can produces distinct zones of clearance within 2
to 3 min after application (see Figure 3.6).187

AL
1.2 ± 0.5 cm

AL-NA
2.45 ± 0.4 cm

Figure 3.6. PA14 Biofilm grown agar plates flooded with Gram’s iodine solution
showing alginolytic zones. Data are represented as mean ± SD.

As shown in Figure 3.6, AL-NA showed a larger alginolytic (lysed alginate) zone
with 2.45 ± 0.4 cm diameter (~ 50% increase compared to free AL). Whereas AL alone
was showed an alginolytic zone which was 1.2 ± 0.5 cm diameter. As confirmed by both
quantitative (Figure 3.5) and qualitative tests (Figure 3.6) AL conjugated nanoassembly
was able to successfully degrade alginates at a better rate than free enzyme AL.
According to these alginate degradation studies, AL conjugated nanoassembly
(AL-NA) has shown increased degradation compared to free AL. This might be due to the
fast recovery of conjugated enzymes allowing multiple reuse of enzymes and continuous
operation of enzymatic processes.192
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3.4.2 Preparation and Characterization of (MSN@Q@Tob)Rh-AL
The (MSN@Q@Tob)Rh-AL nanoassembly was synthesized using mesoporous
core shell nanoparticles and loaded with Tob and QSI. Following drug loading
(MSN@Q@Tob) the mesoporous particles were coated with a rhamnolipid (Rh) liposome
layer tagged with the enzyme alginate lyase (AL) to results in the final nanoassembly
(MSN@Q@Tob)Rh-AL (Scheme 3.2).

Tobramycin (Tob)
OH

O

H 2N

NH2

NH2

O
trans- Cinnamaldehyde (QSI)
O

HO

HO
O

NH2
O

H

HO

OH
NH2

Scheme 3.2. Schematic illustration of synthetic route of (MSN@Q@Tob)Rh-AL .
MSNs were prepared following surfactant-template method as described in Section
3.3.8. Following synthesis of the MSNs, they were loaded with the quorum sensing
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inhibitor (QSI/Q) trans-cinnamaldehyde. Quorum sensing (QS) systems are known to help
forming complex biofilms by upregulating the expression of several virulence factors
through inter-bacterial chemical communications. Pseudomonas aeruginosa (PA) has 3 QS
systems as Las, Rhl, and Pqs which are controlled by their own signal and regulatory
proteins.193 These QS systems will activate in a cell density dependent manner. These cellcell communication systems with the high density of bacteria cells in the biofilm can
coordinate gene regulation, control biofilm formation and host-bacteria interactions
(Scheme 3.3).194

Scheme 3.3. Growth of BF from planktonic cells and associated QS systems.
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RhI and Pqs QS systems regulate the synthesis of Rh, which are glycolipid
biosurfactants composed of rhamnose and 3 (hydroxyalkanoyloxy) alkanoic acid.195
PA, Rhs contribute in maintaining a stable biofilm architecture by reducing adhesion
between bacterial cells. Furthermore, these heat stable extracellular Rhs act as a “biofilm
shield” against antibiotics and act against host immunity by lysing leukocytes

and

monocyte-derived macrophages, resulting in necrotic cell death.61 The inhibition of Rhs or
the QS RhI system would enhance the chances of eradicating the PA biofilms.196 Therefore,
developing a nanoassembly, which can target the virulence factors of biofilm at the same
time is essential for the complete eradication of BFs. It has been found that the QSI, transcinnamaldehyde can inhibit all 3 QS systems in Pseudomonas biofilms to downregulate
the production of virulence factors such as pyocyanin and rhamnolipids.197
After loading the QSI into the mesoporous core of the MSNs, the cationic antibiotic
tobramycin (Tob) was conjugated onto the surface of the MSNs where Tob will be released
to the inner core of the biofilm to inhibit PA bacteria that lie in the biofilm core.101 The
Tob loaded MSNs were coated with a rhamnolipid layer consisting of

DSPE-

PEG(2000)CA. DSPE-PEG(2000)CA was used to facilitate covalent conjugation of AL
enzyme using EDAC/NHS chemistry. The Rh liposomes layer is supposed to transport
nanoassembly through the rhamnolipid shield. Furthermore, the liposome coating supports
the release and stability of the Tob loaded MSNs.65 Upon internalization the liposome layer
will be degraded through bacteria secreted lipases and facilitate Q and Tob release.
Alginate is the main physical barrier for PA biofilms, which is secreted by the
matrix polysaccharide consisting of D-mannuronic acid and L-guluronic acid. This provides
nutritional support to the incorporated bacteria, cell to cell/cell to BF connectivity,
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structural stability and rigidity.198,199 Alginate act as an excellent barrier to antibiotic
therapy by preventing drug penetration, acting against host immunity systems and repelling
antibiotics away from its matrix.200 The alginate in the EPS matrix will be hydrolyzed AL.
The AL enzyme will hydrolyze the glycosidic linkages of alginate polysaccharide. Which
will allow (MSN@Q@Tob)Rh-AL to penetrate further into the biofilm.
The structure of the nanoassemblies were first examined through TEM (Figure 3.7).
The TEM images confirmed the mesoporous structure of bare MSNs (Figure 3.7a). The
reduction of pores was observed with loading of QSI and Tob in (MSN@Q@Tob)
compared to the bare MSNs (Figure 3.7b). Also, MSN@Q@Tob displayed change in
surface morphology probably due to surface interactions with the positively charged Tob
(Figure 3.7b). In (MSN@Q@Tob)Rh , the single lipid layer coated around each
MSN@Q@Tob can be clearly observed through TEM (Figure 3.7c). This further confirms
the presence of Rh liposome layer around the (MSN@Q@Tob)Rh (Figure 3.7c).

a

b

MSN

c

MSN@Q@Tob

(MSN@Q@Tob)Rh

Figure 3.7. TEM images of a) MSNs (b) MSN@Q@Tob and (c) (MSN@Q@Tob)Rh (scale
bar = 50 nm).
Furthermore, the successful synthesis of (MSN@Q@Tob)Rh-AL was confirmed
by the increase in size and the changes of zeta potential after each step (Table 3.2). TEM
images were analyzed using ImageJ to determine the dry diameter of the particles. TEM
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image of MSNs displayed a diameter of 85 ± 12 nm (Table 3.2) and after loading of QSI
the diameter did not change significantly (89 ± 7 nm). After Tob loading the diameter
showed an increased value of 96 ± 11 nm. Liposomal coating increased the diameter to 105
± 5 nm (Table 3.2). This confirmed the successful coating of Rh lipid layers. Final
nanoassembly (MSN@Q@Tob)Rh-AL had a diameter of 112 ± 8 nm. The hydrodynamic
diameter determined by DLS showed 256 ± 11 nm for MSNs to 521 ± 4 nm for the final
nanoassembly (Table 3.2). The larger size determined by DLS was possibly due to
agglomeration of particles in solution and particle swelling.
Table 3.2. Hydrodynamic size (DLS), dried size (TEM) and zeta potential (DLS) of the
nanoassemblies. Data are represented as mean ± SD.
Hydrodynamic size TEM
from DLS (nm)

Size Zeta

(nm)

(mV)

potential

MSN

256 ± 11

85 ± 12

- 25. 4 ± 0.8

MSN@Q

261 ± 5

89 ± 7

- 20.9 ± 1.2

MSN@Q@Tob

344 ± 8

96± 11

+ 2.48 ± 0.6

(MSN@Q@Tob)Rh

424 ± 6

105 ± 5

+ 5.79 ± 0.4

(MSN@Q@Tob)Rh-AL

521 ± 4

112 ± 8

+ 7.81 ± 0.5

The zeta potential measurements reflected the surface charge of the nanoassemblies
(Table 3.2). Zeta potential measurements were used to track the surface change in each step
of the synthesis of the nanoassembly. The negative zeta potential of -25.4 ± 0.8 mV of bare
MSNs was due to the presence of negatively charged silicate on the surface of the MSNs.
The zeta potential increased to -20.9 ± 1.2 mV after loading QSI indicating the loss of
silicate charges on the MSN surface. After loading cationic antibiotic Tob increased the
zeta potential up to +2.48 ± 0.6 mV. Furthermore, the Rh liposome coating increased the
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zeta potential to 5.79 ± 0.4 mV due to the presence of polar head groups of the
phospholipids. Final nanoassembly with AL conjugation further increased the zeta
potential to 7.81 ± 0.5 mV. This was used as proof of successful conjugation of AL enzyme
on the Rh liposome exterior.

Figure 3.8. FTIR spectra of MSN, MSN@Q, QSI, MSN@Q@Tob and Tob.

Products were analyzed qualitatively by Fourier-transform infrared spectroscopy.
FT-IR spectral analysis tracked and confirmed the successful QSI and Tob loading into the
MSNs (Figure 3.8). FT-IR of MSN displayed characteristic absorption peak at 1020 - 1110
cm-1, which can be assigned to the Si-O-Si asymmetric stretching vibration, and a peak at
960 cm-1 indicative of the asymmetric bending and stretching vibration of Si-OH.168
95

Upon Q loading, a clear C=O stretching vibration around 1700 cm-1, aromatic ring C-H
stretching vibration around 3000 cm-1, C-H and CH2 stretching vibrations around 2900 cm1

, a band around 2800 cm-1 for CH stretching of the aldehyde group and aromatic C=C

peak around 1500 cm-1 were appeared (Figure 3.8).201 Peaks corresponding to N-H or O-H
stretching around 3300 cm-1, a band at 1590 cm-1 for N-H bending, a typical band at 1461
cm-1 due to CH2 scissoring, bands at 1349–1380 cm-1 due to O–H in-plane bending
vibrations, and a band at 1032 cm-1 due to C–N or C–O stretching appeared with Tob
loading (Figure 3.8).202 High resolution individual spectra are presented in the Appendix
B Figure B.2, Figure B.3, Figure B.4, Figure B.5, and Figure B.6.

Figure 3.9. FTIR spectra of Rh, AL and (MSN)Rh-AL.
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Following Rh liposome coating, the antisymmetric and symmetric C−H stretching
vibrations for the characteristic lines for the long carbon chain of the lipids were seen
around 2900 and 2850 cm−1, respectively (Figure 3.9). Finally, with the AL conjugation,
C-N bending, N-H bending and N-H stretching vibrations corresponding to appearance of
new amide bonds were seen around 1600 cm-1 , 3300 cm-1 , and 3200 cm-1 respectively
(Figure 3.9) (High resolution individual spectra are presented in the appendix B Figure B.7,
Figure B.8, and Figure B.9).184

Figure 3.10. N2 adsorption−desorption isotherm for MSN, MSN@Q and MSN@Q@Tob.

The typical N2 adsorption−desorption isotherm for MSNs confirmed the porosity
of MSNs (Figure 3.10). As described in the Section 3.3.10, multi point BET analysis by
the BJH method calculated the porosity to be 881 m²/g and a pore volume of 2.732 cm3/g
of the MSNs. The pore size (radius) of the MSNs was calculated to be 19.15 nm according
to BJH method (Table 3.3). BET analysis of MSN@Q had a smaller surface area 705.5
m²/g, a smaller pore volume (2.516 cm3/g) and a smaller pore radius of 18.27 nm (Table
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3.3). The surface area (30 %), pore volume (11.4 %) and pore radius (5.4%) has further
reduced upon Tob loading indicating some Tob also get into the pores of the MSNs other
than attaching onto the MSN surface (Table 3.3).
Table 3.3. Table of surface area, pore volume and pore size data of MSN, MSN@Q and
MSN@Q@Tob from BET analysis.
MSN

MSN@Q

MSN@Q@Tob

Surface area
(MultiPoint BET)

881 m²/g

705.5 m²/g

616.7 m²/g

Pore volume
(BJH method)
Pore size
(BJH method)

2.732 cm3/g

2.516 cm3/g

2.42 cm3/g

19.15 nm

18.27 nm

18.11 nm

The quantitative ligand analysis of the nanoassembly after each synthesis step was
performed by TGA. Percentage (%) weight loss between the MSN@Q and MSN was
calculated to determine the amount of QSI loaded onto MSNs. The QSI loading was found
to be 67.9 ± 5 mg per gram of MSNs (67.9 ± 5 mg/g) which corresponds to 6.71 ± 0.5 %
loading (Figure 3.11). Tob loading was calculated to be 5.06 ± 0.3 % compared to
MSN@Q.

Also,

the

percentage

weight

loss

between

MSN@Q@Tob

and

(MSN@Q@Tob)Rh-AL displayed that the overall weight of AL and Rh layer together is
4.04 ± 0.7 % (39.2 ± 0.6 μg/g of (MSN@Q@Tob)Rh-AL) (Figure 3.11). However, the
quantity of AL calculated by the micro-BCA assay indicated that the final nanoassembly
to have 16.3 ± 0.2 μg/g AL. In conclusion the Rh layer weigh 22.9 ± 0.4 μg/g of
(MSN@Q@Tob)Rh-AL.
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Figure 3.11. TGA curves recorded for MSNs, MSN@Q, MSN@Q@Tob,
(MSN@Q@Tob)Rh and (MSN@Q@Tob)Rh-AL.

Encapsulation efficiency (EE) and the loading capacity (LC) of the Q and Tob in
MSNs were determined using the equations mentioned in the Section 3.3.13. EE of
MSN@Q was calculated to be 87.03 ± 3.4 % and LC was calculated to be 34.81 ± 2.6 %.
Whereas the EE of MSN@Q@Tob was 82.53 ± 5.1 % and the LC was calculated to be
24.49 ± 1.3 %. The lower LC compared to higher EE was probably due to the use of larger
quantity of MSNs (50 mg) compared to the amount of drug (20 mg) been used in loading.
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3.4.3 Assessment of the nanoassembly internalization into the biofilm and subsequent
antibacterial activity

Figure 3.12. Growth of biofilm biomass with different volumes of bacteria PA14.
Error bars represent the SD of the mean.
Biofilm growth was optimized as described in the Section 3.3.6. and the biomass
was determined by the UV-Vis spectroscopy at OD570 (Figure 3.12). After determining the
optimum biofilm growth, the biofilms were grown on cover slips and the permeation of the
nanoassemblies through the biofilm was determined by the confocal laser scanning
microscopy. One of the main aspects of this study was to determine whether the
rhamnolipid liposome layer can migrate through the biofilm rhamnolipid shield to reach
the biofilm inner core bacteria to release the drugs. Therefore, two types of nanoassemblies
were developed, one with a Rh- liposome layer ((MSN@Q@Tob)Rh) and another with
liposome layer without Rh ((MSN@Q@Tob)LL). These two different nanoassemblies
were introduced to biofilms grown on cover slips (Appendix Figure B.10) and their
penetration through the depth of the biofilm was compared with the final nanoassembly
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(MSN@Q@Tob)Rh-AL (Figure 3.13). Both nanoassemblies were conjugated to red
fluorescent DiI dye and the depth of penetration was tested in SYTO 9 stained (green
fluorescent) biofilms. All images were processed using ImageJ software.

Figure 3.13. Quantification of the fluorescence intensity of SYTO 9 stained
biofilms treated with DiI conjugated (MSN@Q@Tob)LL, (MSN@Q@Tob)Rh and
(MSN@Q@Tob)Rh-AL with respect to the depth of the biofilm. Error bars
represent the SD of the mean.

As shown in Figure 3.13, normalized fluorescence intensity of the permeated
nanoassemblies (red), were quantitatively analyzed relative to the distance from the surface
to the base of the biofilm. The mean thickness of the biofilm was 45 ± 0.4 µm.
(MSN@Q@Tob)Rh and (MSN@Q@Tob)Rh-AL showed a similar permeation pattern.
101

However, the AL conjugated nanoassembly (MSN@Q@Tob)Rh-AL, showed slightly
increased permeation compared to (MSN@Q@Tob)Rh without AL, indicating that AL
clears the path for the nanoparticles to migrate through by hydrolyzing the physical barrier
of alginates (Figure 3.13). It was clear that both Rh containing nanoassemblies showed an
increase in permeation until 20-25 µm of the biofilm depth and plateaued and thereafter.
For (MSN@Q@Tob)Rh a small drop in the penetration was seen 25 µm of penetration.
Overall, (MSN@Q@Tob)Rh

and (MSN@Q@Tob)Rh-AL nanoassemblies showed a

lesser distribution on the surface but higher distribution in the depth of the biofilm.
However, non-Rh coated nanoassembly (MSN@Q@Tob)LL seem to strongly adhere to
the surface of the biofilm and did not seem to penetrate well through the rest of the biofilm.
This clearly shows that the Rh coated nanoassemblies promote penetration throughout the
biofilm compared to the non-Rh coated biofilm confirming the fact that Rh liposome layer
support the nanoassemblies to pass through the biofilm rhamnolipid shield.
These results were further confirmed by the orthogonal z stack images from
confocal microscopy. These each orthogonal image in Figure 3.14, was the 3D projection
of nine layers in the biofilm center from the z-stack and the images on the top and the right
side were the central layer from the y-stack and x-stack respectively. The DiI conjugated
nanoassemblies were tracked with time as shown below (Figure 3.14). In each different
time point (2h, 6h, 12h) the biofilms introduced with nanoassemblies were examined under
microscope to evaluate their penetration through the biofilm. The excessive increment of
red intensity with (MSN@Q@Tob)Rh with time indicates that more Rh- liposome coated
nanoassemblies, (MSN@Q@Tob)Rh have penetrated to the depth of the biofilm with time
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compared

to

significantly

low

amount

of

non-Rh

liposome

nanoassemblies

((MSN@Q@Tob)LL) ( Figure 3.14).
(MSN@Q@Tob)Rh

(MSN@Q@Tob)LL

2h

6h

12 h

Figure 3.14. Orthogonal images from confocal laser scanning microscopy of PA14
biofilms treated with Rh containing ((MSN@Q@Tob)Rh) and non-Rh containing
((MSN@Q@Tob)LL) liposome nanoassemblies. Scale bar- 20 μm.
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The penetration of (MSN@Q@Tob)Rh-AL was studied to assess the penetration
in 3D projections. As shown in Figure 3.15, the DiI conjugated (MSN@Q@Tob)Rh-AL
penetration has increased with time. When compared with the 2h and 12 h particle
distribution (red) in the biofilm (green), there is a higher red intensity in 12h biofilm.

(MSN@Q@Tob)Rh-AL
(red)
merged into the biofilm (green)

(MSN@Q@Tob)Rh-AL
particles (red) alone

2h

12h

Figure 3.15. 3D- projections of SYTO 9 labeled biofilms (green) treated with DiI
labeled
(MSN@Q@Tob)Rh-AL
(red).
Topographic
distribution
of
(MSN@Q@Tob)Rh-AL after 2 and 12 h of incubation.

The presence of DiI- (MSN@Q@Tob)Rh-AL (red) at the bottom layers of the
biofilm after 12 h of incubation demonstrates the penetration of final nanoassembly
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through the biofilm with time. These results further confirm the improved availability of
loaded drugs in the biofilm core.
After confirming the successful penetration of the (MSN@Q@Tob)Rh-AL into the
biofilm core, the QSI and Tob release at the inner biofilm core was determined as described
in the section 3.3.16. The QSI and Tob release from (MSN@Q@Tob)Rh-AL has increased
over time indicating that the bacteria secreted lipases and phospholipases successfully
degraded the Rh liposome coating around the drug loaded MSNs (Figure 3.16)176,177. The
QSI release from (MSN@Q@Tob)Rh-AL was measured using UV-vis spectroscopy at 310
nm and the Tob release was detected by HPLC (calibration curves for QSI and Tob are
supplemented in appendix B, Figure B.11 and Figure B.12). After about 40 hours, 78.67 ±

Figure 3.16. Cumulative release of QSI and Tob from (MSN@Q@Tob)Rh-AL.
Error bars represent the SD of the mean.
5 % Tob and 63.33 ± 3 % QSI has been released from (MSN@Q@Tob)Rh-AL (Figure
3.16).
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Slight increase of release in Tob might be due to the fact that Tob was mostly
electrostatically attached to the MSN surface whereas, QSI is mostly loaded inside the
pores of the MSNs which might take more time for it to release.
As the results of QSI and Tob inside the biofilm core were confirmed, the
antibacterial ability of QSI and Tob towards the biofilm in inner core bacteria was assessed
next. Minimum inhibitory concentration (MIC) of PA14 planktonic bacteria and Minimum
biofilm eradication concentration (MBEC) tests were performed as mentioned in the
Section 3.3.17 and 3.3.18.

Table 3.4. Table of MIC and MBEC values obtained for different nanoassemblies (The
concentration of QSI was kept at 20 µM and kept constants for all the assays. Tob
concentration was changed from 3.125 - 200 μg/mL).
Samples

MIC against PA14

MBEC against PA14
biofilm

MSN

>200 µg/mL

>200 µg/mL

QSI (con. kept a constant)

>20 µM

>20 µM

MSN@Q
* With reference to QSI
Tob

>20 µM

>20 µM

37.5 µg/mL

300 µg/mL

MSN@Q@Tob

18.8 µg/mL ([Q ]=20 µM)

200 µg/mL

(MSN@Q@Tob)Rh-AL

9.4 µg/mL ([Q ]=20 µM)

25 µg/mL

As shown in Table 3.4, with the concentration series used in this experiment, no
PA14 planktonic bacteria or biofilm eradicating effect was observed with 200 µg/mL of
bare MSNs, 20 µM QSI and 20 µM MSN@Q. That reflects a higher concentration of the
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above mentioned nanoassemblies will be needed to see PA14 bacteria or bacteria biofilm
eradication. PA14 biofilms could only be completely eradicated with free Tob
concentration of 300 µg/mL (Table 3.4). The amount of free Tob needed is x9 more than
what is necessary to eradicate planktonic PA bacteria (which is Tob 37.5 µg/mL). This
limited efficacy might be due to strong interaction with the biofilm matrix which results in
slow and incomplete Tob permeation into the biofilm core.203 Furthermore, bacteria might
become metabolically less active in the biofilm thereby being less sensitive to Tob.
However, MSN@Q@Tob showed a slight improvement in efficacy with the determined
MBEC value of 200 µg/mL (where the QSI concentration was kept constantly at 20 µM).
However, only 18.8 µg/mL of MSN@Q@Tob was needed to kill planktonic PA bacteria.
These results represent an encouraging proof of concept that Tob and QSI can act
synergistically. Therefore, we hypothesized that simultaneous co-delivery of Tob and QSI
together with a Rh liposome layer and tagged AL would further enhance the efficacy. This
will further facilitate better biofilm penetration of the nanoassembly and therefore better
bioavailability of Tob inside the biofilm. With (MSN@Q@Tob)Rh-AL, MBEC reduced
to 25 µg/mL, which is nearly 12 fold lower than 300 µg/mL needed with free Tob (Table
3.4). This further confirmed the fact that (MSN@Q@Tob)Rh-AL was successful in
treating PA14 biofilms than compared to free Tob. Besides enhanced biofilm penetration
it can be speculated that the nanoassembly enhances the solubility of Tob and QSI which
maximizes the antibiotic effect of Tob and enables PA biofilm treatment at significantly
lower Tob concentrations.
As the nanoassembly was very effective in biofilm treatment, its ability to inhibit
biofilm formation and degrade already formed biofilms were determined by two different
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assays as mentioned in Section 3.3.19 and compared the biofilm inhibition rate and biofilm
degradation rate with other nanoassemblies.
According to the student’s t-test, a significantly high antibacterial activity towards
growing biofilms was seem to be observed between free Tob and the final nanoassembly
(MSN@Q@Tob)Rh-AL staring from 25 µg/mL to 200 µg/mL (Figure 3.17). With increase
in concentration, the antibiofilm forming efficacy of (MSN@Q@Tob)Rh-AL notably
increased over free Tob (14.62 ± 0.41 % increment in 25 µg/mL to 37.43 ± 0.23 % in 200
µg/mL). This could be because alginate lyase can efficiently degrade the alginate, which is

Figure 3.17. Biofilm formation inhibition assay with different concentrations of
Tob, AL, MSN@Q@Tob and (MSN@Q@Tob)Rh-AL. Error bars represent the
SD of the mean. (in student's t-test * indicates p < 0.05).
the core component of the biofilm matrix. Furthermore, QSI in (MSN@Q@Tob)Rh-AL
also contributed to the higher biofilm inhibition affinity compared to free Tob by inhibiting
biofilm inner core bacterial communication.
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In a biofilm degradation assay (Figure 3.17), at 25 µg/mL, the biofilm degradation
ability of (MSN@Q@Tob)Rh-AL was 1.6 fold higher than free Tob (student's t-test was
used for the comparison). Based on both, biofilm formation inhibition (77 ± 2.5 %) and
biofilm degradation (84 ± 2.2 %), (MSN@Q@Tob)Rh-AL showed enhanced efficacy
towards degrading biofilms more efficiently confirming that AL together with a Rh
liposome layer facilitates the enhanced degradation.

Figure 3.18. Biofilm degradation assay with different concentrations of Tob, AL,
MSN@Q@Tob and (MSN@Q@Tob)Rh-AL. Error bars represent the SD of the mean.
(in student's t-test * indicates p < 0.05).
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Figure 3.19. Comparison of antibacterial efficacy of nanoassemblies using BacLight®
live/dead assay. Fluorescence microscopy images showing the presence of live bacteria
(green) and dead bacteria (red) following treatment with MSN, Tob, MSN@Q@Tob, and
(MSN@Q@Tob)Rh-AL at the concentration 50 μg/mL (scale bars represent 20 μm).

The antibiofilm eradication activity of different nanoassemblies was further
evaluated by the live/ dead fluorescence assay (Figure 3.19). Free Tob, MSN,
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MSN@Q@Tob and (MSN@Q@Tob)Rh-AL having a concentration of (50 μg/mL) were
incubated with PA biofilms and the results were observed through fluoresce microscopy.
Green fluorescent nucleic acid dye SYTO 9 penetrates the cell membrane of both live and
dead bacterial cells. Red fluorescent nucleic acid dye propidium iodide (PI) only penetrates
cells with damaged cell membranes. In the presence of both dyes, bacteria with intact cell
membranes appear fluorescent green (live), whereas membrane-compromised bacteria
appear in red (dead).179
Negative control MSN showed high green fluorescence indicative of more live
bacteria in the biofilm. The appearance of red fluorescence indicates compromised
bacterial

membranes

indicating

dead

bacteria.

Tob,

MSN@Q@Tob,

and

Figure 3.20. Production of the virulence factor, Pyocyanin levels after treatment with free
QSI, MSN@Q and (MSN@Q@Tob)Rh-AL. Error bars represent the SD of the mean. (in
student's t-test * indicates p < 0.05).
(MSN@Q@Tob)Rh-AL exhibited strong red fluorescence indicating compromised
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membranes which increases permeability to red fluorescent PI respectively (Figure 3.19).
The intensity of red fluorescence has increased from Tob to MSN@Q@Tob to
(MSN@Q@Tob)Rh-AL reflecting more dead bacteria. The aggregation of dead bacteria
(seen as red clusters) with (MSN@Q@Tob)Rh-AL compared to that of Tob and
MSN@Q@Tob further indicated the ability of (MSN@Q@Tob)Rh-AL to eradicate PA
biofilm bacteria. After confirming the ability of the nanoassembly to destroy bacteria, the
QSI activity of the final nanoassembly, (MSN@Q@Tob)Rh-AL was investigated (Figure
3.20).
Pyocyanin inhibitory efficacy of free QSI and (MSN@Q@Tob)Rh-AL were
compared using EC50 values. EC50 value refers to the half maximal effective concentration
of a drug which can induce a response halfway between the baseline and the maximum.101
As shown in Figure 3.20, the EC50 value of free QSI was 3.9 ± 0.7 µM and the EC50 of
(MSN@Q@Tob)Rh-AL lower (1.3 ± 0.3 µM ) indicating that the (MSN@Q@Tob)Rh-AL

Figure 3.21. Comparison of Pyocyanin production levels with time after treatment with
control (MSN), free QSI, MSN@Q and (MSN@Q@Tob)Rh-AL. Error bars represent the
SD of the mean. ( n = 3, in student's t-test **** indicates p < 0.0001).
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is more efficacious in reducing the virulence factor, pyocyanin production. Furthermore,
this indicates higher availability of hydrophobic drug Tob at the bacteria vicinity.
Pyocyanin production has reduced with increased treatment time. With
(MSN@Q@Tob)Rh-AL, there is a 32.5 ± 0.1 % production of pyocyanin in 12 h whereas
12.3 ± 0.6 % production within 24 h (Figure 3.21). Also, there is a significant difference
in pyocyanin production of free QSI (95.2 ± 0.1 % at 12 h and 62.7 ± 0.3 % at 24h) and
(MSN@Q@Tob)Rh-AL with time as confirmed by student's t-test . This further confirms
the fact that (MSN@Q@Tob)Rh-AL facilitate the release of QSI in the biofilm core and
further inhibit bacterial communication by inhibiting quorum sensing within the biofilm.

3.4.4 Evaluating the antibacterial efficacy of (MSN@Q@Tob)Rh-AL within host
epithelial cells to kill ex-vivo PA14 biofilms
The final nanoassembly was evaluated for its ability to eradicate ex-vivo biofilms
grown on mammalian host epithelial cells. As described in Section 3.3.24. the non-small
cell lung cancer cells (A549) were grown on chamber slides and PA14 bacteria was
FITCPseudomonas antibody

Dapi
stained nucleus

Merge

Dapi

Figure 3.22. Ex vivo biofilms grown on A549 cells. (Scale bar represent 20 µm).
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inoculated with the attached epithelial cells for ex-vivo biofilm growth. The growth of
biofilms was tested using FITC- conjugated PA antibodies (green fluorescence). The
epithelial cells (blue) were incubated with PA14 bacteria in order to form ex-vivo biofilms
(green) (Figure 3.22). The ex-vivo growth of biofilms on the epithelial cells can be seen in
Figure 3.22. The nanoassembly internalization into the biofilm grown on epithelial cells
was investigated through confocal microscopy.
Ex-vivo grown biofilms were treated with RITC-(MSN@Q@Tob)Rh-AL (red
fluorescence) as described before to determine the ability of nanoassemblies to internalize
into the epithelial cells grown biofilms (Figure 3.23). Green FITC Pseudomonas antibody
illustrates the presence of bacteria biofilms inside the Dapi stained (blue) cells. In the
merged image (Figure 3.23), the enhanced red fluorescence around the green FITCPseudomonas antibodies confirmed the internalization of the nanoassemblies into A549
epithelial cells.

FITCPseudomonas antibody

Dapi
stained nucleus

RITC(MSN@Q@Tob)Rh-AL

Merge

Figure 3.23. Internalization of RITC-(MSN@Q@Tob)Rh-AL (red) into ex-vivo
biofilm grown (green) A549 mammalian cells (blue). (Scale bar represent 20 µm).

Figure
Internalization
of RITC-(MSN@Q@Tob)Rh-AL
(red)wasinto
ex-vivo
The3.28.
ability
of the nanoassembly
to exert antibacterial activity
further
studied
biofilm grown ((green) A549 mammalian cells (blue). (Scale bar represent 20 µm)
qualitatively by confocal microscopy and quantified by colony counting assays. For
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Figure 3.29. Internalization of RITC-(MSN@Q@Tob)Rh-AL (red) into ex-vivo
biofilm grown ((green) A549 mammalian cells (blue). (Scale bar represent 20 µm)

qualitative analysis, the ex-vivo biofilms grown on A549 epithelial cells were treated with
(MSN@Q@Tob)Rh-AL, and a live/dead bacteria assay was performed before and after
treatment with (MSN@Q@Tob)Rh-AL (Figure 3.24). The assay conducted before treating
with (MSN@Q@Tob)Rh-AL showed more green bacteria in the merged image indicating
more live cells whereas after treatment most of the biofilm bacteria showed damaged
Dapi
stained nucleus

Dead bacteria

Merge

Dapi

After treatment

Before treatment

Live bacteria

Figure 3.24. Comparison of the antibacterial efficacy of (MSN@Q@Tob)Rh-AL in
eradicating mammalian epithelial cell grown ex-vivo biofilms using BacLight®
live/dead assay. Confocal laser scanning microscopy images showing the presence of
live bacteria (green) and dead bacteria (red) before and after treatment with
(MSN@Q@Tob)Rh-AL (scale bars represent 10 μm).

membranes with red fluorescence (before and after merged images of Figure 3.24). Notable
Figure 3.31Figure 3.32. Comparison of the antibacterial efficacy of (MSN@Q@Tob)Rhincrease in red fluorescence (dead bacteria) after treatment further confirmed the fact that
AL in eradicating mammalian epithelial cell grown ex-vivo biofilms using BacLight®
live/dead assay. Confocalwas
laser
scanning
microscopy
images
showing
thebiofilms
presencefrom
of
(MSN@Q@Tob)Rh-AL
able
to successfully
destroy
ex-vivo
grown
live bacteria (green) and dead bacteria (red) before and after treatment with
(MSN@Q@Tob)Rh-AL
(scale bars represent 10 μm)
mammalian
cells.
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Figure 3.33. Photographs showing the PA14 biofilm colonies after treatment with Tob
and MSN@Q@Tob)Rh-AL

For quantitative analysis, the bacteria colonies before and after treatment were
calculated through micro-broth dilution. There were 32 x 107 CFU/mL of bacterial colonies
in the initial biofilm and after treatment with (MSN@Q@Tob)Rh-AL, the number of
colonies reduced to 650 CFU/mL, which reflects a 99.9 % reduction in colonies. This
quantitative

study

also

confirmed

the

enhanced

antibacterial

activity

of

(MSN@Q@Tob)Rh-AL (Figure 3.25). After treatment with Tob alone the number of
bacterial colonies that survived were 37 x 106 CFU/mL reflecting 88.4% of reduced
colonies (Figure 3.25).

Tob

(MSN@Q@Tob)Rh-AL

Figure 3.25. Photographs showing the PA14 biofilm colonies after treatment with Tob
and MSN@Q@Tob)Rh-AL.

Finally, the cytotoxicity of different concentrations of MSN, MSN@Q@Tob and
(MSN@Q@Tob)Rh-AL towards A549 epithelial cells was investigated using MTT cell
viability assay as described in Section 3.3.26. Metabolically active mammalian cells reduce
the yellow tetrazolium salt in the MTT assay by the action of dehydrogenase enzymes. The
resulting intracellular purple formazan product was identified as an indicator of live cells.183
The results demonstrated that high concentrations (1 mg/mL) of MSN@Q@Tob nor
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(MSN@Q@Tob)Rh-AL have any significant cytotoxicity towards A549 cells (Figure
3.26).

Figure 3.26. Cell viability of A549 cells incubated with different concentrations of
nanoassemblies, MSN, MSN@Q@Tob and Col (MSN@Q@Tob)Rh-AL respectively.
Error bars represent the SD of the mean.
.

Scheme 3.5. schematic illustration of proposed mechanism of action of the dual
Conclusion
targeted
nanoassembly and ROS induced cancer cell deathFigure 3.47. Cell viability of
A549 cells incubated with different concentrations of nanoassemblies, MSN,
In this study, the MSNs were successfully coloaded with two different drugs, using
MSN@Q@Tob and Col (MSN@Q@Tob)Rh-AL respectively.
the advantage of having pores to load hydrophobic drugs and a negatively charged outer
surface to load cationic antibiotic. Following drug loading the MSNs were coated with
Scheme 3.6. schematic illustration of proposed mechanism of action of the dual
rhamnolipid
(Rh) liposomes.
coated
showed a significantly
targeted nanoassembly
and The
ROSrhamnolipid
induced cancer
cell liposomes
death
increased migration through the biofilm depth (100% normalized fluorescence intensity of
Scheme 3.7. Synthesis of (MSN@Px)L-GFScheme 3.8. schematic illustration of
proposed mechanism of action of the dual 117
targeted nanoassembly and ROS induced
cancer cell deathFigure 3.48. Cell viability of A549 cells incubated with different
concentrations
of
nanoassemblies,
MSN,
MSN@Q@Tob
and
Col
(MSN@Q@Tob)Rh-AL respectively.

NP at 25 µm depth) compared to liposomes without rhamnolipids (100% normalized
fluorescence intensity of NPs at 5 µm depth) indicating that the Rh liposomes were able to
pass through the rhamnolipid shield of the biofilm. Furthermore, the liposomal cover was
able to protect the Tob and QSI loaded MSNs until the nanoassembly reaches the inner
core of the biofilm. The liposomal layer passively underwent degradation by the bacterial
secreted lipases and phospholipases to release the encapsulated Tob and QSI. As indicated
by the release studies (MSN@Q@Tob)Rh-AL showed around ~80% of Tob and ~65% of
QSI release in the vicinity of PA bacteria residing in the core of the biofilm after 40 hours
of exposure. Alginate lyase guided rhamnolipid coated (MSN@Q@Tob)Rh-AL
nanoassemblies facilitated 90% of PA biofilm degradation. Furthermore, this
nanoassembly was shown to have 12-fold increased antibacterial activity in eradicating
biofilms compared to the free antibiotic Tob.
Also, the (MSN@Q@Tob)Rh-AL nanoassembly was able to eradicate ~99% exvivo biofilms grown in mammalian lung cancer cells without causing any cytotoxic effects
on the mammalian cells. This confirms the nanoassemblies are biocompatible and could be
used in in-vivo studies.
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4. CHAPTER 4

DUAL TARGETING DRUG DELIVERY NANOASSEMBLY FOR
TARGETING NON-SMALL CELL LUNG CANCER

Introduction
Targeting specific cancerous cells can be achieved by using cancer biomarker
recognizing ligands. Therefore, dual targeted delivery of chemotherapeutic drugs to solid
tumors using smart drug delivery systems can take advantage of tumor microenvironment
for controlled drug delivery. Herein, it was investigated how an engineered dual targeted
drug delivery platform effectively targets and inhibits non-small cell lung cancer (NSCLC).
We hypothesize that the drug delivery platform alongside with the encapsulated drug will
increase reactive oxygen species (ROS) induction and microtubule damage which will
promote cell apoptosis. Paclitaxel (Px) a popular chemotherapeutic agent promotes the
generation of ROS through enhancing the activity of NADPH oxidase associated with the
plasma membrane, which leads to ROS-dependent mitochondrial damage and activation
of apoptotic cell death.204-206 Due to its lower water solubility, Px is administrated in a
mixture of Cremophor EL and ethanol.207 Therefore, encapsulation of Px in a
biodegradable, non-toxic nano drug delivery vehicle will overcome its low water solubility
and protect the drug from degradation lowering its toxicity to other cells.
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A drug delivery platform was designed consisting of a mesoporous silica core with
surrounding liposomal shell. The liposomal layer was functionalized with a folate receptor
targeting folic acid (FA) and epidermal growth factor receptor (EGFR) targeting peptide
GE11 as a dual biomarker target for cancer cells. The final nanoassembly is labelled as
(MSN@Px)L-GF. Px released from the nanoassembly produce ROS oxidative stress,
which leads to mitochondria dysfunction (Scheme 4.1).
Furthermore, released Px will destabilize the microtubule structure and following
apoptosis through caspase activation. Wang et al. reported the use of Px loaded mesoporous
nanoparticles for effective lung cancer therapy.208 They have reported a ~ 4 fold increased
efficiency in Px loaded mesoporous nanoparticles compared to free drug Px.208
(MSN@Px)L-GF, showed a ~ 8 fold increase in efficiency compared to the free drug Px.
This depicts the fact that the enhanced efficacy of our nanoassembly is due to the dual
targeting affinity and the controlled release of Px at the tumor vicinity.
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Scheme 4.1. schematic illustration of proposed mechanism of action of the dual targeted
nanoassembly and ROS induced cancer cell death.
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Materials
In addition to the materials listed in Chapter 3.2, the following materials were used.
Wortmannin, chlorpromazine, nystatin, and folic caid were purchased from Sigma-Aldrich
(Missouri).

1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene

glycol)-2000] (ammonium salt) (DSPE-PEG(2000) amine) was purchased from Avanti
Polar Lipids (Alabama). GE11 peptide (Tyr-His-Trp-Tyr-Gly-Tyr-Thr-Pro-Gln-Asn-ValIle) was obtained from Phoenix Pharmaceuticals Inc. (California).
The CellEvent™ caspase 3/7 green detection reagent, live/dead® viability kit,
MitoProbe™ JC-1 assay kit, Tubulin Tracker™ Green detection kit, micro-BCA™ protein
assay kit, and Invitrogen™ ATP Determination kit were purchased from ThermoFisher
Scientific (Massachusetts). Fluorometric intercellular ROS kit was purchased from SigmaAldrich (Missouri). The GSH-Glo™ Glutathione assay was purchased from Promega
corporation (Wisconsin).
Absorbance and fluorescence measurements were taken from a SpectraMax M2
multimode microplate reader (Molecular Devices, California). Drug release studies were
conducted with High Performance Liquid Chromatography (HPLC) using a Hitachi
Primaide Separation module and a 1430 diode array detector.
The viable bacteria count was determined from the CytoSMART automated cell
counter (Corning, New York).

Methods
4.3.1 Synthesis of MSNs
MSNs were synthesized as described in previous chapters.
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4.3.2 Px Encapsulation in MSNs (MSN@Px)
MSNs (5 mg/mL) were loaded with Px (10 mg) in 5 mL of DMSO by stirring the
mixture overnight at 37 °C temperature. The unconjugated Px was removed by
centrifugation at 12,000 rpm for 10 min, yielding MSN@Px.

4.3.3 Liposome Preparation
Liposomes were prepared, as described by Rathnayake et al. with minor
modifications.184 Briefly, DPPC (15 mg, 20 μmol), DOPE (1.25 mg, 1.7 μmol), cholesterol
(7.5 mg, 3.2 μmol), and DSPE-PEG(2000) amine (1.25 mg, 0.45 μmol) were dissolved in
3 mL of chloroform and evaporated in a rotary evaporator, which yielded a thin lipid film.
The lipid film was rehydrated in 2.5 mL of PBS (pH 7.4) at a lipid concentration of 10
mg/mL and extruded 15 times through a polycarbonate membrane (pore size 400 nm) using
the mini extruder. Resultant liposomes were stored at 4 °C until further use.

4.3.4 Modification of Liposomes with GE11 and FA
GE11 and FA were conjugated to the exterior of the liposomes by EDC activation
chemistry. GE11 (100 μg) and FA (30 μg) at a molar ratio of 90:10 was activated with
EDC (3.29 μmol) and sulfo-NHS (8.24 μmol) for 2 h at 37 °C. Thereafter, the liposomes
containing DSPE-PEG(2000) amine (1.25 mg, 0.45 μmol) were added to the activated
GE11 and FA mixture and incubated overnight at 37 °C. At the end of the incubation
period, GE11 and FA-modified liposomes were purified by centrifugation at 12,000 rpm
for 30 min at 4 °C and resuspended in PBS (pH 7.4). The purified product was lyophilized
and stored at −20 °C until further use. The amount of conjugated FA was determined by
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analyzing the supernatant after conjugation by UV-Vis spectroscopy at 310 nm. Also, the
conjugated GE11 was assessed through micro-BCA protein assay.

4.3.5 Encapsulations of MSN@Px into liposomes ((MSN@Px)L)
To prepare liposome coated MSN@Px, 25 mg of MSN@Px was resuspended in
liposomes (2 mL, 25 mg/mL) in PBS and mixed for 20 min on ice. The liposome-coated
nanoassembly (MSN@Px)L was separated from empty liposomes by centrifugation at
12,000 rpm for 5 min and repeatedly washing in PBS. The resultant (MSN@Px)L was
lyophilized and dried at −20 °C until further use.
4.3.6 Characterization through TEM and DLS
The ultrastructure of bare MSNs, MSN@Px, and (MSN@Px)L was examined
through TEM as described in Chapter 2 & 3.

4.3.7 Surface Area and Pore Volume Determination of MSNs and MSN@Px
The surface areas of MSN and MSN@Px were determined using the
Brunauer−Emmett−Teller (BET) method.

4.3.8 TGA of the Px content in MSN@Px and (MSN@Px)L-GF
TGA was carried out under an argon atmosphere (99.999%) as described in Chapter
2 & 3.
4.3.9 Stability of the nanoparticles
The stability of the (MSN@Px)L-GF was evaluated by monitoring changes in
particle size, zeta potential, and turbidity in cell culture medium. (MSN@Px)L-GF (5 mL
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,10 µg/mL) was kept in cell culture medium for 5 days at 37 °C to mimic the static
conditions for in vitro experiments. The above parameters were determined using the DLS
at the same time in all the 5 days.

4.3.10 Px release studies from (MSN@Px)L-GF
(MSN@Px)L-GF 5 mL (5 mg/mL), was dispersed in 10 mL of PBS buffer
containing 0.1% Tween 80 at pH 5.5 and pH 7.4 and incubated while shaking at 200 rpm
at 37 °C. An aliquot of 1 mL of solution was withdrawn at predetermined time intervals
and replaced with an equivalent amount of fresh medium. The removed sample was
centrifuged at 10,000 rpm for 10 min. Following that the pellet was dissolved in fresh PBS
buffer containing 0.1% Tween 80 at respective pH values (pH 5.5 and pH 7.4). Then the
sample was filtered through a 0.5 μm nylon syringe filter. The release profile of Px from
(MSN@Px)L-GF was observed through reverse phase (Welch C-18 column; dimensions
4.6 mm, 200 mm, particle size (dp): 5 μm) HPLC. The mobile phase consisted of a mixture
of ACN and HPLC grade water (W) containing 0.1% trifluoroacetic acid (TFA) in a ratio
of 70:30. The pH of the mobile phase was adjusted to 5 with acetic acid and filtered through
a 0.22-mm nylon filter. HPLC measurements were carried out in isocratic mode. Injection
volume was 20 µL with a flow rate of 1 mL/min. Column temperature was maintained at
25 0C and elution absorbance was monitored at 227 nm using a photo diode array detector.
The drug loading capacity (LC) and encapsulation efficiency (EE) of Px in (MSN@Px)LGF was determined also through HPLC.
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The percentage of LC and EE of Px were calculated according to the following
formula (Equation 4.1):
Equation 4.1. Formula for calculating EE% and DLC%

EE% =

total mass of drug added- mass of unencapsulated drug
× 100
total mass of drug added

DLC % =

total mass of drug added- mass of unencapsulated drug
× 100
total mass of MSNs

4.3.11 A549 cell proliferation
A549 cells were grown in T75 flasks as mentioned in Chapters 2 & 3.

4.3.12 In vitro cellular uptake
A549 cells were seeded on the 24-well plates (103 cells per well) for 24 h. The cells
were co-cultured with RITC-conjugated MSNs, MSN@Px, (MSN@Px)L and
(MSN@Px)L-GF with encapsulated Px equivalent of 10 μg/mL for 6 h. Thereafter the cells
were washed with PBS for three times. The nuclei were stained by DAPI (blue) for 10 min
and fixed with 4% paraformaldehyde for 30 min and washed with PBS. The cellular uptake
ability was examined by inverted fluorescence microscopy.
4.3.13 Cellular Uptake mechanism of (MSN@Px)L-GF
Red fluorescent dye RITC labeled MSN@Px and (MSN@Px)L-GF were used to
quantify internalization in the presence of various endocytosis inhibitors. A549 cells (103
cells per well) were treated with chlorpromazine (20 µg/mL), nystatin (20 µg/mL) and
wortmannin (1 µg/mL) for 1 h prior to the addition of RITC-labeled nanoassemblies.
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Following that the cells were vigorously washed with PBS to remove free particles and the
cells were stained with Calcein AM and DAPI. The cells were then examined by
fluorescence microscopy. The fluorescence intensity of the internalized nanoassemblies
was measured from microplate reader at 576 nm.
4.3.14 Determination of intracellular ROS levels
Intracellular ROS levels were quantified using a fluorescent probe following the
manufacturer’s instructions. A549 cells were seeded into 24-well plates at a density of 103
cells per well, incubated overnight and then treated with the MSNs, MSN@Px, and
(MSN@Px)L, and (MSN@Px)L-GF (encapsulated Px is equivalent to 10 µg/mL) for 4 h.
Then the cells were incubated with the ROS-detection reagent for 1 h at 37 °C in the
presence of 5% CO2. The fluorescence intensity measured at lex 490nm and lem 520 nm
on a microplate reader.

4.3.15 Mitochondrial membrane potentials assay
A JC-1 probe was employed to evaluate the mitochondrial depolarization in A549
cells. Briefly, cells were cultured in a 24-well plate with a cell density of 103 cells per well
and then incubated for 24 h. Cells were then washed with PBS and treated with MSNs,
MSN@Px, (MSN@Px)L, (MSN@Px)L-GF, and the free drug Px at a Px equivalent to 10
μg/mL for about 6 h. The cells were washed and treated with an equal volume of serumfree medium containing JC-1 dye (5 mg/L) and incubated at 37 °C for 20 min. Cells were
rinsed twice with PBS, then replaced with fresh medium without serum. Fluorescent
images were taken using inverted fluorescent microscope. The images were obtained of lex
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488 nm and lem 530 nm emission to visualize green JC-1 monomers and lex 543 nm and
lem 590 nm for red fluorescent JC-1 aggregates.

4.3.16 Intracellular GSH measurement
Levels of intracellular reduced glutathione (GSH) were quantified using a luciferin
derivative. Briefly, A549 cells were seeded on 24‐well plates (103 cells per well) and were
incubated overnight, with 25 μL of different nanoassemblies (MSNs, MSN@Px, and
(MSN@Px)L, (MSN@Px)L-GF, and free drug Px) having a Px concentration equivalent
to 10 μg/mL for 4 h. Cells were then washed with PBS three times and the incubated with
the GSH-Glo reagent and the luciferin detection agent for 30 and 15 min respectively,
according to the manufacturer’s instructions. The luminescence intensity was measured
after 15 min at 37°C from a microplate reader.

4.3.17 Measurement of cellular ATP levels
The intracellular ATP levels were measured using ATP determination kit according
to the manufactures’ instructions. A549 cells were seeded at a density of 103 cells per well
and then incubated for 24 h prior to experiments. Then the cells were treated with
MSN@Px, and (MSN@Px)L, (MSN@Px)L-GF and the free drug Px at a Px equivalent to
10 μg/mL for about 6 h in growth medium supplemented with 10% FBS and 1% pen-strep
at 37 °C and in 5% CO2. Thereafter, the cells were washed with PBS and harvested with
trypsin EDTA (200 μL) for 5 min at 37 °C. Cold PBS was added to terminate the reaction,
and cells were collected by centrifugation at 10,000 rpm for 10 min. Following that 30 μL
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of each sample was mixed with 270 μL buffer and the luminescence was checked at 560
nm using a plate reader.

4.3.18 Tubulin polymerization fluorescence assay
The direct effect of the nanoassemblies on tubulin polymerization was determined
in a biochemical fluorescent-based detector (ThermoFisher), according to manufacturer’s
protocol. The cells (103 cells per well) were incubated with MSNs, MSN@Px, and
(MSN@Px)L, (MSN@Px)L-GF and the free drug Px at a Px equivalent to 10 μg/ mL for
6 h. The culture medium was removed, and cells were washed twice with PBS and stained
with diluted Tubulin Tracker Green reagent for 30 min at 37°C and in the presence of 5%
CO2. Nuclei were stained with DAPI for 15 min. Blue fluorescence (nucleus) and green
fluorescence were observed using a fluorescence microscope.

4.3.19 Caspase activity assay
CellEvent caspase-3 and 7 assay kit was used to evaluate membrane permeability
and caspase activation. A549 cells (1 × 103 cells/well) were seeded in a 24 well plate for
24 h, MSNs, MSN@Px, and (MSN@Px)L, (MSN@Px)L-GF, and the free drug Px at a Px
equivalent to 10 μg/mL were added and incubated for 6 h. A volume of 100 μL of the
caspase 3/7 reagent was added into each well and incubated for 30 min at 37°C in the
presence of 5% CO2, protected from light. The cells were then observed from an inverted
fluorescence microscope. Finally, the fluorescence intensity was measured with a
microplate reader using an excitation of lex 360 nm, and lem 460 nm.
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4.3.20 Live/dead assay
A live/dead assay was performed for the analysis of cell viability. Cells (1 × 103)
grown on 24 well plate were treated with MSNs, MSN@Px, (MSN@Px)L, (MSN@Px)LGF and the free drug Px at a Px equivalent to 10 μg/mL for 6 h. The wells were washed
twice with cold PBS and incubated for 30 min with the live dead reagent (2 µM Calcein
AM and 4 µM ethidium bromide) according to the manufacturer’s instructions. The
samples were washed twice with PBS and imaged by fluorescence microscopy.

4.3.21 In-vitro cytotoxicity Assays
Mammalian cell viability was evaluated by using an MTT assay. A549 cells were
seeded onto 24-well plates at a density of 103 cells per well. After 24 h, they were incubated
with different nanoassemblies (MSN@Px, (MSN@Px)L, (MSN@Px)L-GF, and free drug
Px) having a Px concentrations equivalent to 1, 5, 10, 25, 50, 100 µg/mL for 24 h. Then,
100 μL of the MTT solution (1 mg/mL) was added into each well, and the cells were further
incubated for 4 h. Afterward, the culture medium was discarded, and 150 μL of DMSO
was added into each well. The absorbance intensity was determined at 540 nm by a
microplate reader. The results were presented as the percentage of viable cells with respect
to the untreated control cells. Statistical analysis comparing free Px with the final
nanoassembly (MSN@Px)L-GF was conducted using student's t-test.
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Results & Discussion
4.4.1 Synthesis and characterization of nanoassemblies
MSNs were prepared following the previously reported surfactant-template method
as mentioned in Section 2.3.1.184 The synthesized MSNs were finally purified and
redispersed in water. Thereafter, the widely used tumor agent paclitaxel (Px) was loaded
into the MSNs (Scheme 4.2). Px promotes ROS production and tubulin dimerization and
inhibits the depolymerization of microtubules, resulting in the formation of abnormally
stable and non-functional microtubules.209 Px was incorporated into the pores of MSN
using solvent evaporation.210 Px was incorporated using different solvents to screen drug
loading capacity (Figure 4.1). And, DMSO was used as the preferred drug loading solvent,
as it yielded the highest loading of Px (28.7 ± 0.6).

Figure 4.1. Drug loading capacity of msn with different solvents. Error bars represent
the SD of the mean.

Px-loaded MSN (MSN@Px) was encapsulated within a liposome layer
(MSN@PX)L (Scheme 4.2). The liposome layer acts as a gatekeeper and restricts the
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premature release of Px. The exterior of the liposome was tagged with two different cancer
targeting ligands to enhance the effectiveness. The liposomes were synthesized using the
extrusion method using phospholipids: DPPC, DOPE, DSPE-PEG(2000) amine, and
cholesterol. MSN@Px was encapsulated within the liposome in an ice bath, where the
amphiphilic phospholipids self-assemble around the MSN@Px to create a spherical bilipid
layer (LL). The protonated NH3 of the phospholipid DOPE and DPPC respectively provide
hydrophilicity to the bilayer, which allows encapsulation of hydrophilic MSNs.145,
184

Cholesterol in the lipid layer enhances the membrane fluidity and Px retention.211 The

PEG chain of DSPE-PEG(2000)amine is known to reduce immunogenicity and
antigenicity and facilitates the targeting peptide binding onto the liposome.212
Folic acid (FA) and the peptide GE11 were conjugated onto the surface of the
liposome layer with the help of ECD and sulfo-NHS chemistry (Scheme 4.2). Folate
receptors (such as FR-α) are known to be overexpressed on the surface of cancer cells with
an epithelial origin, such as breast, lung, and ovarian cancers.213 Therefore, these FRs are

Scheme 4.2. Synthesis of (MSN@Px)L-GF.
Scheme 4.2. Synthesis of (MSN@Px)L-GF
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Scheme 4.3. Synthesis of (MSN@Px)L-GF

commonly used as cancer biomarkers.213 Non-immunogenicity, stability, tissue
permeability, and the ease of bioconjugation makes FA an ideal cancer-targeting agent.166,
214-216

FA conjugation helps cell internalization through receptor-mediated endocytosis.217

Using a second targeting moiety, such as epidermal growth factor receptor (EGFR),
increases drug carrier interaction with cancer cells. GE11 (YHWYGYTPQNVI) is a
dodecapeptide that binds specifically to EGFR, which is overexpressed in a number of
tumors of epithelial origin.218 These small peptides are also non-immunogenic and
facilitate good penetration into tumor tissues. Also, it has been found that GE11 possesses
a high potential to accelerate endocytosis through an alternative EGFR-dependent actindriven pathway.219
Furthermore, successful attachment of both targeting ligands (FA and GE11) on the
nanoassembly was confirmed. (MSN@Px)L-GF was qualitatively characterized by DLS,
TEM, and FTIR and quantitatively characterized by BET and TGA. The synthesis of the
nanoassembly was confirmed primarily through TEM (Figure 4.2). Upon Px loading, there
was a clear reduction of porosity of the MSN (Figure 4.2B). Following Px loading, the
MSNs were coated with a liposome layer. A lipid bilayer around each MSN@Px was
clearly observed, as shown in arrows in Figure 4.2C.

A

B

C

Figure 4.2. Characterization of nanoassemblies by TEM. TEM images of A. MSNs, B.
MSN@Px, and C. (MSN@Px)L respectively (scale bar = 100 nm).
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The size of the nanoassemblies was determined by DLS and TEM. As shown in
Table 4.1, the diameter from TEM was 83 ± 4 nm, while the hydrodynamic diameter was
around 310 ± 5.2 nm observed through DLS. The larger hydrodynamic size from the DLS
indicates particle swelling and possibility of the formation of aggregated clusters.

Table 4.1. Dried (TEM) and hydrodynamic diameter (DLS) of nanoassemblies (n=3). Data
are presented as mean ± SD.

Diameter from TEM
(nm)

Hydrodynamic
diameter (nm)

MSN

83 ± 4

310 ± 5.2

MSN@Px

86 ± 5.1

350 ± 6

(MSN@Px)L

99 ± 1.3

426 ± 8.4

(MSN@Px)L-GF

138 ± 4.5

585 ± 5.5

Upon liposome coating, the diameter of the MSNs increased from 83 ± 4 nm to 99
± 1.3 nm determined by TEM analysis. Upon conjugation with targeting ligands, the size
further increased up to 133 ± 4.5 nm (Table 4.1).
The surface electrical potential was determined by measuring the zeta potential in
each and every step to confirm the successful synthesis of the nanoassembly (Figure 4.3a).
MSNs showed a negative zeta potential (-31 ± 1.6 mV), indicating the negatively charged
silicate ions on the surface of MSNs (Figure 4.3a).
After Px loading, the zeta potential increased to -26.9 ± 1.1 mV, indicating that the
Px is loaded into the pores of MSN and the Px loading did not significantly affect the
surface charge of the MSNs.220
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a.

b.

Figure 4.3. (a.) Zeta potential change in various steps of the synthesis of the
nanoassemblies. (b.) N2 adsorption−desorption isotherm for MSNs and MSN@Px.

Furthermore, the zeta potential increased to + 4.7 ± 1.8 mV in (MSN@Px)L, which
confirmed the presence of positively charged phospholipid heads in the liposome layer.
With the conjugation of targeting moieties, the zeta potential of the nanoassembly further
increased up to 9.8 ± 0. 8 mV. The increase in zeta potential might be due to the conjugation
of FA and GE11 onto the liposome. The positively charged zeta potential of the final
nanoassembly favors uptake of nanoparticles by negatively charged cancer cells.221, 222
The change in porosity of the MSNs and MSN@Px was assessed by N2 adsorption–
desorption isotherms (Figure 4.3b). The decreased absorbed volume in MSN@Px
compared to the bare MSNs reflects the reduction in porosity. Furthermore, the reduction
in porosity was also confirmed by BET analysis (Table 4.2). As shown in Table 4.2, the
pore size of MSNs has reduced from 19.17 nm to 10.85 nm in MSN@Px. Also, the surface
area and pore volume of MSN has reduced from 37.2 % and 49.2% respectively.
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Table 4.2. Surface area, pore volume and pore size analysis of MSN and MSN@Px.
MSN

MSN@Px

Surface area
(Multipoint BET)

842.7 m²/g

529.3 m²/g

Pore volume (BJH
method)

2.616 cc/g

1.330 cc/g

Pore size (BJH method)

19.17 nm

10.85 nm

FTIR was conducted as another qualitative confirmation of the nanoassembly
synthesis in each and every step to verify chemical characteristics (Figure 4.5). FTIR of
the MSNs were similar to the data presented in Chapter 3.3. Upon Px loading, the
MSN@Px, the FTIR spectrum indicated the corresponding Px peaks (structure of Px in
Figure 4.4).210
O
O
O

O HO

NH O
O
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HO
O
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H
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Figure 4.4. Structure of Paclitaxel.

Asymmetric and symmetric stretching vibrations of CH2 groups can be seen at 2976
cm–1 and 2885 cm–1. The peak at 1734 cm–1 corresponds to C=O stretching vibrations of
the ester groups. Furthermore, C-N stretching vibrations are located at 1276 cm–1.
Absorption at 1647 cm–1 and 709 cm–1 are associated with the aromatic bonds (Figure
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4.5a).223,225 The liposome layer on (MSN@Px)L was identified by the presence of very
strong peaks at 2918 cm-1 and 2850 cm–1 corresponding to the antisymmetric and
symmetric C–H stretching respectively, in the long carbon chains of the lipids used.224, 225
Also, the C═O stretching vibration around 1735 cm–1 and the PO2- symmetric stretching
vibration around 1090 cm–1 are from phospholipids and confirm successful liposome
coating (Figure 4.5a).184
Specific C=O absorption at 1500 cm-1 in (MSN@Px)L-GF was similar to the C=O
absorption of GE11 indicating the presence of GE11 (Figure 4.5b).226, 227 The characteristic
IR absorption peaks of FA can be seen at 1605 cm-1, 1693 cm-1, and 1485 cm-1, which
correspond to amide N-H bending, C=O stretching of the α- carboxyl group and absorption
band of phenyl ring respectively, and are also represented in (MSN@Px)L-GF.
Furthermore, the FTIR spectra of (MSN@Px)L-GF showed an intense broad peak at 1650
cm−1 (Figure 4.5b), which can be attributed to the new carbonyl (C=O) stretching of amide
I absorption of the newly formed amide bond with the NH2 of liposomes and COOH of
FA and GE11.228, 229 High resolution spectra of all FTIR spectra are presented in Appendix
C, Figure C.1, Figure C.2, Figure C.3, Figure C.4, Figure C.5, Figure C.6, and Figure C.7.
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a.

b.

Figure 4.5. (a.) FTIR spectra of MSNs, MSN@Px, Px, and (MSN@Px)L. (b.) FTIR
spectra of dual targets showing FA, GE11, and L-GF.

Figure 4.6. TGA curves recorded for MSNs,
138 MSN@Px, (MSN@Px)L, and
(MSN@Px)L-GF

Quantitative ligand analysis of the nanoassembly after each step of synthesis was
performed using TGA (Figure 4.6). Percentage (%) weight loss at each step was calculated
to determine the amount of ligand conjugated. The Px loading on the MSNs was found to
be 98 ± 1.9 mg/g of MSNs, which corresponds to 9 ± 0.5 % loading. Also, the percentage
weight loss between (MSN@Px)L and MSN@Px indicated the coated lipid layer is 6 ± 0.8
% (MSN@Px)L. A TGA compariosn between the (MSN@Px)L-GF and (MSN@Px)L
indicated a total percentage weight loss of 4 ± 0.4 % indicating that the total targeting
ligand (GE11 and FA) content was 38 ± 4 μg/g in (MSN@Px)L-GF (Figure 4.6). The FA
quantification using the absorbance assay was 21 ± 1.6 μg/g and the GE11 content
determined by the micro - BCA assay 15 ± 2.3 μg/g (calibration curves of FA and GE11
are presented in Appendix C Figure C.8 & C.9 respectively).

Figure 4.6. TGA curves recorded for MSNs, MSN@Px, (MSN@Px)L, and
(MSN@Px)L-GF.
Figure
4.23Figure
4.24.
TGA curvesis recorded
MSNs,
MSN@Px,
(MSN@Px)L,
The
stability of
nanoparticles
crucial tofortheir
applications,
such
as long-term
and (MSN@Px)L-GF
storage stability, prolonged biological activities at tumor site, and circulation in body.230
Figure 4.25. Zeta potential change of MSN@Px
139 and (MSN@Px)L at 37 0C over 5
days

Liposomal coating affords stability to nanoparticles. The stability of the (MSN@Px)L was
tested against the uncoated nanoparticles MSN@Px by monitoring the changes in the zeta
potential, and turbidity of the particles in the A549 growth medium. The averaged results
of three experiments confirmed that the zeta potential was quite stable in the liposomecoated particles compared to the uncoated particles throughout the 5 days at 37 °C under
pH 7.4 (Figure 4.7). These positively charged (MSN@Px)L can bind strongly to the
negative charged cell membrane of cancer cells by electrostatic interactions and facilitate
a high cellular uptake and afford high stability.231

Figure 4.7. Zeta potential change of MSN@Px and (MSN@Px)L at 37 0C over 5 days.

Encapsulation efficiency (EE) and drug loading capacity (LC) are two important
parameters in determining drug release. EE and LC were quantified by RP-HPLC. EE%
was calculated to be 89.4 ± 1.2 % and 85. 2 ± 3.5 % for MSN@Px and (MSN@Px)L-GF
respectively, which was conducive to drug delivery. The LC was calculated to be 27.8 ±
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3.2 % and 24.5 ± 2.1 % for MSN@Px and (MSN@Px)L-GF respectively. The Px
calibration curve is supplemented in the Appendix C Figure C.10.

4.4.2 Cellular uptake and Drug release
Cellular uptake and targeting affinity of the nanoassemblies was further determined
using fluorescence microscopy (Figure 4.8). Higher red fluorescence was observed with
(MSN@Px)L-GF (Figure 4.8c) when compared to single ligand conjugated nanoassembly:
((MSN@Px)L-FA) (Figure 4.8b) and non-targeted nanoassembly: (MSN@Px) (Figure
4.8a). Higher red fluorescence reflects higher internalization of nanoparticles, which is
possibly due to the presence of dual targeting ligands, FA and GE11.

Calcein - Cytoplasm

Dapi - Nucleus

RITC-NPs

Merged

MSN@Px

a

(MSN@Px)L-GF

(MSN@Px)L-FA

b

c

Figure 4.8. Ability of (MSN@Px)L-GFs to target A549 cells compared to single ligand
targeted (MSN@Px)L-FA and non-targeted MSN@Px. a) MSN@Px b) (MSN@Px)LFA c) (MSN@Px)L-GFs were conjugated with RITC (red) and the A549 cells and the
nuclei were stained with Calcein AM (green) and DAPI (blue) respectively (scale bar 50
µm.).
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In vitro drug release profiles of Px from (MSN@Px)L-GF were determined using
RP-HPLC analysis at pH 5.5 and 7.4, as shown in Figure 4.9.

Figure 4.9. Evaluating the nanoparticle internalization and drug release profiles.
Cumulative release of Px from (MSN@Px)L-GF at pH 5.5 and pH 7.4.

The cumulative Px release at pH 5.5 was remarkably higher than at pH 7.4. The
acidic microenvironment of the cancer cells allows nanoassembly to release Px at a higher
rate reducing off target toxicity and enhancing drug therapeutic efficacy.230, 232 The pH
value of the extracellular tumor environment (6.5–6.8) tends to be more acidic than that of
the normal tissues and further decreases to 4.5–5 in lysosomes and 5.5–6.0 in
endosomes.233 In addition, (MSN@Px)L-GF presented a rapid release (65%) in the first 20
hours at pH 5.5 compared to at pH 7.4 (40%) at the same time period (Figure 4.9). After
around 55 hours, the release at pH 5.5 reached more than 80% (Figure 4.9). This confirms
that (MSN@Px)L-GF exhibits pH-dependent and rapid drug release in the acidic tumor
microenvironment. Furthermore, degradation of the liposome layer can be attributed to the
intracellular enzymes, such as lipases, upon endocytosis into the cancer cells.234-236
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Figure 4.10. Percentage of (MSN@Px)L-GF cytoplasmic delivery after treatment
with various inhibitors.

Dapi - Nucleus

RITC-NPs

Merged

Nystatin

Wortmannin

Chlorpromazin

Calcein - Cytoplasm

Figure 4.11. Fluorescence microscopy images of the A549 cells treated with various
inhibitors showing the difference in cellular internalization (scale bar, 100 µm).
Furthermore, an endocytosis inhibitor study was conducted to understand the
mechanistic pathway of cellular internalization of these nanoassemblies (Figure 4.10 &
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Figure 4.11). A549 cells were treated with a clathrin-mediated endocytosis inhibitor chlorpromazine (Cpz), a caveolin-medicated endocytosis inhibitor - nystatin (Nys) and a
macropinocytosis inhibitor - wortmannin (Wort) for 1 h prior to the addition of RITClabeled (MSN@Px)L-GF. 237-239 After incubation for 6 h, cells were vigorously washed to
remove free nanoparticles and was examined under fluorescence microscopy (Figure 4.11).
As shown in Figure 4.11, in the presence of Wort and Nys, the red labeled particles
have internalized into the cells and they gathered around the Dapi stained nucleus.
Whereas, with the presence of Cpz, particles are seemed to be gathered outside the cells
(outside the calcein stained cytoplasm). The fluorescence intensity was quantified using a
fluorescence plate reader. The quantitative analysis results confirmed a significant
reduction in uptake in the presence of Cpz when compared to Nys and Wort inhibitors
(Figure 4.10). Therefore, it is possible the internalization mechanism occurs through a
clathrin-mediated pathway.

4.4.3 Monitoring intracellular ROS, mitochondria damage, GSH and ATP levels
ROS are generated as a result of the reduction of oxygen during aerobic respiration
and by various enzymatic systems within the cell.240 It has been reported that nanoparticleinduced cell toxicity leads to ROS generation and consequent oxidative stress.241
Physiological levels of ROS mediate crucial intracellular signaling pathways that are
essential for cell survival. However, an excess of ROS leads to cell death.242

144

Figure 4.12. Quantitative determination of ROS generation detected by fluorometric
intracellular ROS assay. Data is presented as the mean ± SD ( n = 3, in student's ttest *** indicates p < 0.001).
Once (MSN@Px)L-GF internalize, the intracellular enzymes degrade the
protective lipid layer and permit Px to release.243 The release of Px, produces intracellular
ROS such as O2- and H2O2.244 ROS cause mitochondrial membrane depolarization and
impair the ability of mitochondria to synthesize ATP which ultimately results in
apoptosis.245,

246

The production of ROS was determined using a ROS-specific dye,

H2DCFDA following manufacturer guide line as mentioned in Section 4.3.14. Following
1 h of incubation, H2DCFDA penetrates the cellular membrane and will be cleaved by an
esterase. Upon deacetylation, H2DCFDA is converted to a non-fluorescent H2DCF, which
is then rapidly oxidized to highly fluorescent 2’,7’-dichlorofluorescein (DCF) in the
presence of ROS. DCF can be detected at an emission of 520 nm.247 ROS levels were
shown to increase in the presence of (MSN@Px)L-GF compared to MSNs alone (Figure
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4.12). This confirms that, the release of Px after internalization of (MSN@Px)L-GF leads
to higher ROS production inside the cells.
As resulted from the ROS assay, the intrinsic apoptotic pathway is mainly activated
by an ROS induction, which ultimately damage mitochondrial function which may cause
the release of proapoptotic molecules, such as cytochrome c - an intermembrane space
protein to the cytosol.248 Mitochondrial release of cytochrome c is required for caspase
activation and further processing of apoptosis of the cells.249
Mitochondrial dysfunction followed by excessive ROS induction was investigated
by evaluating the mitochondrial membrane potential using JC-1 staining (Figure 4.13).249
JC-1 dye has long been used to examine the mitochondrial status in apoptosis studies.250
The green fluorescent monomer of JC-1 can enter the cytoplasm and aggregate in healthy

a

Px

b

MSN@Px

c

(MSN@Px)L

d

(MSN@Px)L-GF

e

Merged

J-monomer

J-aggregate

MSN

Figure 4.13. Fluorescence microscopy images of JC-1 stained A549 cells after
different nanoassembly treatment a) MSN b) Px c) MSN@Px d) (MSN@Px)L e)
(MSN@Px)L-GF. The fluorescence transition from red (live) to green (dead) indicates
significant mitochondrial damage (scale bar, 20 µm).
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mitochondria, forming red fluorescent J-aggregate, which emits orange-red fluorescence
with a maximum at 595 nm.250 Therefore, the fluorescence transition from red to green
suggests loss of membrane potential and significant mitochondrial damage (Figure 4.13).
After 12 h of exposure to (MSN@Px)L-GF, the appearance of higher green fluorescence
in the merged image of Figure 4.12e indicates damaged mitochondria compared to MSNs
(Figure 4.13a) with healthy mitochondria represented in red fluorescence. These data
indicate considerable mitochondria dysfunction with the final nanoassembly.
Also, intracellular GSH levels are an indicator of oxidative stress in response to
elevated ROS levels.251

252

Therefore, intracellular GSH levels were quantified using a

luciferin derivative that was capable of converting into luciferin in the presence of GSH.
The conversion of luciferin derivative to luciferin in the presence of GSH was determined
using luminescence analysis. GSH levels were quantitatively determined using the GSHGlo glutathione assay according to the manufactures guidelines as mentioned in section
4.3.16. This assay determined the GSH levels in A549 cells exposed to different
nanoassemblies encapsulated with equal amount of Px concentrations. GSH levels in cells
treated with MSNs were 5.99 ± 0.3 mM (Figure 4.14). GSH levels decreased when cells
were exposed to MSN@Px, (MSN@Px)L, and (MSN@Px)L-GF. GSH content in the
presence of (MSN@PX)L-GF was as low as 1.9 ± 0.2 mM (Figure 4.14) and could be
related to increase in oxidative stress.253 Higher intracellular GSH level relates to apoptosis
resistance and lower GSH levels will ultimately lead to apoptosis.253, 254
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Figure 4.14. Cellular GSH level after treatment with different nanoassemblies.
Data are presented as the mean ± SD (n = 3, in student's t-test **** indicates p <
0.0001)
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levels were tested after treating with the nanoassemblies (Figure 4.15). Loss of ATP
levels were seen with (MSN@Px)L-GF with respect to Px itself (reduction from 7.65 ± 0.6
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Figure 4.67Figure 4.68. Cellular GSH level after treatment with different
nanoassemblies. Data are presented as the mean ± SD (n = 3, **** indicates p <
0.0001)
Figure 4.69Figure 4.70. Cellular GSH level after treatment with different
nanoassemblies. Data are presented as the mean ± SD (n = 3, **** indicates p <
0.0001)
Figure 4.15. Concentration of ATP present after treatment with different
nanoassemblies. Data is presented as the mean ± SD (n = 3, *** indicates p <
0.001)
Figure 4.14. Cellular GSH level after treatment with different nanoassemblies.
Data are presented as the mean ± SD (n = 3,148
**** indicates p < 0.0001)
Figure 4.71Figure 4.72. Cellular GSH level after treatment with different

Figure 4.15. Concentration of ATP present after treatment with different
nanoassemblies. Data is presented as the mean ± SD (n = 3, in student's t-test ***
indicates p < 0.001)

This confirmed the fact that apoptosis requires energy since it depends on a few
highly regulated processes involving a number of ATP-dependent steps, such as caspase
activation, enzymatic hydrolysis of macromolecules, chromatin condensation, bleb
formation, and apoptotic body formation.255-257 The results so far verify the ROS induced
mitochondria-mediated apoptotic pathway which is triggered by the nanoassembly,
(MSN@Px)L-GF.
Based on these results, it can be concluded that the increase in ROS levels induce
ROS-triggered (Figure 4.12) in situ mitochondrial damage (Figure 4.13). This will result
in a decrease of mitochondrial membrane potential. Breakdown of mitochondria will
further amplify oxidative stress and decreases GSH levels in the cells (Figure 4.14). This
could initiate cell death by consuming much more intracellular ATP as shown in Figure
4.15.249
149

4.4.4 Detection of microtubules using tubulin assay
Px is known to interfere with the function of microtubules by hyper-stabilizing their
structure. Microtubules are important structural components of the cytoskeleton and are
composed of polymerized α-tubulin and β-tubulin. Taxanes, specially Px, is a well-known
microtubule targeting agent that promotes the disassembly of microtubules.258 Px is able to
stabilize microtubule polymers by binding to β-tubulin. This will induce apoptosis by
disrupting the dynamic remodeling of microtubules during mitosis.259, 260 The change in
the microtubule structure was observed and correlated to the effect of the released Px.
Px

MSN@Px

(MSN@Px)L

(MSN@Px)L-GF

Merge

nucleus

DAPI

Tubulin green

MSN (Control)

Figure 4.16. Assessment of microtubule morphology after treatment with
nanoassemblies. (a) Fluorescence staining of tubulin (green) and nuclei of A549 cells
(blue) treated with different nanoassemblies. The data are representative of three
independent experiments (scale bar = 50 µm).

The effect of released Px on microtubule organization was monitored (Figure 4.16).
Figure 4.16. Assessment of microtubule morphology after treatment with
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clearly observable when cells were treated with the control, MSNs (Figure 4.16). Px (10
µg/mL) treatment led to an observable thickening of the microtubule fibers, with less green
fluorescence in the cytoplasm compared to the control with only MSNs. However, when
treated with (MSN@PX)L-GF, the cells clearly displayed a loss of structured microtubular
network with more scattered microtubules and condensed nuclei. This demonstrated the
ability of Px to disrupt microtubular network. The more scattered tubular network with
(MSN@PX)L-GF can be explained by the fact that the nanoassemblies were targeted
properly and more Px is released from the targeted nanoassembly than by Px alone.

Tubulin green

DAPI nucleus

Merge

Nuclear fragmentation

Nuclear blebbing

Figure 4.17. Scattered cytoskeleton with fragmented and blebbed nuclei upon treatment
with (MSN@Px)L-GF for 24 hours (scale bar = 50 µm).

After 24 h upon treatment with (MSN@PX)L-GF, the structure of microtubular
Figure 4.97. Scattered cytoskeleton with fragmented and blebbed nuclei upon treatment
with (MSN@Px)L-GF
forTubulin
24 hours
(scalegreen
bar =and
50 µm).
network
was observed with
tracker
DAPI stained (blue) nuclei. Nuclear
fragmentation and blebbing can be seen in Figure 4.17. After 24 h, the microtubule
Figure 4.98.
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with 4.17).
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structure
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(Figure
with (MSN@Px)L-GF for 24 hours (scale bar = 50 µm).
Furthermore, the increased cell blebbing and cell shrinkage from MSN@Px to
(MSN@Px)L-GF is also indicative of apoptosis induction (Figure 4.18). (MSN@Px)L-GF
Figure 4.99. Scattered cytoskeleton with fragmented and blebbed nuclei upon treatment
with (MSN@Px)L-GF for 24 hours (scale bar = 50 µm).
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Figure 4.17. Scattered cytoskeleton with fragmented and blebbed nuclei upon treatment
with (MSN@Px)L-GF for 24 hours (scale bar = 50 µm).

was able to induce apoptosis within 24 h of interaction whereas MSN@Px was unable to
show any apoptosis induction within the time frame .
Overall results indicate a clear distinguishable change in tubulin structure upon
interaction with different nanoassemblies. 260, 261 The more distinguishable changes on the
microtubule structure and nuclei are seen with (MSN@Px)L-GF. Therefore, it can be
concluded that (MSN@Px)L-GF has the ability to deliver comparatively more Px to A549
cells than other nanoassemblies. Moreover, delivering Px through (MSN@Px)L-GF is
more successful than delivering the free drug Px.

RITC-NPs

Merged

(MSN@Px)L-GF

MSN@Px

Calcein - Cytoplasm

Figure 4.18. Morphology of cells after treatment with MSN@Px and (MSN@Px)L-GF for
24 hours (Both having a Px concentration equivalent to 10 mg/mL). The cells are stained
with Calcein AM (green), the particles are RITC conjugated (red). As clearly seen with
time, (MSN@Px)L-GF was able to induce apoptosis followed by cell shrinkage and
blebbing. After about 24 hours MSN@Px still doesn’t show any cell blebbing.
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4.4.5 Assessment of caspase 3/7 activation
Activation of caspases is the initial stage of apoptotic process and responsible for
the cell changes during apoptosis, such as DNA fragmentation, nuclear chromatin
condensation, and plasma membrane blebbing.262 The observation of nuclear condensation,
fragmentation and blebbing in the earlier section indicates that the cells may have begun
the apoptosis pathway. Therefore, two key executioner enzymes in apoptosis (caspase-3
and caspase-7) were assesd to further confirm the initiation of intrinsic apoptotic pathway.
Caspase-3 (Cas-3) and caspase-7 (Cas-7) are cysteine-aspartic acid proteases, which can
directly execute apoptosis following sequential activation from caspase-8 (Cas-8) or
caspase-9 (Cas-9).263 Both quantitative and qualitative expression of cas-3/7 was used to
observe the initiation of intrinsic apoptotic pathway upon treatment with nanoassemblies.
Cas-3/7 specific caspase-cleavable, peptide imaging probe has been extensively
used to monitor apoptosis and caspase activity in tumor cells .264 The imaging probe
consists of a four amino acid peptide: DEVD, D- aspartic acid, E- glutamic acid, V-valine,
and is conjugated to an intrinsically non-fluorescent dye. After the activation of Cas-3/7 in
apoptotic cells, the DEVD peptide is cleaved enabling the dye to bind to DNA producing
a bright, green fluorescence.265 Therefore, Cas3/7 activation can be observed through
fluorescence microscopy and can be quantified at ~ 530 nm (Figure 4.19 & Figure 4.20).
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Results showed that MSNs did not appear to activate Cas-3/7 in A549 cells (Figure
4.19).
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(MSN@Px)L-GF

Merge
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Caspase 3/7FITC stained

MSN

Figure 4.19. Analysis of apoptosis induction. Fluorescence microscopy images of
caspase 3/7 activation in A549 cells after treatment with different nanoassembly
treatments. (scale bar, 50 mm).

Stronger Cas-3/7 activity was observed from MSN@Px and (MSN@Px)L-GF as
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intensity observed for free Px in the Cas-3/7 assay was 41.41 ± 3.5, while the
intensity was 185.37 ± 3.7 for (MSN@Px)L-GF (Figure 4.20). These data clearly
Figure 4.112. Quantitative analysis of caspase 3/7 activity through a fluorometric
assay.
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Figure 4.113Figure 4.114. Analysis of apoptosis induction. Fluorescence microscopy
images of caspase 3/7 activation in A549 cells after treatment with different
nanoassembly treatments. (scale bar, 50 mm.

Figure 4.115Figure 4.116. Analysis of apoptosis
induction. Fluorescence microscopy
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images of caspase 3/7 activation in A549 cells after treatment with different
nanoassembly treatments. (scale bar, 50 mm.

Figure 4.20. Quantitative analysis of caspase 3/7 activity through a fluorometric
assay. Data are presented as the mean ± SD (n = 3, in student's t-test **** indicates
p < 0.0001)

4.4.6 Synergistic apoptosis and cytotoxicity
Live and dead cell assay can distinguish the live and dead cells by simultaneously
staining the cells with green fluorescent Calcein-AM and red-fluorescent ethidium
homodimer-1(EthD-1). In this assay, live cells are distinguished by their intracellular
esterase activity. This nonfluorescent Calcein AM dye is converted into intensely uniform
green fluorescent Calcein by the esterase activity. EthD-1 basically can only enter cells
with damaged cell membranes and produce bright red fluorescence upon binding to nucleic
acids in dead cells. 266
A549 cells were incubated with the different nanoassemblies to assess their
viability using live-dead assay (Figure 4.21). There is a clear increase in red fluorescence
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from MSNs to (MSN@Px)L-GF, indicating an increase in dead cells confirming the
effectivity of the nanoassembly (Figure 4.21). Cells treated with MSNs have pronounced
green fluorescence and can be considered non-toxic to the cells.

Px

MSN@Px

(MSN@Px)L

MSN@Px)L-GF

Merge

Dead cells

Live cells

MSN

Figure 4.21. Fluorescence images of A549 cells treated with different
nanoassemblies. Live cells were stained with Calcein AM and the dead or apoptotic
cells were stained with EthD-1 (scale bar = 50 mm).

The cytotoxicity of the nanoassemblies towards the mammalian cells was
evaluated. To evaluate the cytotoxicity of the Px-loaded nanoassemblies, a standard series
of MSN@Px, (MSN@Px)L, (MSN@Px)L-GF, and free Px having a Px concentration of
1, 5, 10, 25, 50, 100 μg/mL was prepared and cultured with A549 cells for 24 h as
mentioned in Section 4.3.21.
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a.

b.

Figure 4.22. (a.) Cell viability percentage of A549 cells treated with different
concentrations of different nanoassemblies for 12 hours. Data are presented as the mean
± SD (n = 3, in student's t-test * indicates p < 0.05) (b.) Cell viability percentage of
A549 cells treated with different concentrations of different nanoassemblies for 12 h.
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Scheme 4.9. Schematic illustration of the design of Lectin conjugated silica coated
Magnetic nanocomposite (SMNP-PEG-NHS-Lectin)Figure 4.19. (a.) Cell viability
percentage of A549 cells treated with different concentrations of different

concentration. The enhanced inhibition by (MSN@Px)L-GF is attributed to the (a) dual
targeting ligands - which affords increased internalization (b) the liposomal shell – which
prevents premature drug release outside the cell, and (c) the mesoporous structure of the
nanoassembly – which offers high loading of hydrophobic Px.208, 233

Conclusion
In summary, a drug delivery nanoassembly (MSN@Px)L-GF was synthesized as a
delivery system for the hydrophobic anticancer drug Px for non-small lung carcinoma cells.
(MSN@Px)L-GF provided tumor targeting capability via folate receptor EGF receptors
found commonly on tumor cells. (MSN@Px)L-GF displayed high clathrin mediated
endocytosis rate, and controlled Px release. (MSN@Px)L-GF displayed ~ 8x increase in
the efficacy compared to the free drug Px. In the presence of (MSN@Px)L-GF, cells
underwent apoptosis through an ROS-triggered mechanism where mitochondria damage
led to the amplification of oxidative stress and final cell death.
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5. CHAPTER 5

CONCLUSIONS
Conclusions
Nanomaterials as drug delivery vehicles for therapy and diagnosis have been
investigated for many years. Up to now, several approaches have been employed in order
to develop smart nanotheranostics, which combine bioactive targeting on specific tissues
as well as diagnostic properties. However, some of these approaches have loopholes in
detecting and delivering targeted therapeutic needs to intercellular bacteria, bacterial
biofilms, and cancers as a whole.
In this dissertation, attempts to address these loopholes were taken by developing
targeted liposome coated mesoporous silica core shell nanoassemblies to deliver
therapeutic agents to Pseudomonas aeruginosa (PA) infected mammalian cells
(intracellular PA), ex-vivo Pseudomonas biofilms and lung cancer cells. Those developed
nanoassemblies have shown increased therapeutic efficacy with the developed
nanoassemblies in targeting and eradicating bacteria and tumor cells compared to using the
therapeutic agents alone. In all these studies, the therapeutic agents were loaded into the
mesoporous silica nanoparticle core and coated them with a liposome coating to prevent
premature drug release and improve the stability of the nanoassembly. The liposome
coatings were conjugated with relevant targeting molecules to selectively target bacteria of
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cancer cells.

These studies showed that the developed nanoassemblies with selective

targeting and therapeutic ability have much potential to be used to eradicate other types of
intracellular bacteria and tumor cells with the correct use of specific targeting moieties and
therapeutic agents.
The joint project, which is discussed in the dissertation of Unnati Patel discusses a
lectin conjugated silica coated magnetic nanoparticle nanoassembly for the detection of
Mycobacteria smegmatis within less than a minute without any instrumental help.133 This
rapid test showed capture of low concentrations of bacteria, demonstrating its potential to
be expanded into a point of care triage test kit which can be used in the field.
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APPENDIX A

Figure A.1. FTIR spectrum of MSN.
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Figure A.2. FTIR spectrum of Col@MSN.
181

Figure A.3. FTIR spectrum of Col@MSN@LL.
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Figure A.4. FTIR spectrum of pure Colistin.
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Figure A.5. FTIR spectrum of Col@MSN@LL-(LL37).
184

Figure A.6. FTIR spectrum of pure LL-37 peptide.
185

Figure A.7. TGA curve for SNP and Col@SNP.

Synthesis of Col@MSN@LL-(PAB)
PAB was conjugated to the liposomes by EDC activation chemistry. Liposomes
containing DSPE-PEG (2000) CA (2.25 x 10-1 mmol) were activated with EDC (2.25
mmol) and sulfo-NHS (5.6 mmol) for 2 h at 37 °C. Thereafter, PAB (1 mg) was added to
the activated liposomes in a molar ratio of 1:10. The mixture was incubated for 24 h at 37
°C. At the end of the incubation period, PAB-modified liposomes (LL-(PAB) were purified
by centrifugation at 12000 rpm for 30 min at 4 °C and resuspended in PBS (pH 7.4). The
purified product was lyophilized and stored at −20 °C until further use. To prepare PAB
tagged liposome coated Col@MSN (Col@MSN@LL-(PAB), 50 mg of Col@MSN was
resuspended in PAB modified liposomes (LL-(PAB)) (2 mL) in PBS and mixed for 20 min
on an ice bath. Col@MSN@LL-(PAB) particles were separated from empty liposomes by
centrifugation at 12000 rpm for 5 min and repeated (3x) washing in PBS. The resultant
Col@MSN@LL-(PAB) was lyophilized and dried at −20 °C until further use.
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APPENDIX B

Figure B.1. Calibration curve of Alginate Lyase (AL) by micro BSA assay.
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Figure B.2. FTIR spectrum of MSN.
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Figure B.3. FTIR spectrum of MSN@Q.
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Figure B.4. FTIR spectrum of QSI.
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Figure B.5. FTIR spectrum of MSN@Q@Tob.
191

Figure B.6. FTIR spectrum of pure Tob.
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Figure B.7. FTIR spectrum of (MSN)Rh-AL.
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Figure B.8. FTIR spectrum of AL.
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Figure B.9. FTIR spectrum of Rh.
195

Figure B.10. Quantification of the fluorescence intensity of SYTO 9 stained biofilms
treated with DiI conjugated (MSN@Q@Tob)LL and (MSN@Q@Tob)Rh with respect to
the depth of the biofilm.

Figure B.11. Calibration curve of QSI determined by UV-Vis spectroscopy.
196

Figure B.12. Calibration curve of Tob determined by HPLC.

197

APPENDIX C

Figure C.1. FTIR spectrum of MSN.
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Figure C.2. FTIR spectrum of MSN@Px.
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Figure C.3. FTIR spectrum of Px.
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Figure C.4. FTIR spectrum of (MSN@Px)L.
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Figure C.5. FTIR spectrum of pure FA.
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Figure C.6. FTIR spectrum of pure GE11.
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Figure C.7. FTIR spectrum of L-GF.
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Figure C.8. Calibration curve of Folic Acid (FA).
Figure C.4. Calibration curve of GE11 by micro BSA
assayFigure C.3. Calibration curve of Folic Acid (FA)
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Figure C.9. Calibration curve of GE11 by micro BSA assay.
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Figure C.10. Calibration curve of Px performed by RT-HPLC.
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